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The nature of the relationship between attention-deficit/hyperactivity disorder 
(ADHD) and borderline personality disorder (BPD) has been a subject of debate in 
recent years. The current thesis brings together a diversity of methodologies and 
approaches to investigate the similarities and differences of emotional dysregulation 
and mind wandering in ADHD and BPD. 
Analyses in chapters 3, 4, and 5 are based on data from the PRIDE project, a case-
control study of 114 adult females:  32 with ADHD, 19 with BPD, 27 with 
comorbid ADHD/BPD, and 36 psychiatrically healthy controls. Analyses in 
chapter 6 represent findings from a systematic review and meta-analysis 
investigating the effects of stimulants and atomoxetine on symptoms of emotional 
dysregulation in ADHD. 
All the findings in this thesis point to the transdiagnostic nature of the overlapping 
symptoms of ADHD and BPD and of related impairments in various life domains, 
reflecting the heterogeneous picture of both conditions. The empirical findings of 
this thesis challenge the value of the categorical classification of ADHD and BPD, 
supporting instead a more dimensional and symptom-led approach of classification. 
The research presented here has clinical implications for the identification and 
treatment of ADHD and BPD in adulthood. 
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1.1 Aim of this chapter 
This thesis originates from clinically driven questions about the relationship 
between adult attention-deficit/hyperactivity disorder (ADHD) and borderline 
personality disorder (BPD). It aims to contribute to the understanding of the 
similarities and differences in the type of emotional dysregulation and mind 
wandering associated with both disorders. Ultimately the aim of this research is to 
inform future classification of these disorders. The general introduction is a 
synopsis of what is currently known about adult ADHD and BPD in general and 
more specifically about their clinical overlap. I present a detailed literature review 
relevant to the topics discussed in subsequent experimental chapters. Subsequently, 
I describe the overall aims and outline of this thesis. 
1.2 Overview 
In recent years, a debate has ensued over the nosological distinction between 
ADHD and BPD (Van Dijk, Lappenschaar, Kan, Verkes, & Buitelaar, 2012). 
Impulsivity, irritability and other symptoms of emotional dysregulation are 
characteristically seen in both disorders, but the nature of the relationship between 
ADHD and BPD requires clarification (Asherson et al., 2014). Key questions that 
arise include the extent to which: ADHD and BPD co-occur; they reflect distinct 
disorders or alternative expressions of the same underlying disorder; they share 
common genetic or environmental risk factors; or one of the disorders has a 
pathoplastic effect on the other (Storebø & Simonsen, 2014; Xenaki & Pehlivanidis, 
2015). In this chapter I review the current literature regarding these key questions.  
1.3 An introduction to attention-deficit/hyperactivity disorder 
1.3.1 Historical context 
ADHD is a common neurodevelopmental disorder, emerging in childhood or early 
adolescence, characterised by a pervasive pattern of developmentally inappropriate 
levels of inattention and/or hyperactivity/impulsivity that lead to clinically 
significant functional and psychosocial impairments (American Psychiatric 
Association, 2013). The first reference of inattentive problems in children dates to 
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the late 18th century by the Scottish physician Alexander Chrichton and the 
German physician Melchior Adam Weikard (Barkley & Peters, 2012). From 1968, 
several diagnostic formulations for ADHD-like behaviours were incorporated in the 
Diagnostic and Statistical Manual for Mental Disorders (DSM). The first, 
‘hyperkinetic reaction of childhood’, was accompanied by a shift in focus towards 
identifying and measuring behavioural features of the disorder (DSM-II; American 
Psychiatric Association, 1968). The second, heavily influenced by work on the 
central role of attention in the syndrome (Douglas, 1972), was labelled ‘attention 
deficit disorder ‘(DSM-III; American Psychiatric Association, 1980). With 
emphasis returning to hyperactivity symptoms, ADHD was introduced in the 
DSM-III-revised (American Psychiatric Association, 1987). This diagnostic label 
continues to be used today, although instead of a unitary disorder, three ADHD 
presentations have been introduced (American Psychiatric Association, 2013). 
From the second revision of the DSM-II, diagnostic formulations no longer 
included emotional problems previously associated with minimal brain dysfunction 
(Barkley, 2011). From the DSM-III these were reassigned to ‘associated features’, 
where they remain today (American Psychiatric Association, 2013; Reimherr et al., 
2005).  
1.3.2 Diagnostic classification  
There is no objective test for ADHD, and decisions to diagnose and treat ADHD 
are based on subjective (self and informant) reports assessed and interpreted by 
clinicians in light of diagnostic cut-offs (Okie, 2006).  
According to the DSM–5, the diagnosis of ADHD requires six out of nine ADHD 
symptoms of either inattention or hyperactivity/impulsivity in childhood, and five 
out of nine symptoms in adults (American Psychiatric Association, 2013; see Table 
1.1). Additional criteria include childhood age of onset, defined as several ADHD 
symptoms present before the age of 12 years, pervasiveness, defined as symptoms 
present in two or more settings, and impairment, defined as- interference with or 
reduced quality of social, academic or occupational functioning persistent for at 
least six months (Epstein & Loren, 2013). 
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Table 1.1 DSM-5 diagnostic criteria for ADHD 
(A1) Inattention: 
1 Often fails to give close attention to details or makes careless mistakes in schoolwork, at work, or 
during other activities 
2 Often has difficulty sustaining attention in tasks or play activities 
3 Often does not seem to listen when spoken to directly 
4 Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in 
the workplace (not due to oppositional behaviour or failure of comprehension) 
5 Often has difficulty organising tasks and activities 
6 Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as 
schoolwork or homework) 
7 Often loses things necessary for tasks or activities at school or at home 
8 Is often easily distracted by extraneous stimuli (may include unrelated thoughts) 
9 Is often forgetful in daily activities 
 
(A2) Hyperactivity: 
10 Often fidgets with hands or feet or squirms in seat 
11 Often leaves seat in classroom or in other situations in which remaining seated is expected 
12 Often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults may be limited to feeling restless) 
13 Often has difficulty playing or engaging in leisure activities quietly 
14 Often talks excessively 
15 Is often “on the go” or often acts as if “driven by a motor” 
 
Impulsivity: 
16 Often has difficulty awaiting turn in games or group situations 
17 Often blurts out answers to questions before they have been completed 
18 Often interrupts or intrudes on others 
 
Associated features supporting the diagnosis: 
Emotional dysregulation (low frustration tolerance, emotional over-reactivity, or mood lability, as 
featured in the Wender-Utah adult ADHD criteria) a 
Mild delays in language, motor, or social development 
Impaired academic or work performance a 
Increased risk of suicide attempts by early adulthood, primarily when comorbid with mood, conduct 
or substance use disorders a 
a Behavioural symptom that commonly overlaps with BPD diagnosis 
 
In addition to the main symptoms used to classify ADHD, emotional dysregulation 
is considered to be an associated feature supporting the diagnosis of ADHD 
(American Psychiatric Association, 2013; Asherson, Buitelaar, Faraone, & Rohde, 
2016). In ADHD, emotional dysregulation is characterised by problems with 
temper control (feelings of irritability and frequent outbursts of short duration), 
emotional over-reactivity (diminished ability to handle typical life stresses, resulting 
in frequent feelings of being hassled and overwhelmed), and mood lability (short 
and unpredictable shifts from normal mood to depression or mild excitement) 
(Reimherr et al., 2005). 
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Excessive mind wandering is thought to reflect a measurable component of ADHD 
psychopathology, potentially distinguishing it from other psychiatric conditions 
(Mowlem et al., 2016). Mind wandering is a universal phenomenon that takes up 
around 50% of daily thinking time (Smallwood & Schooler, 2015) and occurs when 
one’s mind drifts away from the primary task at-hand and instead focuses on 
internal, task-unrelated thoughts and images (Smallwood, McSpadden, & Schooler, 
2007). Although not all forms of mind wandering reflect pathological processes 
(Seli, Smallwood, Cheyne, & Smilek, 2015), excessive spontaneous mind 
wandering, that is detrimental to performance, has been proposed as a possible 
mechanism underlying many of the impairments of ADHD (Bozhilova, Michelini, 
Kuntsi, & Asherson, 2018; Mowlem et al., 2016).  
1.3.3 Prevalence and gender differences 
ADHD is considered one of the most highly prevalent childhood psychiatric 
disorders, affecting around 5% of children (Polanczyk, De Lima, Lessa Horta, 
Biederman, & Rohde, 2007). Longitudinal follow-up studies of children with 
ADHD show that symptoms of ADHD commonly persist into adulthood, with 
around two-thirds of cases meeting either full or sub-threshold criteria in adulthood 
(Brookes et al., 2006). The prevalence of adult ADHD in epidemiological surveys is 
estimated at around 2.5-4% in the general population (De Graaf et al., 2008; 
Fayyad et al., 2007; Kessler et al., 2006). Although there is the possibility that 
ADHD might emerge after childhood (Moffitt et al., 2015), for most adult patients 
with ADHD there is a clear history of ADHD from childhood. The lower 
prevalence of ADHD in adulthood may be explained by reductions in ADHD 
symptoms and impairment throughout development in a subset of people with 
ADHD, difficulties in self-recognition of ADHD symptoms, and potentially altered 
expression of ADHD symptoms, such as hyperactivity being manifested as feelings 
of restlessness (Asherson et al., 2014). 
ADHD is recognised as a predominantly male disorder in childhood, with male to 
female ratios generally ranging from 3:1 in population-based studies, to 9:1 in 
clinic-referred studies (Ford, Goodman, & Meltzer, 2003; Polanczyk et al., 2007). 
However, in adult clinical samples and epidemiological studies on adult ADHD, 
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the sex difference is less pronounced (Bernardi et al., 2012; Kessler et al., 2006; 
Rucklidge, 2010). In a meta-analysis of epidemiological studies of ADHD in adults, 
Simon and colleagues (2009) identified an age-by-sex interaction, with younger 
adults with ADHD being characterised by a much larger male preponderance. 
1.3.4 Associated impairments and comorbidity 
The symptom profile and severity of ADHD varies greatly between individuals, 
with both inattention and hyperactivity/impulsivity associated with functional 
impairment in multiple domains (Asherson, Chen, Craddock, & Taylor, 2007; 
Asherson et al., 2014). Emotional dysregulation has also been found to be an 
independent predictor of impairment in ADHD, after controlling for the 
confounding effects of core ADHD symptoms (inattention and 
hyperactivity/impulsivity) on impairment (Asherson et al., 2015; Barkley & 
Fischer, 2010; Skirrow & Asherson, 2013). Furthermore, emotional dysregulation 
has been found in cases of ADHD with no co-existing mental health disorders, and 
therefore cannot always be explained by co-occurring conditions (Skirrow et al., 
2014). Impairments can be severe, impacting on education, occupation, social and 
interpersonal relationships (Asherson et al., 2007; Asherson et al., 2014). Adults 
with ADHD are more likely to have lower educational attainment, poorer work 
performance and an increased likelihood of dismissal from work (Gjervan, 
Torgersen, Nordahl, & Rasmussen, 2012; Halmøy, Fasmer, Gillberg, & Haavik, 
2009; Rösler, Casas, Konofal, & Buitelaar, 2010), as well as difficulties in 
maintaining long-term social relationships and higher divorce rates (Barkley & 
Murphy, 2010), serious transport accidents (Chang, Lichtenstein, D'Onofrio, 
Sjolander, & Larsson, 2014), and criminality (Lichtenstein & Larsson, 2013).  
High comorbidity rates are a widespread phenomenon in psychiatric research, even 
in non-referred community samples (Kessler et al., 2005; Weich et al., 2011). 
ADHD seldom exists in isolation and up to 90% of adults with ADHD in clinical 
and population samples are reported to have one or more co-occurring mental 
health disorders (Bolea-Alamanac et al., 2007). Of these disorders, the most 
prevalent include depressive disorders (35-50%), anxiety disorders (40-60%), 
substance use disorders (up to 50%) (Cumyn, French, & Hechtman, 2009; 
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Sobanski, 2006; Xenaki & Pehlivanidis, 2015), and personality disorders including 
BPD (Davids & Gastpar, 2005; van Dijk, Lappenschaar, Kan, Verkes, & Buitelaar, 
2011). This exceptionally high co-morbidity rate could however reflect, at least in 
part, an artefact of overlapping symptoms shared by other mental health disorders 
(Asherson et al., 2016). It could also reflect measurement error, resulting from a 
reliance on self-reported rating scales. Irrespective of the underlying cause of co-
morbidity, several lines of research have investigated the extent to which the shared 
aetiological factors may explain the co-occurrences of these psychiatric conditions 
with ADHD. For example, twin studies suggest moderately large shared genetic 
effects (genetic correlation; rA=.50-.77) for the co-occurrence of ADHD with 
depression and anxiety (Cole, Ball, Martin, Scourfield, & McGuffin, 2009; 
Michelini, Eley, Gregory, & McAdams, 2015), and this is supported from findings 
from the latest genome wide association studies (GWAS) using linkage 
disequilibrium regression analysis (Demontis et al., 2017). 
Despite the high prevalence of adult ADHD and established links to psychosocial 
and functional impairments, as well as its co-occurrence with other psychiatric 
disorders, high rates of undiagnosed or untreated ADHD have been found in 
clinical settings (Huntley et al., 2012). Additionally, understanding the similarities 
and differences between adult ADHD and common co-occurring mental health 
disorders is important to improve understanding of the clinical presentation of 
ADHD in adulthood, reduce under-diagnosis, and provide targeted and effective 
treatments. Further research is needed using neurobiological, genetic and 
environmental measures to better understand the common aetiological mechanisms 
which explain their co-occurrence with ADHD.  
1.3.5 Aetiology of ADHD 
ADHD is a complex disorder with a multifactorial aetiology, which arises from the 
interplay between genetic and environmental risk factors (Faraone et al., 2015). 
During the past decade, quantitative genetic research has established that ADHD 
runs in families and is largely influenced by genetic factors, while individual-
specific environmental factors may also play a limited role. These findings have led 
to efforts to explore and identify the specific genetic variants that underlie the 
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ADHD phenotype. There have also been efforts in identifying environmental risk 
factors in ADHD and studying how they interact with genes. These research efforts 
have highlighted the complexity of aetiological pathways to ADHD and how much 
is still to be learned. Further details of the genetic and environmental risks involved, 
are outlined in section 1.5.5. 
1.4 An introduction to borderline personality disorder 
1.4.1 Historical context 
In the early 1900s, a subset of patients presenting with a pattern of symptoms and 
behaviours that were inconsistent with any predefined diagnostic category and 
considered to lie at the border between neurosis and psychosis, were labelled 
“borderline” (Stern, 1938). These patients who appeared depressed and anxious 
also exhibited temporary psychotic symptoms in stressful situations. The first 
systematic attempt to describe a borderline patient was undertaken by the 
psychoanalyst Adolph Stern in 1938. In the following years, the term “borderline” 
developed from being considered a personality organisation, to a syndrome, then to 
a disorder, with the term BPD first being introduced in the DSM-III (American 
Psychiatric Association, 1980). Since its introduction in the DSM, BPD has 
undergone relatively minor changes to the diagnostic criteria. 
1.4.2 Diagnostic classification 
BPD is a complex and severe mental health disorder, with typical symptom onset 
during adolescence and presence of behavioural precursors in childhood, persisting 
into adulthood (American Psychiatric Association, 2013). BPD is characterised by 
a pervasive pattern of unstable interpersonal relationships, pronounced impulsive 
and self-damaging behaviour, unstable identity, and difficulties with emotional 
dysregulation (American Psychiatric Association, 2013), which substantially impact 
in an enduring way on quality of life and psychosocial functioning (Gunderson, 
Stout, et al., 2011). The DSM-5 diagnosis of BPD requires the pervasive presence of 
a minimum of five out of nine symptoms for at least one year, present in a variety 
of contexts (American Psychiatric Association, 2013; see Table 1.2). 
Introduction  
25 
Table 1.2 DSM-5 symptom criteria for borderline personality disorder 
1 Frantic efforts to avoid real or imagined abandonment 
2 A pattern of unstablea and intense interpersonal relationships 
3 Impulsivity in at least two areas that are potentially self-damaginga 
4 Identity disturbance: markedly and persistently unstable self-image or sense of self 
5 Recurrent suicidal behaviour, gestures, or threats, or self-mutilating behaviour 
6 Affective instability due to a marked reactivity of mooda 
7 Chronic feelings of emptiness 
8 Inappropriate, intense anger or difficulty controlling angera 
9 Transient, stress-related paranoid ideation or severe dissociative symptoms 
 
Associated features supporting the diagnosis 
Recurrent job losses, interrupted education, and separation or divorce are commona 
 
aBehavioural symptoms that commonly overlaps with ADHD diagnosis 
 
Problems with diagnosis and heterogeneity 
The DSM personality disorders criteria, especially for BPD, are of a polythetic 
nature, inevitably resulting in a heterogenous group of patients. There are 126 
different ways to meet the DSM criteria for BPD, and two borderline patients may 
share only one common symptom. This threatens the internal consistency of the 
BPD construct, challenging its validity as a single diagnostic entity (Trull & 
Durrett, 2005). Additionally, people often meet the criteria for more than one 
personality disorder. For example, approximately 25% of people diagnosed with 
BPD also meet the criteria for antisocial personality disorder (Zanarini et al., 1998). 
1.4.3 Prevalence and gender differences 
In the general population, based on cross-sectional and community-based surveys, 
BPD has a prevalence in the range of 1.4% to 6% (Coid, Yang, Tyrer, Roberts, & 
Ullrich, 2006; Grant et al., 2008; Lenzenweger, Lane, Loranger, & Kessler, 2007). 
Within populations of adult psychiatric outpatients and patients in primary care, 
prevalence is around 20% (American Psychiatric Association, 2013; Grant et al., 
2008). The disparity between prevalence figures may be due to variations in 
sampling, study setting and case ascertainment, with higher prevalence marked in 
urban areas (Tyrer, Reed, & Crawford, 2015). 
Most epidemiological surveys report no sex differences for BPD, yet studies of 
clinical populations typically report much higher prevalence in women, than in men 
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(Zimmerman, Rothschild, & Chelminski, 2005). Approximately 75% of BPD 
diagnoses are in females (American Psychiatric Association, 2013). The difference 
in prevalence may reflect real sex differences, although the finding that there is no 
prevalence difference in epidemiological surveys may well reflect variation in 
methodology (population, sampling, case detector) used (Grant et al., 2008). 
Additionally, childhood trauma, notably sexual abuse, is more frequently reported 
in females than males, 70% versus 50% based on epidemiological studies (Jonas et 
al., 2010; Skodol & Bender, 2003). Given the strong association of BPD with sexual 
abuse, this may partly explain the higher incidence in treatment seeking females. 
The sex variations may also reflect a real difference in the biology, with affective 
instability in males more often resulting in externalising behaviour in the form of 
aggression (which may translate to antisocial personality disorder in extreme cases), 
and in women, this more often manifests as internalising pathology in the form of 
depression and self-harm (Paris, 2004). Males may also be less likely to seek out 
psychological help or more likely to end up in the criminal justice system (Bateman 
& Krawitz, 2013; Tyrer et al., 2015). Sansone and Sansone (2011) noted that 
research studies traditionally sample inpatient psychiatric patients to determine 
prevalence of BPD, which would result in an underestimate of the number of men 
with BPD. 
1.4.4 Comorbidities and associated impairments  
Like ADHD, individuals with BPD commonly present with comorbid mental 
health disorders. In particular, around 90% of BPD cases are reported to have co-
occurring mood disorders, including depression and dysthymia (Zanarini et al., 
1998), anxiety, post-traumatic stress disorder, and a high prevalence of substance 
use disorders in the range of 15% to 57% (Sharp & Romero, 2007). This high 
comorbidity could potentially result in some individuals with BPD remaining 
undiagnosed, placing them at risk for ineffective or even harmful treatment (Tyrer 
et al., 2015). 
The potential consequences of BPD for future health and social functioning are 
stark. Studies suggest that approximately 10% of individuals with BPD die 
prematurely by committing suicide (Paris, 2002). Individuals with any personality 
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disorder are also more likely to be separated or divorced, and unemployed or 
economically inactive (Coid et al., 2006). Those with BPD, however, are especially 
likely to demonstrate significant impairment at work, in social relationships and 
leisure pursuits (Skodol et al., 2002). Family life is often affected, and less than half 
of BPD patients get married, with even fewer having children (Paris, 2003). 
Overall, the evidence suggests that individuals suffering from BPD have a severely 
reduced quality of life and sustained functional impairment (Zanarini, 
Frankenburg, Hennen, Reich, & Silk, 2005). 
1.4.5 Aetiology of BPD 
The aetiology of BPD is not fully understood and given the heterogenous nature of 
the disorder, a bio-psychosocial model is likely to be the most informative to 
understand it. Nevertheless, some neurobiological and genetic explanations have 
also been put forth. Neuroimaging studies have shown possible structural 
differences in brain regions of people with BPD, in comparison with matched 
controls (Krause-Utz, Winter, Niedtfeld, & Schmahl, 2014); dysfunctions in the 
prefrontal cortex as a source for attentional mechanisms, and altered activation of 
the orbitofrontal cortex as a core region for impulsivity and emotional instability 
(Krause-Utz et al., 2014, Philipsen, 2006). Like ADHD and other complex 
behavioural disorders, single gene effects have not been identified as causative of 
BPD (Chanen & McCutcheon, 2013), and genetic risks are expected to arise from 
multiple genes of small effect (Amad, Ramoz, Thomas, Jardri, & Gorwood, 2014). 
Genetic vulnerability may begin to explain the development of BPD but must be 
considered alongside developmental processes and the impact of exposure to 
environmental risks.  
Adverse childhood experiences play a key role in the development of BPD and 
include childhood maltreatment (Cohen et al., 2013), and exposure to parental 
psychopathology (Zanarini & Frankenburg, 1997). These experiences appear to 
lead to attachment disturbances (Fonagy, Target, Gergely, Allen, & Bateman, 
2003). Difficulties in development of cognitions (Beck et al., 2001), emotions 
(Carpenter & Trull, 2013), behaviours and interpersonal relationships have also 
been highlighted in BPD. Of note, these processes cannot be considered as 
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exclusive to any one mental health disorder, and this might explain the higher rates 
of comorbidity. Overall, it is likely that a number of different causal factors, 
environmental as well as individual differences in genetics and biology, and 
processes are involved, as individuals with the same risk factors do not all develop 
BPD (Cicchetti, 2014). Further details of the genetic and environmental risks are 
outlined in section 1.5.5. 
1.5 Overlap in ADHD and BPD 
1.5.1 Studies of the co-morbidity between ADHD and BPD 
Psychiatric comorbidity is commonly found across all mental health disorders 
(Kessler et al., 2005) and is defined as the presence of two or more disorders in the 
same individual at a given time. In principle, each of the disorders should make a 
unique contribution to the clinical presentation of the individual (Vella, Aragona, & 
Alliani, 2000). However, estimates of comorbidity prevalence may be inflated if 
there is marked overlap in the symptom criteria of two disorders, leading to poor 
diagnostic delineation i.e. artefactual co-morbidity (Skirrow, Hosang, Farmer, & 
Asherson, 2012). Furthermore, it remains unclear to what extent psychiatric 
diagnoses reflect entirely distinct disorders, rather than overlapping syndromes 
(Vella et al., 2000). This is a particular problem for psychiatry, because as yet, there 
are no validated biomarkers or other objective markers with sufficient sensitivity or 
specificity to be used in clinical practice to distinguish aetiologically distinct mental 
health conditions. Regarding ADHD and BPD, while the specific symptoms used 
to classify the two disorders are different, many clinical characteristics are shared, 
including emotional dysregulation, impulsive risk-taking behaviour, and unstable 
interpersonal relationships.  
A high prevalence of co-occurring ADHD and BPD is consistently reported in the 
literature. In a large in- and outpatient cohort of 372 adults with ADHD referred for 
ADHD assessment and treatment at a tertiary referral centre, 27.2% also met 
criteria for BPD assessed by the Structured Clinical Interview for DSM-IV Axis II 
(SCID-II) (Jacob et al., 2007). Similarly, in another sample of 335 adults referred by 
family physicians, community health clinics or self-referred, BPD, assessed by the 
SCID-II, was reportedly present in 10% of patients with DSM-IV inattentive 
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subtype ADHD (six or more symptoms of inattention) and 24% of patients with 
combined subtype ADHD (six or more symptoms of both inattention and 
hyperactivity/impulsivity) (Cumyn et al., 2009). Likewise, in a sample of 181 adult 
patients diagnosed with BPD by general practitioners and referred for treatment, 
38.1% had comorbid ADHD, with 22.7% meeting the combined type criteria 
(Ferrer et al., 2010). 
In a sample of 118 adult women from out-patient clinics seeking treatment for 
BPD, a high co-occurrence rate was reported: 41.5% met criteria for childhood 
ADHD (assessed retrospectively), and 16.1% met current criteria for the DSM-IV 
combined subtype, as well as meeting ADHD criteria as children (Philipsen et al., 
2008). However, as opposed to the previous studies where diagnoses were 
confirmed by clinical interviews (Cumyn et al., 2009; Ferrer et al., 2010; Jacob et 
al., 2007), severity of borderline personality disorder and ADHD symptoms were 
assessed using self-report questionnaires (Philipsen et al., 2008). 
In a sample of adolescents (n=107) with emerging BPD drawn from a European 
research project investigating the phenomenology of BPD in adolescence, the 
prevalence of ADHD was 11%, an estimate that was not attenuated even when 
excluding symptoms of impulsivity accounting for possible symptom overlap 
(Speranza et al., 2011). This rate was close to the 16% rate found by Philipsen and 
colleagues, where current ADHD symptoms were assessed by self-report measures 
(Philipsen et al., 2008), as opposed to clinician-based interviews. Moreover, the 
samples significantly differed in regard to participants’ age. 
Regarding population samples, results from the National Epidemiologic Survey on 
Alcohol and Related Conditions of more than 34,000 adults, found that lifetime 
comorbidity with BPD in the ADHD population was 33.7% compared with a lower 
prevalence of BPD of only 5.2% in the general population (Bernardi et al., 2012).  
1.5.2 Symptomatic overlap 
There is considerable overlap in the symptoms of BPD and the associated features 
of ADHD (see Table 1.3). Considering the onset and developmental trajectory, 
both disorders can be considered ‘developmental’ in the sense that they both emerge 
Introduction  
30 
during childhood or adolescence and reflect enduring trait-like (non-episodic) 
symptoms and behaviours (Winsper et al., 2016). The shared general features of 
trait-like symptoms that characterise both ADHD and BPD; means that 
differentiating between these diagnoses cannot easily be established by considering 
age of onset and course of symptoms. This means that to a large extent, differential 
diagnosis is based on the specific symptoms and behaviours used to define the two 
disorders. 
1.5.2.1 Impulsivity 
The most noticeable overlap among the core symptoms used to classify both 
conditions is impulsivity (Speranza et al., 2011; Van Dijk et al., 2012). 
Nevertheless, there are important qualitative differences in the manifestation of 
impulsivity used in the classification of ADHD and BPD. In ADHD, impulsivity 
refers to difficulty waiting or taking turn, blurting out during conversations (e.g. 
interrupting or talking over people), and intruding on others (e.g. butting into 
conversations or activities, taking over what others are doing) (American 
Psychiatric Association, 2013). These impulsive symptoms are not always severe in 
adults with ADHD, but when severe, can lead to impairment in social functioning 
and self-damaging or risk-taking behaviour. The consequences of severe impulsivity 
in ADHD include reckless driving, promiscuity, interpersonal relationship 
problems and aggressive behaviour (McNamara, Vervaeke, & Willoughby, 2008; 
McNamara & Willoughby, 2010). In BPD, impulsivity is defined by self-damaging 
behaviour, such as reckless driving, shoplifting, spending, binge eating, substance 
abuse and promiscuity (American Psychiatric Association, 2013). People with 
either of these disorders may therefore display impulsive risk-taking behaviour, but 
from a diagnostic perspective, this is a core symptom of the BPD diagnosis, but 
only an associated feature of ADHD. 
1.5.2.2 Emotional dysregulation 
The other key area of symptom overlap is emotional dysregulation. Emotional 
dysregulation reflects a core symptom domain in the diagnostic classification of 
BPD (American Psychiatric Association 2013), whereas in ADHD it is recognised 
as an associated clinical feature that supports the diagnosis (Wender, 1995; Wood, 
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Reimherr, Wender, & Johnson, 1976). Nevertheless, emotional dysregulation is 
commonly seen to accompany ADHD, even in non-comorbid cases (Skirrow et al., 
2012), and is an independent source of psychosocial impairment. This draws strong 
comparisons with emotional dysregulation in BPD, particularly when the 
emotional dysregulation that accompanies ADHD is severe (Berger, Kofman, 
Livneh, & Henik, 2007). At a descriptive level, the emotional symptoms of ADHD 
were well captured by Wender, Reimherr and colleagues in the earlier Wender-
Utah criteria for ADHD and show substantial overlap with the emotional 
dysregulation symptoms in the DSM-5 BPD criteria (Philipsen et al., 2008; Xenaki 
& Pehlivanidis, 2015). 
Emotional dysregulation is a dimensional construct (Shaw, Stringaris, Nigg, & 
Leibenluft, 2014), referring to rapid and exaggerated changes in emotional states 
such as heightened irritability or hot temper (Berger et al., 2007). A review by 
Asherson and colleagues reported that emotional dysregulation is present in 72-90% 
of adults with ADHD, and independently of other symptoms of ADHD predicts 
impairments in social, educational and occupational domains (Asherson, Kuntsi, & 
Taylor, 2005). In contrast, emotional dysregulation is one of the core symptom 
domains of individuals with BPD, who nearly always suffer from severe persistent 
affective instability, inner tension and difficulty controlling emotions such as anger 
(Davids & Gastpar, 2005; Philipsen, 2006; Philipsen et al., 2008, 2009). It has been 
suggested that patients with BPD have higher frequency and intensity of affective 
instability and aggressive impulsive reactions, compared to adults with ADHD 
(Ebner-Priemer, Welch, et al., 2007; Philipsen et al., 2009; Van Dijk et al., 2012). 
Others describe ADHD patients as being high novelty seekers, who regulate their 
emotions through extreme external stimulation (e.g. sexual activity, aggressive 
behaviour), as opposed to those with BPD, who tend to engage in self-mutilating 
behaviour to alleviate negative affect and inner tension (Philipsen, 2006). However, 
self-harming behaviour and suicidality in ADHD has been highlighted in recent 
literature (Allely, 2014). Yet, phenomenologically, emotional dysregulation is a 
complex construct, with shared characteristics in both ADHD and BPD, 
particularly pertaining to feelings of heightened anger and difficulty controlling 
anger (criterion eight in BPD) (Philipsen et al., 2008). Others suggest that emotional 
dysregulation reflects an underlying cyclothymic temperament present in both 
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disorders (Eich et al., 2014). Arguments in favour of considering emotional 
dysregulation as a core component of ADHD include the evidence that ADHD 
medication has a similar effect size (ES) on reducing emotional dysregulation as the 
core ADHD symptoms of inattention and hyperactivity/impulsivity (Reimherr, 
Marchant, Gift, Steans, & Wender, 2015; Rosler et al., 2010). On the other hand, 
emotional dysregulation is a domain that is seen to occur across a wide range of 
other psychiatric and neurodevelopmental disorders (American Psychiatric 
Association, 2013). 
Regarding the overlap between ADHD and BPD, it remains unclear whether the 
type of emotional dysregulation seen in ADHD is qualitatively similar or different 
from that seen in BPD. One way to investigate this issue with precision is by using 
ambulatory assessments. 
Table 1.3 Overlapping features between ADHD and BPD 
ADHD BPD 
• Childhood or early adolescent onset (note: 
recent literature highlights early adult onset in 
some cases) (Moffitt et al., 2015) 
• Adolescent or early adult onset 
• Chronic (trait-like) symptoms and persistent 
course 
• Chronic (trait-like) symptoms and persistence 
course 
• Pattern of unstable interpersonal relationships 
is a common associated characteristic 
• Pattern of unstable interpersonal relationships 
• Affective instability is common associated 
characteristic 
• Affective instability 
• Risk taking behaviour (behavioural 
impulsivity) is an associated characteristic 
• Behavioural impulsivity/risk taking 
• Inappropriate anger or difficulty controlling 
anger is a common associated characteristic 
• Inappropriate anger or difficulty controlling 
anger 
1.5.3 Emotional dysregulation in ambulatory assessments 
Emotions are time- and context-dependent processes which are not adequately 
captured by retrospective and cross-sectional reports (Ebner-Priemer & Trull, 2009). 
Yet, within clinical environments, assessment of emotional dysregulation relies 
entirely on interviews and self-report rating scales, which may be highly subjective 
and based on retrospective recall. These methods limit the validity of assessments of 
fluctuating emotional symptoms by the reliance on the individual’s memory and the 
skills of the interviewer. They may also be coloured by the subject’s mental state at 
the time of the assessment (Ebner-Priemer & Trull, 2009; Trull & Ebner-Priemer, 
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2014). For instance, it has been reported that BPD patients fail to remember their 
most extreme and intense mood changes (Santangelo, Bohus, & Ebner-Priemer, 
2012). One alternative approach with greater ecological validity is to use repeated 
ratings of real-time experiences (Santangelo et al., 2014) - an approach which is 
termed ecological momentary assessments, ambulatory assessment or experience 
sampling method (ESM). ESM provides an effective way of precisely measuring 
emotional dynamics and variation within individuals, over time (Myin-Germeys et 
al., 2009; Skirrow et al., 2014). 
In BPD, eight ESM studies have investigated the dynamics of emotional instability 
(Ebner-Priemer et al., 2015; Ebner-Priemer, Kuo, et al., 2007; Ebner-Priemer & 
Sawitzki, 2007; Ebner-Priemer & Trull, 2009; Ebner-Priemer, Welch, et al., 2007; 
Santangelo et al. 2014). In one study of 50 BPD and 50 healthy controls using 24-
hour ambulatory monitoring (intervals of 15 minutes), the BPD group was found to 
overestimate emotions with negative valence and underestimate emotions with 
positive valence, when comparing retrospective with ESM ratings (Ebner-Priemer, 
Kuo, et al., 2007; Ebner-Priemer et al., 2006). In contrast, the healthy control 
sample overestimated emotions with positive valence and underestimated emotions 
with negative valence (Ebner-Priemer, Kuo, et al., 2007; Ebner-Priemer et al., 
2006). Individuals with BPD have also been found to report greater levels of intra-
individual variability and short-term fluctuations in overall affect valence. In 
another study comparing 34 outpatients with BPD and 26 with current depression, 
using ESM for nearly one month, ratings indicated greater instability (i.e. more 
changes from one assessment to the next) over time for fear, hostility and sadness in 
the BPD group (Trull et al., 2008). It has also been reported using ESM that 
compared to healthy controls, BPD patients experience a higher frequency and 
increased intensity of negative affect and a lower frequency and decreased intensity 
of positive affect (Ebner-Priemer, Kuo, et al., 2007; Ebner-Priemer & Sawitzki, 
2007; Ebner-Priemer & Trull, 2009; Ebner-Priemer, Welch, et al., 2007). In 
addition, a recent review of 34 ESM studies found that BPD patients experience 
longer durations of aversive tension and therefore a slower return to their baseline 
affective state (Santangelo et al., 2012). 
Introduction  
34 
To our knowledge, there has been only one ESM study looking at the variation in 
emotional instability in adults with ADHD (Skirrow et al., 2014). Compared to 
healthy controls (n=47), patients with ADHD (n=41) showed significantly 
increased instability and intensity of negative emotions (irritability, frustration and 
anger). They also showed greater reactivity of negative emotions, such as anger, to 
‘bad’ life events. This study included only males and specifically excluded patients 
with comorbid conditions (Skirrow et al., 2014).  
Critically, from the standpoint of contrasting emotional dysregulation in 
populations of patients with ADHD and BPD, there have been no studies of the 
phenomenon in both patient groups using ESM. Furthermore, additional 
information could also be collected regarding the naturalistic context and situation 
when emotional changes occur (e.g. where they are, who they are with, what has 
just happened); which might identify disorder specific contextual triggers for 
emotional changes in different disorders. Clearly this area needs more research 
before conclusions can be drawn about the similarity or differences of emotional 
dysregulation in BPD and ADHD. 
1.5.4 Neurobiological correlates of emotional dysregulation in ADHD 
and BPD 
The overlap in symptoms of emotional dysregulation in ADHD and BPD raises the 
question of a common neurobiological substrate for emotional dysregulation in the 
two conditions. In ADHD, two competing hypotheses have been proposed for 
emotional dysregulation. First, the ‘dyscontrol hypothesis’ proposes that emotional 
dysregulation is driven by the same cognitive and neural processes that drive 
ADHD; for example, deficits in top-down executive control (from the prefrontal 
cortex to the amygdala), or bottom-up state regulation factors (from the limbic 
system to higher cortical regions) (Posner, Kass, & Hulvershorn, 2014; Thompson, 
2011). In this model, emotional dysregulation reflects an alternative expression of 
the same underlying neurocognitive deficits that lead to ADHD symptoms. The 
alternative ‘affectivity hypothesis’ states that emotional dysregulation reflects 
deficits in neural processes related directly to emotional regulation, separate from 
those that lead to ADHD symptoms (Posner et al., 2014). To date the accumulating 
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evidence is pointing to the affectivity hypothesis. Two key publications support this 
conclusion (Banaschewski et al., 2012; Hulvershorn et al., 2014). First, a large 
multi-site investigation of cognitive performance deficits in 424 carefully diagnosed 
ADHD cases and their 564 unaffected siblings (including inhibition, working 
memory, impulsive responding, slow and variable reaction times), found these were 
associated with ADHD symptoms independently from emotional dysregulation 
(Banaschewski et al., 2012). This suggests that different processes would explain the 
presence of emotional dysregulation in ADHD. Subsequently, a resting state 
functional Magnetic Resonance Imaging (fMRI) study in children with ADHD, 
found that emotional dysregulation, independently from ADHD, was associated 
with increased positive intrinsic functional connectivity (iFC) between bilateral 
amygdala and medial prefrontal regions, and reduced iFC between amygdala and 
bilateral insula/superior temporal gyrus. These findings suggested that emotional 
dysregulation is linked to specific disruptions in emotional control networks, more 
specifically in the amygdala networks, that underlie emotion regulation 
impairments not linked directly to core ADHD symptoms (Hulvershorn et al., 
2014). 
Regarding ADHD, several different processes have been implicated, reflecting the 
potential heterogeneity of causal processes underpinning the development of 
ADHD symptoms (Faraone et al., 2015). These include: (1) reduced connectivity in 
the ventral fronto-striato-parietal (cognitive control) circuit; (2) reduced connectivity 
in the dorsal fronto-striato-parietal attention circuit; (3) reduced connectivity in 
inferior fronto-supplementary–motor-area-parieto-cerebellar networks for timing 
function; (4) reduced connectivity in orbitofrontal-ventral striatal (salience/reward) 
circuit; (5) reduced connectivity between the default mode network (DMN) and 
cognitive control circuits, linked to reduced deactivation of the DMN during 
cognitive tasks and reduced connectivity between components of the DMN 
(Cortese et al., 2012; Faraone et al., 2015). 
Regarding BPD there are overlapping findings implicating the central role of 
emotional control networks. A critical review of fMRI studies concludes that 
emotional sensitivity, including emotional hypersensitivity and intense emotional 
reactions, was associated with increased amygdala activity and decreased activity 
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with prefrontal cortical control regions (van Zutphen, Siep, Jacob, Goebel, & 
Arntz, 2015). In particular, a consistent decrease in anterior cingulate activity and 
anterior insula was identified, while the medial and dorsolateral prefrontal areas 
showed variable activity across studies. Overall, increased limbic and diminished 
prefrontal cortical activity suggested an impaired fronto-limbic inhibitory network 
(van Zutphen et al., 2015). 
A multi-centre study of resting-state fMRI, before and after an emotion regulation 
task in 48 patients with BPD from mental health clinics and 39 non-patients from 
the general population, further supports disrupted regulation of emotional circuits 
(Baczkowski et al., 2017). Emotional hypersensitivity in BPD was associated with 
increased intrinsic connectivity between the amygdala and bilateral insula together 
with dorsal anterior cingulate cortex, while their impaired control over emotional 
reactions was associated with diminished intrinsic connectivity between the central 
executive fronto-parietal regions and salience network (Baczkowski et al., 2017).  
Overall, the pattern of findings in relation to emotion regulation was similar to that 
reported for emotional dysregulation in patients with ADHD by Hulvershorn et al. 
(2014). The overlap of these findings in relation to emotional dysregulation in the 
two disorders suggests that there may be a common substrate for emotional 
dysregulation in the two conditions, involving altered top-down and bottom-up 
regulation of amygdala function and neural circuits. However, as discusse woleb d , 
evidence-based treatments are entirely different for the two disorders, suggesting 
that the underlying cause of the disrupted emotional circuits may differ in ADHD 
and BPD, potentially explaining differences in response to different treatments. 
Nevertheless, these findings suggest that there could also be common forms of 
treatment in at least a subset of patients with a comparable neurobiological basis for 
emotional dysregulation. 
1.5.5 Genetic and environmental risk factors 
1.5.5.1 Attention-deficit/hyperactivity disorder 
It is firmly established that genetic factors play a central role in the aetiology of 
ADHD. The disorder aggregates among biological relatives of ADHD probands 
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(Epstein et al., 2000; Sprich, Biederman, Crawford, Mundy, & Faraone, 2000), and 
twin studies estimate heritability in the range of 70-80% for parent and teacher 
ratings of ADHD symptoms in children, with similar estimates for clinically 
diagnosed cases of ADHD (Epstein et al., 2000; Sprich et al., 2000). In adults, self-
rating of ADHD symptoms lead to lower heritability estimates in the range of 30-
50% (Brikell, Kuja-Halkola, & Larsson, 2015). However, heritability estimates are 
similar to those seen in children for the clinical diagnosis of ADHD, in adults, or 
when combining parent ratings and self-reports (Brikell et al., 2015; Chang, Zheng, 
Lichtenstein, Asherson, & Larsson, 2013; Larsson, Chang, D’Onofrio, & 
Lichtenstein, 2014). These studies find that the variance in ADHD in both 
childhood and adulthood is best explained by genetic and non-shared 
environmental factors, with no role for shared environmental factors independent 
of genetic influences (Brikell et al., 2015). 
Earlier candidate gene studies found significant associations with genetic variation 
within dopamine and serotonin system genes (Gizer, Ficks, & Waldman, 2009), 
although the specific genes implicated in these earlier studies have not been 
identified in a more recent GWAS. Until recently, GWAS had not identified 
specific genetic variants that increase the risk of ADHD, although heritability due 
to the measured genetic variance was estimated to be around 30% (Middeldorp et 
al., 2016; Neale et al., 2010). The most recent GWAS, using a much larger sample 
of 20,183 ADHD cases and 35,191 controls identified twelve independent loci 
above genome-wide levels of significance   (p< 5x10-8), confirming the existence of 
numerous common variants of small effect that influence the development ADHD 
(Demontis et al., 2017). As these are recent findings, further research examining the 
role of these variants is required. 
1.5.5.2 Borderline personality disorder 
Though not as widely developed as the genetic literature on ADHD, there is a 
growing body of research implicating genetic influences in the aetiology of BPD. 
There is evidence to support familial aggregation of BPD features (Gunderson, 
Zanarini, et al., 2011; Zanarini et al., 2004) and findings from twin studies report 
heritability estimates in the range of 35%-67% (Distel et al., 2010; Reichborn-
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Kjennerud et al., 2013; Torgersen et al., 2012). There is consensus between the 
studies that the remaining variance may be explained by unique rather than shared 
environmental influences, similar to ADHD. 
To date there have been two GWAS studies of BPD. One study dimensionally 
assessed two Dutch cohorts (n= 7125) using the Personality Assessment Inventory-
Borderline Features Scale and found a promising signal on chromosome-5, which 
corresponds to SERINC5, a protein involved in myelination (Lubke et al., 2014). 
Seven single nucleotide polymorphisms (SNP) in this region had p-values between 
3.28x10-6 and 8.22x10-7, which are suggestive findings, but still fall below genome-
wide levels of significance (Lubke et al., 2014). The other more recent and also first 
case-control GWAS study was performed in 998 BPD patients and 1545 psychiatric 
controls (Witt et al., 2017). While gene-based analysis yielded two significant genes 
for BPD, DPYD on chromosome 1 (1.20x10-6) and PKP4 on chromosome 2 
(8.24x10-7), no genome-wide significant association was found for any SNP (Witt et 
al., 2017). To date, these specific findings in BPD do not overlap with the findings 
from ADHD.  
1.5.5.3 Common genetic risk factors for BPD and ADHD  
Though there is evidence for symptom overlap between the two disorders, to date 
only one study has explored whether this could reflect overlapping genetic 
influences. Using a population twin sample, a high phenotypic correlation (r = 0.59) 
was estimated between ADHD symptoms and borderline personality traits; 
consisting of four subscales - affective instability, identity problems, negative 
relationships and self-harm (Distel et al., 2011). The authors found that the 
phenotypic correlation was explained by 49% genetic factors and 51% 
environmental factors, suggesting that shared aetiology could be a cause of 
comorbidity between ADHD and BPD traits (Distel et al., 2011). No further studies 
have been reported to date, although the availability of GWAS means that the data 
to estimate the genetic correlation between the two disorders from SNP data is now 
available.  
Overall, twin studies of ADHD and BPD show a similar pattern of genetic versus 
environmental influences, with slightly higher heritability estimates in most ADHD 
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studies. Yet it is important to note that heritability is also a function of the reliability 
of the measures being used, with the residual non-shared environment including 
measurement error. Heritability estimates from self-reported scales of symptoms are 
similar for ADHD and BPD (Brikell et al., 2015; Distel et al., 2010).  Although for 
both ADHD and BPD there is no evidence for a main effect of shared environment 
(environmental effects shared by co-twins that explain co-twin similarity), shared 
environment may still play a major role through gene by environment interactions. 
It is therefore likely that for both disorders there are genetically-driven individual 
differences in susceptibility to environmental stressors. The relatively high genetic 
correlation between ADHD and BPD is based on the correlation of trait scores in 
the general population, rather than diagnosed cases, but suggests a considerable 
degree of underlying shared aetiology that may explain the frequent co-occurrence 
of ADHD and BPD. Further studies are needed to investigate the genetic overlap 
between the two disorders, but also the overlap with specific symptom domains 
such as emotional dysregulation. 
1.6 Treatment approaches 
1.6.1 Pharmacological  
Treatment approaches to ADHD and BPD are widely divergent. According to 
evidence-based clinical guidelines, in BPD there is limited evidence that 
medications reduce borderline personality symptoms, including emotional 
dysregulation, and psychological treatments are the cornerstone of treatment 
(NICE, 2009). In contrast, in ADHD, there is good evidence for effects of 
medication on reducing ADHD symptoms (Faraone & Glatt, 2010; Meszaros et al., 
2009; Spencer et al., 2005) and emotional dysregulation (Lenzi, Cortese, Harris, & 
Masi, 2017; Moukhtarian, Cooper, Vassos, Moran, & Asherson, 2017), and only 
limited evidence for effects of psychological treatments (NICE, 2008). 
Clinical trials support the safety and efficacy of stimulants (methylphenidate, 
dexamphetamine, lisdexamfetamine) and atomoxetine, with reductions in the 
ADHD symptoms of inattention, impulsivity and hyperactivity, with moderate to 
large effect sizes ranging between .4 and .7 in adults (Castells, Ramos-Quiroga, 
Bosch, Nogueira, & Casas, 2011; Castells, Ramos-Quiroga, Rigau, et al., 2011; 
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Cunill, Castells, Tobias, & Capellà, 2013; Koesters, Becker, Kilian, Fegert, & 
Weinmann, 2009). Pharmacological treatments have been found to improve quality 
of life and daily functioning in addition to ADHD symptoms (Surman, 
Hammerness, Pion, & Faraone, 2013). In addition, several randomised controlled 
trials (RCT) have evaluated the effects of pharmacological treatments on emotional 
dysregulation in ADHD patients, and found comparable treatment responses to the 
primary symptoms of the disorder (Reimherr et al., 2005; Rosler et al., 2010; 
Wender et al., 2011). These findings are further validated by the results of two 
recent meta-analyses that found moderate effects of stimulants (methylphenidate, 
dexmethylphenidate, amphetamines, lisdexamfetamine) and atomoxetine on 
emotional dysregulation in ADHD (average Cohen’s d across studies was around 
0.4) (Lenzi et al., 2017; Moukhtarian et al., 2017). In these studies, emotional 
dysregulation was assessed with various measures including emotional 
dysregulation subscales of the Wender Reimherr Adult Attention Deficit Disorder 
Scale, the Behaviour Rating Inventory of Executive Function, the Conner’s Adult 
ADHD Rating Scales and the Brown Attention Deficit Disorder Scale.  
1.6.2 Non-pharmacological treatments 
In contrast to treatment of ADHD, psychotherapy is regarded as first line treatment 
for people with BPD (American Psychiatric Association, 2013). The most common 
therapies are Dialectical Behaviour Therapy (DBT) (Lynch, Trost, Salsman, & 
Linehan, 2007), Transference-focused Therapy (Kernberg, Yeomans, Clarkin, & 
Levy, 2008), Schema Therapy (Kellogg & Young, 2006), Mentalization-based 
Treatment (Bateman & Fonagy, 2010), Systems Training for Emotional 
Predictability and Problem Solving. DBT is the most intensively studied 
intervention for BPD, and has been shown to significantly reduce anger 
(standardized mean difference (SMD = -0.83) and self-harm (SMD= -0.54), and 
improve overall mental health functioning (SMD= 0.65) (Kliem, Kroger & 
Kosfelder, 2010; Stoffers-Winterling et al., 2012). Not only is psychotherapy 
regarded as first line treatment for BPD, UK NICE guidelines stipulate that 
pharmacological treatments should not be used for managing BPD, nor for 
individual symptoms or behaviours associated with the disorder (NICE, 2009). The 
guidelines recommend the use of pharmacotherapy only as a short-term treatment 
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measure during a crisis or in the instance of co-occurring mental health disorders 
(NICE, 2009). 
Currently, there is insufficient data on the treatment of co-occurring BPD and 
ADHD. With regard to drug treatment, there have been no RCTs of stimulants or 
atomoxetine in BPD alone or in co-occurring ADHD/BPD cases (Moukhtarian et 
al., 2017). 
There have however been only two uncontrolled case reports (Hooberman & Stern, 
1984; Van Reekum & Links, 1994) of successful methylphenidate treatment in 
patients with co-occurring BPD and ADHD, and two open-label studies 
(Golubchik, Sever, Zalsman, & Weizman, 2008; Prada et al., 2015). In one 
adolescent female-only study, patients with co-occurring ADHD and BPD (n=14) 
reported significant improvement of BPD symptom severity (SMD= -1.5) and 
aggressive impulsive behaviour (SMD= -1.31) following treatment with 
methylphenidate for 12 weeks (Golubchik et al., 2008). In a four-week study of 47 
adults looking at effects of methylphenidate in addition to DBT, comorbid 
ADHD/BPD patients who were on stimulant medication (n=24) showed a 
statistically significant improvement in anger control (SMD= 0.14), motor 
impulsiveness (SMD= -0.62), depression (SMD= -1.09) and ADHD severity 
(SMD= -0.5), compared to those without medication (n=23) (Prada et al., 2015). 
Similarly, there are various psychotherapeutic treatments available for adults with 
ADHD, who are either unresponsive to stimulants and/or atomoxetine, or in need 
of adjunctive psychotherapy. There have been two exploratory open label studies 
(Hesslinger et al., 2002; Philipsen et al., 2007) examining effects of psychotherapy 
in adult ADHD. According to the multicentre open label study of 72 patients with 
ADHD, an adaption of DBT, addressing emotion regulation, depression, impulse 
control, stress management, neurobiology of ADHD and ADHD in relationships, 
DBT has a therapeutic benefit for people with ADHD (Philipsen et al., 2007). 
There was a statistically significant decrease on all psychometric measures in the 
study after DBT treatment; SMD= -.74 for the ADHD-Checklist, SMD= -.5 for the 
Beck Depression Inventory (BDI) and SMD= -.34 for the adapted Symptom Check 
List (SCL-16) measuring agitation, disorganised behaviour, emotion dysregulation 
and irritability among other traits (Philipsen et al., 2007). Similarly, in the open 
Introduction  
42 
label pilot study of eight patients with ADHD, an adaption of cognitive behavioural 
therapy led to improvement in the same psychometric elements listed above;      
ES= .99 for the BDI, ES= 2.22 for the ADHD-Checklist and ES= 1.35 for the  
SCL-16 (Hesslinger et al., 2002).   
There have been three RCTs testing the effectiveness of cognitive therapy for 
ADHD (Hirvikoski et al., 2011; Safren et al., 2005; Stevenson, Whitmont, 
Bornholt, Livesey, & Stevenson, 2002) with relatively small sample sizes (n=31, 
n=43 and n=51 respectively). These trials have attempted to investigate the effects 
of psychotherapy (in conjunction with medication in some cases) in adult ADHD 
on severity of ADHD symptoms < d <75.( 1 7. ), depression, anxiety, anger  
control and organisation skills among other outcomes. More recently, a large 
multicentre RCT (n=433) has tested the effectiveness of tailored group 
psychotherapy versus clinical management (CM) reflecting optimal usual clinical 
care, with both groups randomised to methylphenidate or placebo (Philipsen et al., 
2015). While methylphenidate significantly reduced ADHD symptoms compared 
to placebo (p=.003), there were no significant differences in ADHD symptoms for 
those receiving tailored group psychotherapy or CM (p=.160). In fact, in this trial, 
medication proved to be superior to intensive behavioural therapy, yet the latter 
resulted in better outcomes when combined with medication as compared to 
placebo (Philipsen et al., 2015).  
Overall, while DBT modules and other systematically tailored psychotherapies 
appear to be helpful in ADHD, it is not yet clear whether they improve the core 
symptoms of ADHD (inattention, and hyperactivity/impulsivity), and there is 
insufficient data reported for effects on emotional dysregulation in ADHD 
(Corbisiero, Stieglitz, Retz, & Rosler, 2013; Hesslinger et al., 2002; Hirvikoski et 
al., 2011; Philipsen et al., 2015; Philipsen et al., 2007; Safren et al., 2005; Stevenson 
et al., 2002). This needs further investigation, since the evidence to date is based on 
relatively small samples, and there has been only one trial of cognitive behavioural 





Clinical Implications  
In clinical practice, it should be acknowledged that the co-existence of ADHD with 
BPD will complicate the diagnostic process, and hinder treatment outcomes. 
Currently, patients with co-occurring ADHD and BPD are often seen by different 
specialists and provided treatments for one condition or the other, but only rarely 
for both. In fact, there is a lack of empirical data to guide future clinical practice. 
Beyond the issues of differential diagnosis, there is insufficient awareness within 
specialist ADHD and BPD services of the potential benefits of treating the other 
condition. This needs to be addressed because treatment of both conditions may 
have positive benefits for individuals with overall better control of ADHD and BPD 
related symptoms and behaviours. Indeed, open clinical trials indicate the value of 
such a dual treatment approach.  
Commonly in BPD patients with co-occurring ADHD, inattention and so called 
executive function deficits (i.e. sustained attention, forgetfulness, planning, 
organising, working memory), as well as physical restlessness and impatience, lead 
to difficulties in commitment and adherence to psychological therapies (Matthies & 
Philipsen, 2014). For example, this could be manifested in difficulties remaining 
seated, feeling restless and impatient, difficulties focusing on conversations and 
retaining information during therapy sessions, or insufficient planning and 
organisation to regularly attend therapy sessions (Matthies & Philipsen, 2014). 
A further potential benefit in a subpopulation of individuals with co-occurring 
ADHD and BPD may be a reduction in emotional dysregulation and impulsivity 
following medication treatment of ADHD. Similarly, psychotherapeutic 
interventions may be helpful for ADHD cases with high levels of emotional 
dysregulation with partial or no response to ADHD drug treatments, which could 
be accounted for by BPD. 
An important question arising from the literature is the specificity of emotional 
symptoms that are seen in both ADHD and BPD. However, symptoms reflecting 
dysregulation of emotional responses are also seen in other mental health disorders.  
A recent ESM study examined the dynamics of affective instability in patients with 
BPD compared with post-traumatic stress disorder and bulimia nervosa (Santangelo 
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et al., 2014). Using the same ESM protocol, all three conditions showed a similar 
degree of heightened affective instability regarding both the valence of emotional 
changes, and the level of associated distress (Santangelo et al., 2014). Although 
BPD is the only disorder for which emotional dysregulation is part of the core 
diagnostic criteria (American Psychiatric Association, 2013), it is possible that the 
emotional dysregulation present in individuals with BPD may be qualitatively 
distinct from that seen in other clinical groups, particularly in individuals with 
ADHD. 
Given the emerging genetic findings in relation to ADHD and BPD, and the 
overlap of symptoms such as emotional dysregulation, there may be gains from 
comparing the neuro-cognitive underpinnings for ADHD and BPD, as well as 
overlapping symptom domains such as emotional dysregulation. At this stage, 
clinical trials are needed to evaluate the role of both ADHD medication and 
psychotherapy in the treatment of comorbid ADHD/BPD, and to identify 
treatment prognostic indicators. 
1.7 Aims and outline of this thesis 
This chapter reviewed the clinical profiles of ADHD and BPD. It also highlighted 
several areas in which further research is needed. Although it is beyond the scope of 
the current thesis to address all of these, an attempt will be made to shed light on 
several key issues raised. The overall aim of this thesis is to further our 
understanding of the phenotypic association between ADHD and BPD in 
adulthood, using a case-control design. Data presented in chapters three, four and 
five are from the Personality Research in ADHD and Emotional Instability 
(PRIDE) study. The overarching aim of these studies was to investigate whether 
symptoms of BPD and ADHD could be used to distinguish between the two 
disorders. 
Chapter 2 provides a detailed description of the sample and methodology used in 
the PRIDE study.  
In chapter 3, latent class analyses are undertaken to identify mutually exclusive 




based on an empirical analysis of the data rather than using pre-determined DSM-5 
diagnostic criteria. The latent classes are then compared against the clinical groups 
based on DSM classification, and differences in symptom profiles are explored across 
both DSM-5 clinical groups and latent classes.  
Chapter 4 examines the association of mind wandering with ADHD and BPD. 
Although excessive mind wandering has been reported in the ADHD literature, there 
is limited prior data using ESM in daily life, and inattentiveness has been largely 
overlooked in the BPD literature. I address the question of whether patterns of mind 
wandering can be used to distinguish ADHD from BPD.  
In chapter 5, using a similar ESM approach, I investigate the role of emotional 
dysregulation in the differentiation of adult females with ADHD and BPD using 
ESM. The main question addressed is whether the pattern of emotional symptoms is 
similar or different in patients with ADHD and BPD and could therefore be used to 
distinguish the two conditions. 
In chapter 6, I present the results of a systematic review and meta-analysis examining 
the effects of stimulants and atomoxetine on emotional dysregulation in adults. This 
is a key question, as the findings could potentially be used to support the investigation 
of ADHD medications in the treatment of emotional dysregulation in other disorders 
that overlap with ADHD, including BPD.   
Finally, in chapter 7, all the studies presented in this thesis are integrated and a 
critical discussion highlighting the clinical implications of the findings along with 
suggestions for future directions presented. 





2.1 Aim of this chapter 
All data presented in the following three chapters (Chapters 3, 4 and 5) is drawn 
from the PRIDE (Personality Research in ADHD and Emotion instability) study. 
The specific aim of this chapter is to provide an overview of the methodologies used 
including study design, recruitment procedure, research assessment tools,  dna testing 
procedure.  
Although most measures used in the study are outlined in this chapter, these are not 
exhaustive, but limited to those which are used in the studies reported in this thesis. 
Additional questionnaire and experimental data not reported here will be 
incorporated into publications at a later date. 
2.2 Study overview 
2.2.1 Location of study, funding and ethical approval 
The PRIDE study was conducted at the Social, Genetic and Developmental 
Psychiatry (SGDP) Centre at the Institute of Psychiatry, Psychology and 
Neuroscience in conjunction with several National Health Service Trusts. The 
study was funded by Professor Philip Asherson’s departmental research support 
account (PAD-9122). Research ethics approval for this study was granted by the 
National Research Ethics Service Committee London – London Bridge (reference: 
15/LO/1280). Full informed consent was given by all subjects participating in the 
study. 
2.2.2 Design 
The study was a multi-centre case-control study, which included three clinical 
groups and one psychiatrically healthy control group. The study consisted of one 3-
hour research assessment session, followed by 5-day experience sampling 




Since the main aim of the PRIDE study was to investigate similarities and 
differences in attention-deficit/hyperactivity disorder (ADHD) and borderline 
personality disorder (BPD), care was taken to ensure that confounding 
psychopathologies would not compromise the interpretability of results. Therefore, 
strict exclusion criteria were applied to all study groups to ensure that differences 
between participants with and without ADHD and BPD would not reflect co-
occurring psychiatric illnesses, psychoactive medication, neurological conditions or 
substance abuse problems. 
2.3.1 Inclusion and exclusion criteria 
Eligible participants were female adults aged 18-65 years. They had either an 
established (a pre-existing diagnosis by a clinician) or working/research (previously 
undiagnosed patients) diagnosis of ADHD, BPD or comorbid ADHD/BPD 
according to the Diagnostic and Statistical Manual of mental disorders (DSM) 
definitions of the disorders. 
Exclusion criteria for the clinical and control groups were: male gender; not fluent 
in English (to understand or answer detailed questions about mental health 
symptoms); history of bipolar I and II, recurrent depressive episodes, and 
schizophrenia; current Axis I disorders; head injury that have caused long-term 
neurological and behavioural problems; IQ<70 (assessed during the research 
session); and current treatment with mood stabilisers and/or anti-psychotics. 
Participants on stimulant medication for ADHD were asked to come off this 
medication for 48 hours before the baseline assessment and the following five days 
during the experience sampling assessments (see section 2.4.3). Due to the frequent 
drug and alcohol use in ADHD (Bernardi et al., 2012; Fayyad et al., 2007; Kessler 
et al., 2006) and BPD (Fyer, Frances, Sullivan, Hurt, & Clarkin, 1988; Zanarini et 
al., 1998) populations, I excluded individuals with addiction disorders, but not for 
elevated alcohol and drug use (see section 2.4.1.6). 
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2.3.2 Recruitment sources 
2.3.2.1 Control participants 
Control subjects, not meeting criteria for ADHD or BPD, were recruited from 
volunteer databases held at the SGDP, King’s College London, and through 
advertising around the university and within the local community (e.g. community 
centres, supermarkets). Initial contact was made by post, email, or telephone. 
Those who expressed an interest in participating in the study underwent a 
structured telephone screening (Appendix 1) of exclusionary criteria, which 
involved detailed questions assessing previous or current neurological problems, 
mental health problems (including presence, treatment for or diagnosis of anxious, 
depressive and manic/hypomanic symptoms), and drinking and dru esu g  habits. If 
deemed suitable following the telephone screening, they were then booked in for a 
research assessment. 
2.3.2.2 Clinical cases 
Recruitment of clinical cases occurred through seven sources, of which five were 
the following NHS trusts: South London and Maudsley NHS Trust, Camden and 
Islington NHS Trust, Northamptonshire NHS Trust, Leicestershire NHS Trust and 
West London Mental Health NHS Trust. The research team regularly attended the 
clinical team meetings at these NHS trusts to communicate the study to members of 
the healthcare team. Members of the clinical team identified suitable participants 
from their services. Those deemed eligible based on the study’s exclusion/inclusion 
criteria were either given in person or sent by email/post study information sheets, 
a response slip and a stamped addressed envelope by clinicians with the help of a 
member of the PRIDE research team (TRM, DW, KW, JP or RM) who held 
honorary clinical contracts or research passports with the trusts. Where no response 
slip was returned, participants were contacted by telephone to determine their 
interest in participating. Those who expressed an interest in participating in the 
study underwent a structured telephone screening (Appendix 2) of exclusionary 
criteria by telephone. If deemed suitable following the telephone screening, they 
were then booked in for a research assessment. 
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Recruitment was also done through databases of participants who took part in 
previous studies at the SGDP and consented to be contacted again for future 
studies, in addition to self-referrals through advertisements in certain clinics, 
charities and public community spaces (e.g. library, community centres). Initial 
contact in these cases was done by members of the research team (TRM, DW, KW, 
JP or RM) by post, telephone or email, followed by the same procedure outlined 
above. 
Figure 2.1 Flow diagram of recruitment and exclusions 
 
2.3.3 Sample 
2.3.3.1 Clinical diagnosis 
Clinician diagnoses were based on DSM criteria for ADHD and BPD (American 




Screening by telephone (n=137)
Recruitment phase
229 women referred to the study by NHS 
clinics, self-referrals, recruitment 
databases, advertisements
16 individuals excluded 
• Unable to contact: n=2 
• On psychoactive medication: n=3 
• Unable to stop stimulant medication: n=1 
• On anti-depressant (control subject): n=1 
• In recurrent depressive episode: n=3 
• Frequent substance use: n=1 
• Losses to non-attendance: n=5 
7 individuals excluded 
• Not meeting diagnostic criteria for ADHD or 
BPD: n=3 
• On anti-psychotic: n=1 
• Meeting ADHD criteria (control subjects): n=3 
 
Common exclusions 
92 individuals excluded  
• Not interested/unreachable: n=82 
• On psychoactive medication: n=4 
• Unable to stop stimulant medication: n=2 
• Clinician advised not to contact: n=1 
• Hospitalised in-patients: n=2 
• Other medical reason: n=1 
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ADHD symptomatology was assessed using the Diagnostic Interview for ADHD 
in Adults (DIVA). The DIVA is a validated structured interview for the assessment 
of adult ADHD according to DSM-IV diagnostic criteria. It consists of 18 questions 
(nine relating to inattentive symptoms and nine to hyperactive/impulsive), scoring 
the presence/absence of DSM-IV symptoms during both childhood and adulthood 
(Kooij, 2013). Symptom onset and chronicity was established before the age of 12 
(by the presence of “several” symptoms, defined as three or more in the PRIDE 
study) and the presence of more than five symptoms of inattention or 
hyperactivity/impulsivity in adulthood (in accordance with DSM-5 criteria; 
American Psychiatric Association, 2013; Kooij, 2013). They met all other criteria 
for DSM-5 ADHD including pervasive impairments from the symptoms in more 
than one setting.  
BPD diagnosis was established by the presence of a pervasive pattern of instability 
of interpersonal relationships, self-image and affects, and marked impulsivity 
beginning by early adulthood and present in a variety of contexts, as indicated by 
five (or more) of the nine diagnostic symptoms for the disorder in accordance to the 
DSM-5 (Association, 2013; First, Gibbon, Spitzer, Williams, & Benjamin, 1997). 
BPD symptomatology was assessed using the Zanarini rating scale for Borderline 
Personality Disorder (ZAN-BPD). The ZAN-BPD is a semi-structured interview 
that generates a continuous measure assessing borderline psychopathology 
(Zanarini, 2003). Each of the nine items is rated on a five-point anchored rating 
(0=no symptoms to 4=severe symptoms), yielding a maximum score of 36. The 
ZAN-BPD has high internal consistency (Cronbach’s α=.85) and significant test-
retest reliability (p< .001). The ZAN-BPD was used as a proxy for BPD diagnostic 
criteria: a symptom was marked as present if an item had a score of two or above, 
which is equivalent to being rated as ‘threshold or true’ on the Structured Clinical 
Interview for DSM-IV (SCID-II) BPD criteria (First et al., 1997). Therefore, a BPD 
research diagnosis was established when a participant had a score of two or above 




As shown in the recruitment flow diagram (see Figure 2.1), a total of 114 adult 
females were recruited, including 32 with ADHD (Mage= 36.94, SD= 11.54), 19 
with BPD (Mage= 35.37, SD= 11.39), 27 with comorbid ADHD/BPD (Mage= 32.81, 
SD= 13.18) and 36 psychiatrically healthy control participants (Mage= 29.44, SD= 
8.29). 
2.4 Research assessment tools 
The following is an overview of the measures used during the testing session. 
2.4.1 Rating scale measures 
All participants completed a number of measures of everyday symptoms and 
problems during their appointment and at home prior to their assessment. 
2.4.1.1 Emotional dysregulation  
Three questionnaires were used to measure emotional dysregulation.  
The self-rated Affective Lability Scale-Short Form (ALS-SF) (Oliver & Simons, 
2004), comprised of 18 items scored 0-3 (very un-descriptive, rather un-descriptive, 
rather descriptive, very descriptive), measures swift fluctuations from normal 
(euthymic) mood to other emotional modalities including elation, depression, and 
anger (Appendix 3). Previous factor analysis confirmed good fit for three domains 
in the ALS-SF: Anxiety-Depression, Depression-Elation and Anger (Oliver & 
Simons, 2004). Total overall score was used as an outcome variable.  
The Affective Reactivity Index (ARI) measures chronic irritability, defined as a 
mood of easy annoyance and touchiness characterised by anger and temper 
outbursts (Stringaris et al., 2012). It contains six symptom items and one 
impairment item about irritability (Appendix 4). The ARI has shown good internal 
consistency and factorial structure across both clinic and community-based samples 
(Stringaris et al., 2012).  
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The Wender-Reimher Adult Attention Deficit Disorder Scale- Emotional 
dysregulation subscale (WRAADDS-EDS) (Wender, 1995), was administered as an 
interviewer-rated measure to assess temper, affective lability and emotional over-
reactivity (Appendix 5). The WRAADDS shows high internal consistency 
(Cronbach’s α= .78) and good test-retest reliability (r= .96) (Wender, 1995). 
2.4.1.2 Mind wandering 
Self-reported excessive mind wandering was assessed using the Mind Excessively 
Wandering Scale (MEWS) (Mowlem et al., 2016). It consists of 15 items rated on a 
4-point Likert-scale (0=not at all to 3=nearly all the time or constantly) (Appendix 
6  .) The MEWS in adults with ADHD shows good internal consistency (α > .9), and 
high sensitivity (.9) and specificity (.9) (Mowlem et al., 2016). 
2.4.1.3 Functional impairment 
Impairment in major life domains was assessed using the Weiss Functional 
Impairment Rating Scale-Self-report (WFIRS-S), which measures impairments in 
several everyday situations (Appendix 7). These include impairments in the areas of 
family, work, social function, life skills (e.g. managing money, hygiene, 
appearance, sleep, health), self-concept (e.g. feeling about oneself, incompetent) 
and risk-taking behaviours (e.g. drug taking, drinking, aggressive behaviour, illegal 
actions, sexually risky behaviours).  
2.4.1.4 Childhood maltreatment 
The Childhood Trauma Questionnaire (CTQ) is a 28-item self-report questionnaire 
that measures five categories of childhood trauma experience; emotional, physical, 
and sexual abuse, and emotional and physical neglect (Appendix 8). Reliability for 
the CTQ is good with high internal consistency scores. Factor analysis tests on the 
five-factor CTQ model showed structural invariance, which demonstrates good 
validity (Bernstein & Laura, 1998).  
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2.4.1.5 Co-occurring depressive and anxious symptomatology 
Co-occurring depression and anxiety was measured by the Brief Symptom 
Inventory (BSI) (Derogatis, 1993). The BSI is a self-rated measure consisting of 53-
items evaluating psychological distress and psychiatric disorders in nine domains 
including depression and anxiety on a 4-point Likert-scale (0=not at all to 
3=extremely) (Appendix 9). The BSI has good internal reliability of .7 and robust 
test-retest reliability of .68 (Derogatis, 1993).  
2.4.1.6 Alcohol and drug use 
The following two self-report measures (Appendix 10) were administered to check 
for drug and alcohol use and were not used as outcome measures in subsequent 
analyses. Possible alcohol dependence in the last 12 months (i.e. a score of 20 and 
above) was assessed by the Alcohol Use Disorders Identification Test (AUDIT-C), 
an alcohol screen that can help identify individuals who are hazardous drinkers or 
have active alcohol use disorders (abuse or dependence).  It was scored on a scale of 
0 (no alcohol use) to 4 (daily or almost daily) (WHO, 2001). Frequent drug use in 
the last 12 months (i.e. use of recreational drugs several times a week or more) was 
assessed by the Substance Use Checklist (SUC v.1.1), a short screen to identify 
patterns of illegal drug use in the past 12 months measured on a scale of 0 (never 
used) to 5 (several times a day). 
2.4.2 Intellectual function 
Intellectual function was assessed using the Wechsler Abbreviated Scale of 
Intelligence- Second edition (WASI-II). Two subtests (vocabulary and matrix 
reasoning) of the WASI-II were administered to derive an estimate of IQ 
(Wechsler, 2011). 
2.4.3 Experience sampling assessments 
2.4.3.1 Rationale 
Although rating scale and interview measures are frequently used in psychiatry, 
extensive research has now highlighted limitations of retrospective recall. Of 
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particular note is research that identifies different recall biases in psychiatrically ill 
and healthy populations (Ebner-Priemer et al., 2006; Taylor & Brown, 1988). These 
methodological problems can be overcome by observational studies, in which a 
behaviour is elicited and coded, or prospective longitudinal data collection 
measures, such as in experience sampling assessments. Experience sampling 
method (ESM), also called ecological momentary assessment, involves repeated 
assessments over time, erehw  series of immediate reports can be statistically 
summarised to obtain indices of daily experience without relying on participant’s 
memory (Trull et al., 2008), resulting in reduced systematic and random sources of 
measurement error, increased ecological validity and reliability (Bolger, Davis, & 
Rafaeli, 2003), and enhanced generalisability of findings (Ebner-Priemer & Trull, 
2009). Specifically, this methodology lends itself to the investigation of instability or 
change in certain behaviours, which can be measured directly from one moment to 
another in everyday life. 
2.4.3.2 Methodology 
Experience sampling was carried out using an iOS app called MoodMapper, 
designed for the investigation of emotional dysregulation and mind wandering by 
Dr. Celine Ryckaert and Professor Philip Asherson. MoodMapper was uploaded 
onto Apple iPods with all other functions disabled. Participants started the ESM 
phase the day after their research appointment for five consecutive days. Signals for 
the onset of each monitoring period was provided by Vibralite 12 wristwatches that 
were synchronised with the iPods giving silent vibration signals eight times a day, 
at the onset of each rating period. Participants were instructed to complete each 
rating based on the time-period just before the signal. Following the protocol of 
Skirrow and colleagues (Skirrow et al., 2014), signals occurred following a 
pseudorandomised schedule, with a minimum inter-rating interval of 65 minutes 
and a maximum interval of 135 minutes (around 10 hours of data collection each 
day). Start and end times were the same each day. 
In ESM research other response schedules are also widely used, such as fixed 
response schedules (Ebner-Priemer et al., 2006), schedules which include a fixed 
number of random prompts within specific time periods of a day (Solhan, Trull, 
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Jahng, & Wood, 2009), and schedules which include a fixed period of reassessment 
with a shorter random interval (e.g. every hour, with a 5-minute random interval 
(Hoeksma, Oosterlaan, & Schipper, 2004). Since the equipment used in this study 
did not allow for the programming of a randomised response schedule, a 
pseudorandomised, fixed schedule was adopted. This was to facilitate data 
collection that would not be anticipated by the participants, and to enable capture 
data whilst participants were engaging in their normal everyday activities.  
MoodMapper employed continuous analogue scale questions or multiple-choice 
questions (see Figure 2.2 for examples). On questions regarding mood and 
frequency of mind wandering (e.g. “How frustrated do you feel NOW?”, “How 
much is your mind on what you are doing or elsewhere NOW?”), participants 
responded on a numerical scale, with ratings ranging from 0 (not at all) to 100 
(extremely). Additionally, content and awareness of mind wandering, as well as 
good or bad experiences that had occurred to participants during the hour preceding 
each monitoring period (e.g. “Did any good things happen to you in the PAST 
HOUR?”), were assessed by multiple-choice questions. Details of each item used in 
the ESM analyses are presented in subsequent chapters (i.e. mind wandering items 
in chapter 4 and emotion items in chapter 5). 




2.4.3.3 Compliance rates 
To reduce the likelihood of participant bias from self-selection of monitoring 
instances, all reports not completed within 16 minutes after the vibration signal 
were excluded from analysis. Allowing a choice in the self-selection of monitoring 
instances runs the risk of introducing each participant’s bias in selecting some 
instances and overlooking others (Bolger et al., 2003). Compliance rates for each 
participant were obtained by identifying the proportion of monitoring instances 
completed within the 16-minute window.  
Several steps were implemented to promote compliance and were incorporated into 
the testing protocol, including telephone calls to prompt participants when they 
were required to start monitoring, a follow-up call during the monitoring week, 
providing a ‘mood monitoring hotline’ telephone number and e-mail address, and 
an instruction leaflet. Overall compliance was satisfactory across the whole sample 
with a mean of 74.8% and SD of 14.9. 
2.5 Testing procedure 
2.5.1 Initial contact 
Throughout the recruitment process, a strong emphasis was placed on the voluntary 
nature of research participation and ensured full informed consent before 
individuals took part in the study. The study was designed in such a way that for 
cases from clinics, participation would not result in interference with or impact 
adversely on the nature or quality of the clinical care they received. 
Potential clinical participants were approached face to face by a member of the 
clinical care team who briefly explained what the study is about, handing over a 
patient information sheet, and asked if they are willing to have their personal details 
passed onto a member of the research team. Alternatively, potential suitable 
participants identified through the clinics’ databases received an invitation letter 
along with the information sheet, to which they could have responded with their 
details in the post or via email, by a member of the clinical care team. Those who 
did not respond to the initial correspondence within two weeks, were contacted by 
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telephone to ask whether they received the information, had any questions and 
would be interested to take part in the study. Once permission was granted by a 
potential participant, their contact details were passed on to the research team by 
members of the clinical care team. 
For potential participants who had taken part in previous similar studies at the 
SGDP centre, their consent forms were thoroughly checked to make sure they had 
given prior consent to be contacted again in the future, and were then contacted by 
telephone, post or email to briefly explain what the study was about and check 
whether they would be willing to participate. 
Control volunteers, self-referred participants through advertisements or word of 
mouth made initial contact to the research team to enquire further about the study. 
Once a brief summary was given, they were also sent an information sheet and a 
response slip. 
2.5.2 Telephone screening 
Once the research team was given permission from the clinical care team to contact 
individuals or had received confirmation from self-referred or previous volunteers, a 
follow-up call was arranged, and exclusion and inclusion criteria were checked. 
During the telephone call, the project was briefly summarised again, and 
individuals were given the opportunity to ask any questions they may have before 
proceeding to the screening phase. 
All individuals who agreed to proceed to the screening phase were told that 
information collected during the call will be kept confidential and no data will be 
used until the participant attends the research appointment and signs a consent 
form. All subjects then underwent structured telephone screening (Appendix 1 and 
Appendix 2). 
2.5.3 Research assessment 
Those not excluded after the telephone screening were invited for an assessment. 
Participants were sent a letter by post, confirming their agreed appointment date, 
time and location, in addition to a questionnaire booklet, which included the ALS, 
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 ,S-SRIFW CTQ and MEWS (see section 2.4.1 for details of each measure).  
sa erew stnapicitraP ked to complete these and bring them along when attending  
 .tnemtniopp rieht a Participants were also asked to refrain from drinking caffeine and 
 gnimusnoc alcohol on the day of the study and during the preceding night.  
 siht ot snoitcurtsnI effect were included in the appointment confirmation letter  
 yb nevig osla erew dna telephone during appointment reminders. ADHD cases on  
 noitacidem tnalumits were also reminded to stop taking their medication for  
 eht erofe sruoh 84 b assessment.  
At the start of the assessment fully written informed consent was obtained. 
Participants first underwent IQ testing, then the clinical interviews, followed by the 
completion of four self-report questionnaires (BSI, AUDIT-C, SUC, ARI; see 
section 2.4.1 for details of each measure). 
At the end of the testing session, participants were provided with the ESM 
equipment (iPod with MoodMapper app, vibrating wristwatch, as described in 
section 2.4.3, and an instruction leaflet), and were given full instructions and 
training for use. A postage paid envelope was provided for participants to return the 
equipment after completing their monitoring period. 
All participants were compensated for their travel expenses. In addition, all were 
given a monetary incentive upon completion of their monitoring and the return of 
equipment; £50. 
2.6 Preparatory work 
2.6.1 Power calculations 
Our aim was to detect clinically meaningful differences between groups. Given the 
exploratory nature of this study and novel methodologies used, there were no prior 
findings on which I could have based the power analyses. The statistical software 
G*Power 3.0 (Faul, Erdfelder, Lang, & Buchner, 2007) with power set at 80% and 
an alpha set at .05, showed that a sample size of 18 individuals per group, with four 
groups in total, is sufficient to detect effect sizes of .4. 
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2.6.2 Statistical analyses 
For simple group comparisons, normality of data was assessed graphically by 
examining histograms and QQ plots, and with the Shapiro-Wilk statistic. Normal 
or transformed-normal data were tested using univariate ANOVAs.  Data with 
skewed residual distributions that did not normalise with transformations were 
analysed using the Kruskal-Wallis test. Where appropriate, Bonferroni adjusted or 
non-parametric equivalent pairwise comparisons were conducted to discriminate 
which groups differed. 
For the analysis of ESM data in chapters 4 and 5, multilevel models were used ot  
take into account correlated observations nested within individuals, ot dna  
 setar gnitroper ni secnereffid rof tnuocca (individuals with a greater number o dilav f  
 stroper contribute more to the estimation of group means) (Jahn ,.la te g  2008). 
When a predictor varies between and within subject level over time, the coefficient 
for that predictor is a weighted average of the between and within subject 
relationships. It is therefore necessary to separate these variables by rescaling into 
their components at each level. In order to do this, a person-mean centering 
approach was used for all variables to be used as predictors, whereby the mean of a 
variable per individual across subject and time points was subtracted from each raw 
score of that variable (Bolger & Laurenceau, 2013). Moreover, observations from 
the same clusters or groups are usually more identical than observations from 
different clusters. And if they are similar, we can’t use statistical paradigms that 
assume independence, because estimates of variance and consequently p values will 
be incorrect. Mixed models therefore take into account and give an estimate of the 
correlations in the same cluster (Aarts et al., 2014). When there is consistency 
among a cluster’s responses, then there is variation among the clusters’ means. This 
is the between-cluster variance. The ratio of the between-cluster variance to the total 
variance (the sum of between-cluster and within-cluster variability) is called the 
Intra-Class Correlation (ICC) (Heck & Thomas, 2015). I therefore calculated ICC 
for all outcome variables used in the ESM analyses (chapters 4 and 5), and found it 
to be between 30-80%, which is within the acceptable range (Aarts et al., 2014; 
Bolger & Laurenceau, 2013). 
Methods  
61 
Multilevel models were adjusted using Bonferroni and Bonferroni-Holm 
corrections. I investigated group differences in a 2x2-model (ADHD*BPD, 
assuming non-additivity of the ADHD and BPD effects), followed by contrasts 
according to a priori hypotheses defined in each chapter. 
Analyses in subsequent chapters were carried out using STATA (Version 15), SPSS 
(Version 24), SAS University edition- virtualbox and Mplus7. 
Given the large number of subscales used in this study, and therefore the high 
number of statistical comparisons and associated risk of type-I error, all reported p-
values were adjusted for multiple testing using family-wise Bonferroni corrections 
(detailed in subsequent chapters) to maintain α=.05 for all independent tests 
employed in the primary analyses and all subsequent post-hoc comparisons. 
2.6.3 Risks/ethical considerations 
The study was designed in such a way that interruptions with daily routine were as 
limited as possible, reducing the burden associated with participation. More 
specifically, all assessments were grouped into only one research appointment, 
which was held at a location convenient for the participant (i.e. clinics or SGDP). 
The ESM phase was designed in such a way that disruptions to daily function were 
kept to a minimum (i.e. very short questioning sessions, discrete vibrating wrist 
watch to alert subjects, assessment covering only five days and normal waking 
hours). Participants with ADHD already being treated with stimulant medication 
were asked to stop their medication for the week of the ESM. This was an approach 
used in previous research (Skirrow et al., 2014). This was only done with the 
agreement of both the patient and the clinical care team. Short-term drug holidays 
are not uncommon in the clinical management of ADHD and enable patients to 
evaluate how well they are able to manage without their medication (Wilens, 
Morrison, & Prince, 2011). Patients were advised that they could restart medication 
regimens immediately if they felt this to be necessary or if they were advised to do 
so by the clinical care team. 
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Chapter 3: Overlapping symptoms in ADHD and BPD: A comparison of clinical 
profiles by DSM classifications and latent classes  
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3.1 Abstract 
Attention-deficit/hyperactivity disorder (ADHD) and borderline personality 
disorder (BPD) are frequently comorbid and have several overlapping symptoms. 
To contribute to a better understanding of the associations between ADHD and 
BPD, latent class analysis (LCA) was undertaken to identify mutually exclusive 
classes differing in profiles of adult symptoms of ADHD and BPD. First, the latent 
classes were examined in relation to the Diagnostic and Statistical Manual of 
mental disorder 5th edition (DSM-5) classification of ADHD and BPD. Second, the 
latent classes and DSM-5 groups were used to explore the sample’s characteristics 
on different domains of psychopathology. LCA revealed an optimal solution with 
four distinct symptom profiles, mapping on well to the groups pre-defined by the 
DSM classification. All patients with BPD had some ADHD symptoms, and vice 
versa. This study’s findings support the view that emotional dysregulation, mind 
wandering, anxiety, childhood maltreatment and impairments in various domains 
of everyday life reflect non-specific symptoms and outcomes that are seen across 
both disorders and cannot be relied upon to discriminate ADHD from BPD. 
3.2 Introduction 
Attention-deficit/hyperactivity disorder (ADHD), characterised by 
developmentally inappropriate levels of inattention and hyperactivity/impulsivity 
(American Psychiatric Association, 2013), is a common neurodevelopmental 
psychiatric disorder, with symptom onset in childhood (American Psychiatric 
Association, 2013). ADHD persists into adulthood in around two thirds of 
childhood cases, with a prevalence in adults of around 2.5-4% (Fayyad et al., 2007; 
Kessler et al., 2006). Up to 78% of adults with ADHD present with other DSM-5 
disorders such as mood and anxiety disorders, and substance-use disorders (Kessler 
et al., 2006; Wilens, Biederman, & Spencer, 2002), but relatively little attention has 
been given so far on the overlap of ADHD with personality disorders, notably 
borderline personality disorder (BPD). 
BPD is a complex psychiatric disorder, that has a general population prevalence 
between 1.4% and 6% (Coid, Yang, Tyrer, Roberts, & Ullrich, 2006; Grant et al., 
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2008; Lenzenweger, Lane, Loranger, & Kessler, 2007), and around 20% within 
inpatient psychiatric settings (American Psychiatric Association, 2013; Grant et al., 
2008). BPD is characterised by pervasive patterns of unstable interpersonal 
relationships, pronounced impulsivity, unstable identity, and difficulties with 
emotional dysregulation and anger control (American Psychiatric Association, 
2013), substantially affecting one’s quality of life and psychosocial functioning 
(Gunderson et al., 2011). 
ADHD and BPD have many overlapping features, impulsivity and emotional 
dysregulation being the most apparent ones (Asherson et al., 2014; Moukhtarian, 
Mintah, Moran, & Asherson, 2018). These shared features of trait-like symptoms 
that characterise both ADHD and BPD make differential diagnosis challenging. 
Moreover, given the lack of validated objective biomarkers with sufficient 
specificity in clinical practice that would distinguish aetiologically distinct mental 
health conditions, it remains unclear whether ADHD and BPD reflect qualitatively 
distinct disorders, or overlapping syndromes (Vella, Aragona, & Alliani, 2000). 
Furthermore, the phenotypic and aetiological heterogeneity of both ADHD and 
BPD leads to difficulties in clearly defining which characteristics are related to the 
same underlying susceptibility, and which are not (van Dijk, Lappenschaar, Kan, 
Verkes, & Buitelaar, 2011). 
To better understand the similarities and differences between ADHD and BPD, 
latent class analysis (LCA) was carried out on a sample of females selected for 
DSM-5 ADHD, BPD and comorbid ADHD/BPD, as well as healthy controls, to 
identify exclusive classes of subjects with homogenous symptom profiles related to 
ADHD and BPD. LCA is a statistical technique used for exploratory and 
hypothesis-generating purposes (McCutcheon, 1987). Exploration of 
symptomatology using this empirical approach has the major advantage of not 
losing valuable information (i.e. in the DSM classification those who score just 
below the diagnostic threshold are regarded as non-cases, whereas this may not be 
the case using LCA). 
This empirical approach to classification was taken as the DSM-5 approach for 
both ADHD and BPD uses symptom count thresholds, which are to some extent 
arbitrary. Some cases fall just below DSM-5 symptoms thresholds and could 
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therefore be considered subthreshold to the full DSM-5 criteria, but still reflecting 
the same underlying disorder. The aim was to compare the DSM-5 classification of 
individuals to the LCA classification and apply both classification approaches to 
the investigation of symptoms and behaviours associated with both disorders.    
The current study reports data from an adult female sample with DSM-5 ADHD, 
BPD, comorbid ADHD/BPD and a healthy control group. Participants were tested 
using validated rating scales and interviews of psychopathology. I specifically 
aimed to: (1) classify female patients with different profiles of adult symptoms of 
ADHD and BPD into homogenous subsamples; (2) examine the latent classes in 
relation to the DSM-5 classification of ADHD and BPD; and (3) compare ADHD 
and BPD on different domains of psychopathology, first using the clinical groups 
based on DSM-5 diagnostic classification and then the latent classes. 
3.3 Methods 
3.3.1 Sample 
114 females aged 18-65 years participated in this study. Clinical cases were 
recruited from several ADHD and borderline personality specialist clinics in South 
and North London and the Midlands regions of England. Healthy controls were 
recruited from volunteer databases, and through advertisements in King’s College 
London and within the local community. Recruitment is detailed in Chapter 2 
(section 2.3). 
The National Research Ethics Service Committee London – London Bridge, 
granted research ethics approval for this study (reference: 15/LO/1280).  All 
subjects participating in the study gave full informed consent. 
3.3.2 Diagnostic and symptom measures 
ADHD and BPD were assessed by the Diagnostic Interview for ADHD in Adults 
(DIVA) and the Zanarini rating scale for Borderline Personality Disorder (ZAN-
BPD) respectively. For further details on diagnosis refer to section 2.3.3.1 in 
Chapter 2. 
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Emotional dysregulation was assessed using two self-rated questionnaires and one 
interview measure:  
The self-rated Affective Lability Scale-Short Form (ALS-SF) (Oliver & Simons, 
2004), comprised of 18 items scored 0-3 (very un-descriptive, rather un-descriptive, 
rather descriptive, very descriptive), measures swift fluctuations from normal 
(euthymic) mood to other emotional modalities including elation, depression, and 
anger (Appendix 3).  
The Affective Reactivity Index (ARI) measures chronic irritability, defined as a 
mood of easy annoyance and touchiness characterised by anger and temper 
outbursts (Stringaris et al., 2012). It contains six symptom items and one 
impairment item about irritability (Appendix 4).  
The Wender-Reimherr Adult Attention Deficit Disorder Scale- Emotional 
Dysregulation Subscale (WRAADDS-EDS), administered as interviewer-rated 
measure, assesses temper, affective lability and emotional over-reactivity (Wender, 
1995) (Appendix 5). 
Impairment in major life domains was assessed using the Weiss Functional 
Impairment Rating Scale-Self-report (WFIRS-S), which measures impairments in 
several everyday situations. These include impairments in the areas of family, social 
function, life skills (e.g. managing money, hygiene, appearance, sleep and health), 
self-concept (e.g. feeling bad about oneself, incompetent), and risk-taking 
behaviours (e.g. drug taking, drinking, aggressive behaviour, illegal actions, and 
sexually risky behaviours) (Appendix 7). 
Anxiety and depression symptoms were assessed by the Brief Symptom Inventory 
(BSI) (Derogatis, 1993). The BSI is a self-rated measure consisting of 53-items 
evaluating psychological distress and psychiatric disorders in nine domains 
including depression and anxiety on a 4-point Likert-scale (0=not at all to 
3=extremely). Given the significant co-occurrence of depressive and anxious 
symptomatology in both ADHD and BPD populations (Cumyn, French, & 
Hechtman, 2009; Zanarini, Gunderson, Frankenburg, & Chauncey, 1989), 
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excluding individuals presenting with these symptoms would have made our 
findings unrepresentative of the ADHD and BPD populations (Appendix 9). 
Childhood maltreatment was assessed using the Childhood Trauma Questionnaire 
(CTQ), which is a 28-item self-report screening questionnaire measuring five 
categories of childhood maltreatment: emotional, physical, and sexual abuse, and 
emotional and physical neglect (Bernstein & Laura, 1998) (Appendix 8). 
Intellectual function was assessed using the Wechsler Abbreviated Scale of 
Intelligence- Second edition (WASI-II). Two subtests (vocabulary and matrix 
reasoning) of the WASI-II were administered to derive an estimate of Intelligence 
Quotient (IQ) (Wechsler, 2011).  
3.3.3 Statistical analyses 
3.3.3.1 Latent class analysis 
LCA was used as an empirical method to find the smallest number of groups of 
individuals (i.e., classes) with similar patterns of symptoms and classify them into 
homogenous sub-groups. Instead of using predefined criteria for the presence or 
absence of a disorder, LCA uses ratings of subjects on several symptoms and 
describes the probabilities of a set of observed categorical variables across groups of 
individuals. Individual differences in response patterns are explained only by 
differences in latent class membership, where each class shows a class-specific 
response profile (Geiser, 2010). 
For this study, to identify distinct clinical subgroups, LCA was performed using 18 
adult ADHD items (9 inattentive and 9 hyperactive/impulsive) from the DIVA 
(Kooij, 2013) and 9 BPD items from the ZAN-BPD (Zanarini, 2003) as class 
indicators. All items on the DIVA were scored as present or absent. Given that the 
ZAN-BPD is a continuous measure of borderline personality symptom severity (as 
explained in chapter 2 section 2.3.3.1) a symptom was marked as present if an item 
had a score of two or above, equivalent to ‘threshold or true’ on the Structured 
Clinical Interview for DSM-IV (SCID-II) BPD criteria (First, Gibbon, Spitzer, 
Williams, & Benjamin, 1997); otherwise was marked as absent. 
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Calculations were made with Mplus (Muthén & Muthén, 2006). Mplus provided 
several decision parameters of which the Bayesian Information Criter noi  (BIC) 
and the Akaike Information Criter noi  (AIC) likelihood ratio tests were used in the 
exploratory phase of the analysis, with lower numbers indicating a better fit. The 
BIC is a measure of the goodness of fit of a model that considers the number of 
parameters and the number of observations, whilst the AIC only considers the 
number of model parameters (Nylund, Asparouhov, & Muthén, 2007). The data 
were analysed with an increasing number of classes until there was no 
improvement in any of the decision criteria (i.e., lower BIC and AIC values). A 
small number of candidate models were thus identified for further analysis with the 
bootstrap likelihood ratio test (BLRT), relative entropy and interpretability. The 
BLRT, which is the most sensitive index to identify the correct number of classes, 
examines whether there is significant improvement in model fit when estimating k 
classes relative to the k − 1 class. The BLRT has better type I error and finds the 
right number of classes better than BIC (Nylund et al., 2007). The entropy of a 
model is a measure of classification uncertainty between 0 and 1, with values near 
one indicating high certainty in classification and values near zero indicating low 
certainty (Nylund et al., 2007). All analyses were run with several different starting 
values to minimise the influence of local extremes. 
For the LCA model, 18 ADHD (9 inattention and 9 hyperactivity/impulsivity) plus 
9 BPD variables were used, with a sample size of n=114. The class memberships 
were then compared to the original group membership (i.e. DSM-5 classification of 
ADHD only, BPD only or ADHD plus BPD, and controls). 
3.3.3.2 Group comparisons 
Analyses were completed in SPSS 24, with a nominal level of significance set at 
p<.05. Bonferroni correction was implemented where multiple comparisons were 
carried out. There were 18 different outcome measures, of which six were highly 
correlated (see Table 3.1). The Bonferroni adjusted p-value to account for multiple 
testing was therefore held at p=.004, accounting for 12 independent measures. 
Rating scale data were not normally distributed across the whole sample for all 
variables except IQ and total mean scores for the ALS, and therefore group 
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comparisons for all other variables were carried out using non-parametric Kruskal-
Wallis tests1, followed by Bonferroni adjusted post-hoc tests where appropriate. 
Table 3.1 Pearson correlation coefficients between outcome measures 
 BSI_Depression BSI_Anxiety ARI ALS WRAADDS-
EDS 
MEWS 
BSI_Depression - 0.8 0.7 0.7 0.7 0.6 
BSI_Anxiety 0.8 - 0.7 0.8 0.8 0.7 
ARI 0.7 0.7 - 0.7 0.8 0.7 
ALS 0.7 0.8 0.7 - 0.8 0.7 
WRAADDS-EDS 0.7 0.8 0.8 0.8 - 0.8 
MEWS 0.6 0.7 0.7 0.7 0.8 - 
All correlations are significant at the p<.001 level (2-tailed) 
Note: BSI, Brief Symptom Inventory; ARI, Affective Reactivity Index; ALS, Affective Lability 
Scale; WRAADDS-EDS, Wender-Reimherr Adult Attention Deficit Disorder Scale- Emotional 
Dysregulation Subscale; MEWS, Mind Excessively Wandering Scale. 
3.4 Results 
3.4.1 Fit statistics and identification of the best fitting class solution 
I estimated models with two through five latent classes of adult symptoms of 
ADHD and BPD. The BIC values and corresponding number of free parameters 
were 3302.6 (55), 3111.2 (83), 3103.3 (111), 3168.8 (139), respectively. The 
minimum BIC was found for the 4-class solution (see Table 3.2), suggesting that 
this is the preferred solution. The BLRT also found that the 4-class solution 
provided a significant improvement relative to the 3-class solution. Additionally, 
despite the BLRT for the 5-class solution showing that it provided a better fit than 
the 4-class solution, the best likelihood value was not replicated in 38 out of 49 
bootstrap draws, making the p-value untrustworthy to a local maximum. 
Additionally, the small sample size of 114 individuals, along with 27 variables, 
requires the average number of individuals within a class to be equal to at least the 
number of variables used in the model (Nylund et al., 2007), making solutions more 
than four classes invalid. Based on the fit indices in Table 3.2 along with theoretical 
justification I adopted the 4-class solution. 
                                                 
1 Other transformations such as inverse, square root and log did not normalise data. 
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Table 3.2 LCA fit statistics for 2-5 class models 
Classes LL BIC Adjusted BIC AIC Parameters BLRT Entropy 
2 -1521.06 3302.61 3128.77 3152.12 55 964.15* 1 
3 -1359.05 3111.20 2848.86 2884.10 83 324.02* .98 
4 -1288.79 3103.29 2752.46 2799.57 111 140.52* .98 
5 -1255.23 3168.79 2729.46 2788.46 139 67.11*  .99 
*p<.001; Bold text designates the best fitting model. 
Note: LL, Log-likelihood value; BIC, Bayesian Information criteria; AIC, Akaike Information 
Criteria; BLRT, bootstrap likelihood ratio test. 
3.4.2 Characteristics of the 4-class model 
A visual plot of class probabilities is shown in Figure 3.1 
Class 1 (n=36/114) accounted for 31.6% of the sample and demonstrated overall 
the lowest probabilities for all items. Class 1 will be referred to as ‘control-LC’. 
Class 2 (n=30/114) accounted for 26.3% of the sample and showed high 
probabilities for the inattentive symptoms of ADHD, intermediate to high 
probabilities for hyperactive/impulsive symptoms of ADHD, and very low 
probabilities for most BPD symptoms, except for two; “affective instability” (.47) 
and “self-damaging impulsivity” (.41). This class therefore reflects individuals with 
a diagnosis of ADHD, who also ha ev  a high probability of the two most 
commonly overlapping symptoms with BPD; affective instability and impulsivity. 
Note that although affective instability is not defined as a core symptom in the 
DSM-5 classification of ADHD, it is recognized as a characteristic feature that 
supports the diagnosis of ADHD (American Psychiatric Association, 2013). Class 2 
will be referred to as ‘ADHD-LC’. 
Class 3 (n=27/114) accounted for 23.7% of the sample and showed intermediate to 
high probabilities for both ADHD and BPD symptoms. This class reflects 
individuals meeting diagnosis for both ADHD and BPD, originally identified as 
comorbid ADHD/BPD cases. Class 3 will be referred to as ‘comorbid-LC’. 
Lastly, class 4 (n=21/114) accounted for 18.4% of the sample and demonstrated 
high probabilities for BPD symptoms, low probabilities for inattentive symptoms of 
ADHD except for “difficulty sustaining attention” (.62), and low probabilities for 
hyperactive/impulsive symptoms of ADHD except for “feeling restless” (.72). Class 
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4 represents cases with a diagnosis of BPD, yet also having a high probability for 
overlapping symptoms of ADHD, such as sustained attention and feeling restless. 
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3.4.3 Class membership compared to DSM-5 diagnosis 
The relationship between latent class memberships and DSM-5 diagnoses for the 
female sample in siht  study are summarised in Figure 3.2. 
The individuals identified in the control-LC (n=36) correspond exactly to the same 
individuals identified in the control group, who did not meet criteria for a clinical 
diagnosis.  
Patients diagnosed with DSM-5 ADHD only (n=32), were mostly categorised in 
the ADHD-LC (n=29), reflecting intermediate to high probabilities for ADHD 
symptoms and low probabilities for BPD symptoms. Three individuals with DSM-5 
ADHD only were placed in the comorbid-LC. These three individuals had the 
following four symptoms of BPD marked as present; “inappropriate, intense anger 
or difficulty controlling anger”, “affective instability”, “self-damaging impulsivity” 
and “unstable and intense interpersonal relationships”, making them sub-threshold 
cases for BPD based on the DSM-5 definition of the disorder.  
Of the patients meeting DSM-5 criteria for BPD (n=19), 15 individuals were placed 
in the BPD-LC, marked primarily by high probabilities for BPD symptoms, and 
low probabilities for ADHD symptoms, with the exception of two items. The 
remaining four individuals were placed in the comorbid-LC, two of which reported 
less than three symptoms of ADHD in childhood, and therefore did not meet 
DSM-5 ADHD diagnostic criteria, which requires several symptoms before the age 
of 12 years, defined as three or more in this study (see section 2.3.3.1 in chapter 2 
for more details). This could potentially reflect inaccurate retrospective recall, since 
the study had no prospective or informant data on childhood ADHD to clarify this 
point. One other patient could not provide information about her childhood2 and 
was treated as having no childhood symptoms; and one other reported four adult 
symptoms in each domain of inattention and hyperactivity/impulsivity making her 
sub-threshold to the DSM-5 adult ADHD criteria of five or more in either domain.  
                                                 
2 This patient could not provide any information for childhood symptoms. She met criteria for 
current/adult symptoms (more than five in the domains of inattention and 
hyperactivity/impulsivity), but DSM-5 also requires the presence of several childhood ADHD 
symptoms. She was therefore classified as a BPD case, without ADHD diagnosis. 
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Finally, of the 27 individuals who met DSM-5 criteria for both ADHD and BPD, 20 
showed up in the comorbid-LC, as comorbid ADHD/BPD cases. Six participants 
were placed in BPD-LC, reflecting predominantly a BPD diagnosis. These 
individuals met DSM-5 criteria for both BPD and ADHD yet were placed in the 
BPD-LC. They all had five or less inattentive symptoms and more severe BPD 
symptoms, which could explain their belonging to the BPD-LC, reflecting 
predominantly a BPD diagnosis. In this study, individuals with a DSM-5 ADHD 
diagnosis, who were mostly placed in the ADHD-LC, had a greater number of 
inattentive symptoms and met criteria for the predominantly inattentive presentation 
of ADHD, with less severe hyperactivity/impulsivity symptoms. 
Figure 3.1 Distribution of DSM-5 diagnostic categories across latent classes (LC) 
 
3.4.4 Characteristics of DSM-5 diagnostic groups and the adult latent 
classes 
In the following sections comparing the diagnostic and LCA groups across a range 
of measures, there were similar findings for both the DSM-5 and LCA classifications. 
Given that the latent classes mapped onto well to the DSM-5 classifications, the 
findings are presented first for the DSM-5 classification, and then any differences 
with the LCA classification are indicated. The characteristics of the sample on 
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Age and IQ: 
The DSM groups significantly differed in age, X2(3) = 9.2, p=.027 (Mean in years 
(SD): control=29.44 (8.29); ADHD=36.94 (11.54); BPD=35.37 (11.39); 
ADHD/BPD=32.81(13.18) and IQ, F (3,109) = 7.07, p<.001 (Mean (SD): 
control=108.86(9.84); ADHD= 106.03(13.51); BPD= 97.05(13.82); ADHD/BPD= 
96.73(12.71).  
The latent classes were matched on age X2(3) = 7.75, p=.051, but also differed in 
IQ, F (3, 109) = 9.67, p<.001 (Mean (SD): control-LC=108.86(9.84); ADHD-LC= 
106.13(13.89); BPD-LC= 102.43(11.53); comorbid-LC= 92.96(12.56). 
3.4.4.1 ADHD and BPD symptom severity 
DSM-5 classification: 
Significant group differences were present for current ADHD symptoms (X2(3) = 
85.3, p<.001). Post-hoc analyses indicated that all three clinical groups had 
significantly more current ADHD symptoms than the control group (p<.05). 
Additionally, the ADHD and comorbid ADHD/BPD groups had significantly 
higher ADHD symptoms than the BPD group (p<.05), whereas no significant 
differences were seen between the ADHD and comorbid ADHD/BPD groups 
(p=1). After adjustment for multiple testing (p=.004), differences between the 
control group and the BPD group, as well as comorbid ADHD/BPD and BPD 
groups were no longer significant. 
Ratings on the ZAN-BPD showed significant group differences, X2(3) = 96.52, 
p<.001. All three clinical groups had elevated borderline personality symptoms 
compared to controls (p≤.001). The ADHD group had significantly lower (p≤.001) 
borderline personality symptoms compared to both the BPD and comorbid 
ADHD/BPD groups, who showed no differences between each other on the 
measure (p=1). All comparisons remained robust to Bonferroni correction (adjusted 
p=.004). 
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LCA classification: 
Results were similar using the LCA classifications. For current ADHD symptoms, 
in addition to the parallel results found with the DSM diagnostic groups, a 
Bonferroni adjusted significant difference was also found between comorbid-LC 
and BPD-LC (p<.001). Regarding borderline symptomatology, the results of the 
latent classes matched the DSM group comparisons.  
3.4.4.2 Emotional dysregulation 
DSM-5 classification: 
Significant group differences were detected for the ALS-SF (X2(3) = 65.66, p<.001), 
WRAADDS-EDS (X2(3) = 79.99, p<.001) and ARI (X2(3) = 60.27, p<.001). All 
three clinical groups reported significantly elevated levels of emotional 
dysregulation on all measures compared to controls (p<.001), and these significant 
differences were robust to the adjusted p=.004. Additionally, no differences were 
detected between the ADHD and BPD groups, as well as the BPD and comorbid 
ADHD/BPD groups on all three measures (p>.05). The ADHD group reported 
significantly lower levels of emotional dysregulation on all three scales compared to 
the comorbid ADHD/BPD group (p<.05), which was not robust to the Bonferroni 
adjusted p=.004. 
LCA classification: 
Regarding case-control differences, the latent classes displayed an equivalent 
picture compared to the DSM-5 diagnostic groups on all three measures. 
Differences between clinical latent classes also matched to the DSM group 
comparisons. Regarding the ARI and WRAADDS-EDS, in addition to the 
matching results obtained from DSM group comparisons, after Bonferroni 
correction for multiple testing (adjusted p=.004), the difference between ADHD-LC 
and comorbid-LC remained significant (p≤.001). 
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3.4.4.3 Co-occurring depression and anxiety 
DSM-5 classification: 
There were significant group differences on depression, X2(3) = 75.90, p<.001 and 
anxiety, X2(3) = 79.96, p<.001. Post-hoc tests showed elevated self-reported 
depression and anxiety in the clinical groups compared to controls (p<.05). 
Additionally, the ADHD group showed less anxiety and depression compared to 
both BPD and comorbid ADHD/BPD groups, yet no differences were seen 
between the BPD and comorbid ADHD/BPD groups. Except for the depression 
subscale between the control and ADHD groups, and the anxiety subscale between 
the ADHD and BPD groups, comparisons were robust to the Bonferroni adjusted 
p=.004. 
LCA-classification: 
Regarding latent classes, all comparisons were analogous to the DSM group 
comparisons, except for the anxiety subscale between the ADHD and BPD groups 
not showing any significant differences. 
3.4.4.4 Childhood trauma 
DSM-5 classification: 
Ratings on different domains of childhood maltreatment showed significant group 
differences for physical abuse, X2(3) = 25.97, p<.001, emotional neglect, X2(3) = 
35.03, p<.001, emotional abuse, X2(3) = 44.59, p<.001, physical neglect, X2(3) = 
36.49, p<.001 and sexual abuse, X2(3) = 27.45, p<.001. The control group reported 
significantly less emotional abuse than the ADHD group (p=.004), which was 
robust to Bonferroni adjustment (p=.004). Differences between the control and 
ADHD groups on all other subscales of childhood maltreatment were non-
significant. Both BPD and comorbid ADHD/BPD groups significantly differed 
from controls, reporting more severe childhood trauma in all five domains, and all 
differences were robust to the Bonferroni corrected p=.004. 
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Regarding comparisons in the clinical groups, there were no differences in any 
domain of childhood trauma between the BPD and comorbid ADHD/BPD groups 
(p=1). The ADHD and BPD groups only differed in the domain of physical neglect 
(p=.036), with the latter reporting more severe physical neglect, but this difference 
was not robust to the Bonferroni corrected p=.004. Finally, the ADHD and 
comorbid ADHD/BPD groups were significantly different in all domains of 
childhood trauma, apart from physical abuse, but differences were robust to 
Bonferroni correction, only in the domains of physical neglect and sexual abuse 
(p<.004). 
LCA-classification: 
Regarding the latent classes, the comparisons between the control-LC and the other 
latent classes reflecting a clinical diagnosis all displayed a similar picture compared 
to the case-control differences found in the DSM group comparisons. There were 
some differences between the ADHD-LC and comorbid-LC, as well as between 
ADHD-LC and BPD-LC, yet none were robust to Bonferroni correction. 
3.4.4.5 Mind wandering 
The DSM groups significantly differed on the MEWS, X2(3) = 69.30, p<.001. Post-
hoc tests revealed that all three clinical groups reported more frequent mind 
wandering than the control group (p<.001) but were not significantly different from 
one another.  
An equivalent picture was displayed by the latent class. 
3.4.4.6 Functional impairment 
DSM-5 classification:  
Ratings in different domains of impairment showed significant group differences for 
family, X2(3) = 49.95, p<.001, social function, X2(3) = 70.25, p<.001, life skills, 
X2(3) = 66.92, p<.001, self-concept, X2(3) = 74.48, p<.001, and risk-taking 
behaviours X2(3) = 32.39, p<.001. The clinical groups reported significantly 
elevated impairment on all five subscales of the WFIRS-S (family, social function, 
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life skills, self-concept, risk-taking behaviour) compared to the control group 
(p<.05). With the exception of the risk-taking behaviour subscale between the 
control and BPD groups (p=.006), all differences were robust to the Bonferroni 
corrected p=.004. There were no significant differences between the BPD and 
ADHD groups, as well as the BPD and comorbid ADHD/BPD groups (p>.05) in 
all five domains of functional impairment. The ADHD group showed significantly 
less impairment in the domains of family and self-concept, with the latter only 
being robust to Bonferroni correction. 
LCA classification: 
Regarding case-control differences, a similar picture to the DSM group 
comparisons was displayed by the latent classes. Regarding comparisons between 
clinical latent classes, in addition to the non-significant differences between BPD-
LC and ADHD-LC, as well as BPD-LC and comorbid-LC which was also 
comparable to the DSM group comparisons, the ADHD-LC reported significantly 
less impairment in the domains of family (p=.008), social (p=.005) and self-concept 
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3.5 Discussion 
This study investigated the phenotypic overlap between ADHD and BPD. The 
main aim was to explore the similarities and differences between female patients 
with ADHD, BPD, comorbid ADHD/BPD and healthy controls on various 
measures of psychopathology. The DSM-5 approach to classification for both 
ADHD and BPD relies on symptom count thresholds, which are to some extent 
arbitrary, given that both disorders reflect impairing extremes of dimensional traits 
(Chen et al., 2008; Clark, 2007). Therefore, LCA was undertaken as an empirical 
approach to classification, and results were compared using both DSM-5 and LCA 
defined clinical groups. 
The LCA and DSM-5 diagnostic classification groups cross-validated well. Despite 
the overlap of certain symptoms in ADHD and BPD, the DSM-5 criteria, that relies 
on clusters of symptoms by applying symptom count thresholds, appears to be 
specific enough to delineate the disorders from one another in a similar way to the 
more empirical approach using LCA, indicating the validity of the constructs used. 
Regarding the LCA, the results indicated that the four-class solution best fits the 
data, which was identical to the number of groups participants were classified in by 
using predefined DSM-5 criteria. Furthermore, the number of individuals classified 
in each latent class was similar to the number of individuals in the pre-defined 
DSM groups, with only very few cross-over of cases. 
Regarding the characteristics of the sample, overall the results indicated that the 
empirical and DSM-5 diagnostic approaches gave comparable results. One class 
(control-LC) had the lowest probability for all clinical symptoms, thus referring to 
the healthy control group. The other three classes all had a mixture of ADHD and 
BPD symptoms with varying probabilities. One class (ADHD-LC) had 
predominantly symptoms of inattentive ADHD, with less severe symptoms of 
hyperactivity/impulsivity, and a very low occurrence of BPD symptoms, except for 
affective instability (criterion 6 of BPD) and impulsivity (criterion 2 of BPD). One 
class (comorbid-LC) had symptoms of the combined type of ADHD together with 
symptoms of BPD. And the last class (BPD-LC) had a high BPD symptoms 
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probability combined with symptoms of inattention and hyperactivity/impulsivity 
to different degrees. In fact, symptoms of BPD were not found to occur without at 
least some ADHD symptomatology, and vice versa.  
These findings are not in line with the only other latent class study results of 
ADHD and BPD females, where the model resulted in one class of patients with a 
primary diagnosis of ADHD and no symptoms of BPD (van Dijk et al., 2011). 
Some significant methodological differences could explain the discrepancies. In the 
current study, comorbid axis I or II disorders were excluded to associate significant 
findings to ADHD or BPD, rather than other co-occurring conditions. 
Comorbidities, other than schizophrenia, were not excluded in van Dijk et al.’s 
study, in addition to having a bigger clinical sample size of 103 patients compared 
to 78 in the current study. 
When examining further the symptom probabilities of the latent classes, it appeared 
that all three LCA classes reflecting a clinical diagnosis could not be easily 
distinguished on the amount of ADHD symptoms. Specifically, 
hyperactivity/impulsivity symptoms had higher probabilities than inattentive 
symptoms in the BPD-LC, indicating the relative lack of specificity and broad 
formulation of the hyperactivity/impulsivity criteria in the DSM-5 (e.g. “fidgeting 
and often restless”, “feeling restless”). These hyperactivity/impulsivity symptoms 
were found to be less specific to the latent classes compared to symptoms of BPD, 
which had much lower probabilities in the ADHD-LC, with the exception of 
“affective instability and “impulsivity” (both commo yln  associated features of 
ADHD). 
The fact that the three LCA classes incorporating the clinical cases had symptoms 
of both diagnoses to varying degrees, illustrates the heterogenous profile of ADHD 
and BPD, and their comorbid and overlapping picture (Philipsen, 2006; Philipsen et 
al., 2009). 
Regarding the rating scale and interview measures, increased levels of emotional 
dysregulation, depression and anxiety, mind wandering, functional impairment, 
and current ADHD and BPD symptoms were seen in all three clinical groups 
compared to controls, whether defined using DSM-5 or LCA. 
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Regarding childhood maltreatment, the BPD and comorbid ADHD/BPD groups 
reported significantly more severe childhood abuse and neglect compared to 
controls, but non-significant differences compared to the ADHD group. However, 
no differences were seen between the ADHD and control groups. This is explained 
by the fact that mean ranks of the childhood trauma subscales for the ADHD group 
were intermediate between the control and BPD groups. To explain these 
differences further, a larger sample is required to clarify whether CTQ scores for the 
ADHD group are similar to the BPD group, the control group, or are indeed 
intermediate with differences from both controls and BPD. 
A key aim of this thesis was to investigate cross-disorder similarities and differences 
between patients meeting clinical criteria for ADHD and BPD. By taking an 
exploratory approach, I hypothes si ed that some symptoms such as emotional 
dysregulation or mind wandering might show differences across the disorders; for 
example, with higher levels of mind wandering in ADHD than BPD. However, the 
results presented in this chapter using rating scale measures of psychopathology 
show either no difference or only subtle differences between the disorders across a 
wide range of measures. In particular,  evitcepsorter self-report measures of mind  
 dna gnirednaw emotional dysregulation were not able to distinguish the two clinical 
 htiw ,sredrosid elevated ratings seen in both. These two findings provide a basis  
 deliated erom a rof investigation using experience sampling method in chapters four 
 siht fo evif dna thesis.  
 
 
Regarding childhood trauma, this study suggests that trauma is not only related to 
BPD (Golier et al., 2003; Zanarini & Frankenburg, 1997), but also to ADHD, as 
previously reported (Ferrer et al., 2017). There were no significant differences 
between the disorders on all subscales of the CTQ. Although, as discussed above, 
small differences in exposure to trauma may emerge in larger datasets, these may be 
relatively subtle and insufficient to discriminate one condition from the other. This 
is important since some are unlikely to make a diagnosis of ADHD in people who 
give an account of childhood maltreatment, potentially compromising the targeting 
of appropriate treatments (Ferrer et al., 2017). Whereas experiencing childhood 
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traumas is associated with later development of more general psychopathology 
(Teicher & Samson, 2013), to date, there is no data to suggest that a history of 
childhood trauma moderates the effects of medications on ADHD; and the findings 
reported here do not find a clear distinction in reporting of childhood trauma in 
ADHD and BPD. Future studies are needed to explore the moderating role of 
childhood maltreatment in the treatment of ADHD. 
As expected, current ADHD symptoms measured by the DIVA interview were 
significantly elevated in the ADHD groups compared to the BPD groups. Similarly, 
current symptoms of BPD were significantly elevated in the BPD groups compared 
to the ADHD groups. Despite these groups not being different on several measures 
of psychopathology as discussed above, the clinical interviews designed to identify 
and diagnose patients with each of the disorders seem to discriminate well between 
ADHD and BPD. One reason for this could be that each of the disorders have more 
unique and specific symptoms than overlapping ones. In fact, symptoms such as 
chronic feelings of emptiness, dissociation and identity disturbances, problems with 
abandonment, and self-mutilating or suicidal behaviour, which are all core 
symptoms of DSM-5 BPD diagnosis, had high probabilities in the BPD-only class, 
and much lower probabilities in the ADHD-only class. 
This study therefore supports the view that individual symptoms and associated 
factors (such as emotional dysregulation, mind wandering, anxiety, childhood  
maltreatment and impairments in various domains of everyday life) are non-specific 
measures that are seen across both disorders and cannot be relied upon to 
discriminate ADHD from BPD. On the other hand, self-reported depression, 
although significantly elevated in both ADHD and BPD groups compared to 
controls, was significantly higher in the BPD groups than the ADHD groups. In 
this study, 79% of the BPD group were on concomitant anti-depressants, compared 
to a much lower rate of 19% in the ADHD group, which could be explained by the 
higher levels of depressive symptoms in the BPD group. 
Regarding symptoms of emotional dysregulation, these are considered to be a 
characteristic feature of ADHD that supports the diagnosis according to the DSM-
5, yet they are a core criterion of BPD (American Psychiatric Association, 2013). 
Nonetheless, the data provided here, and previous research suggests that emotional 
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dysregulation may be as much a part of ADHD as the core symptoms of inattention 
and hyperactivity/impulsivity (Barkley & Fischer, 2010; Skirrow et al., 2014). The 
reason for excluding this from the DSM-5 ADHD diagnostic criteria reflects the 
fact that emotional dysregulation is seen in many different mental health disorders 
and is not good at discriminating one condition from another. Related to this, the 
classification systems are designed to provide an optimal algorithm for use by 
health care professionals to separate one condition from another, yet some 
symptoms reflect dimensions of psychopathology and are often seen across various 
mental health conditions. This was shown in the LCA results by the presence of 
‘affective instability’ and ‘impulsivity’ in the ADHD-LC, which are specific 
diagnostic criteria of BPD; as well as the presence of some core symptoms of 
ADHD, ‘fidgeting and often restless’ and ‘feeling restless’, in the BPD-LC. Despite 
the DSM criteria working well to classify patients with ADHD and BPD, in 
comorbid ADHD/BPD cases it is unclear how transdiagnostic symptoms, such as 
affective instability, are related to the two conditions, and what to expect from 
specific treatments. For example, stimulants may reduce emotional instability in 
some comorbid cases and not others, depending on the origin of emotional 
instability. More detailed investigations are needed to evaluate whether there are 
qualitatively distinct types of emotional instability related to ADHD and BPD, or 
whether these are indistinguishable. Related to this question, are there stimulant 
responsive and non-responsive types of emotional dysregulation depending on the 
origins of the symptoms? Further work is required to clarify these points.     
In general, the comorbid ADHD/BPD groups seemed to be more similar to the 
BPD group than the ADHD group, particularly for anxious and depressive 
symptoms, but not for mind wandering, in which they were more similar to the 
ADHD group. 
Overall, these findings illustrate the considerable overlap of ADHD and BPD but 
should be considered in light of some limitations. First, the generalisability of the 
results is limited by the specific patient sample I recruited for this study. The study 
had strict inclusion criteria (see section 2.3.1 in chapter 2), and specifically excluded 
individuals on antipsychotics and mood stabilisers. Yet, a national audit of 
prescribing for patients with personality disorders in England showed that one in 
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five patients are being prescribed mood stabilisers HMOP( , 20 41 ). This sample  
might therefore have less severe mood and other symptoms than the majority of 
BPD patients seen in clinical settings. Moreover, the results cannot be generalised 
to males, as the sample consisted of only females. Given that it is mostly women 
who receive therapy for BPD while the sex ratio for adult patients with ADHD is 
more equally divided, the results of this study are more representative for the 
clinical population with BPD than those with ADHD. However, an advantage of 
this approach is that sex differences are not included as a confounder, and most 
studies of ADHD focus on male only samples or samples with a higher proportion 
of males to females. It is therefore valuable to the understanding of ADHD to 
investigate female only samples. 
Second, this study employed a retrospective design in identifying onset of 
symptoms during childhood or adolescence, which is susceptible to recall bias. 
There was no information from informants when making a diagnosis based on the 
DSM-5 definitions of the disorders, although the accuracy of retrospective 
informant reports has also been questioned (Olino & Klein, 2015). The recall bias is 
particularly  na issue in the DIVA (Kooij, 2013) interview, where symptoms of 
childhood ADHD are assessed retrospectively, and several participants disclosed 
having little or no memory of their childhood experiences. Thus, it was decided to 
exclude childhood symptoms from the LCA. 
Despite these limitations, which should be addressed in future research, several 
clinical implications arise from the findings reported here. A first implication is that 
in cases of a diagnosis of BPD or ADHD, the other condition should always be 
considered. Both disorders are considered to reflect the extreme and impairing end 
of a dimensional trait, and symptoms commonly may also occur at sub-diagnostic 
levels (Chen et al., 2008; Clark, 2007). Therefore, it is expected that patients with 
BPD display some ADHD traits as part of a normal population distribution, and 
patients with ADHD may display some traits of BPD.  
A second implication is that ADHD and BPD cannot be easily differentiated on the 
basis of individual symptoms and impairments, particularly those that overlap both 
disorders. A key point is that the full DSM-5 criteria for ADHD and BPD, using 
clusters of symptoms to define clinical syndromes, appears to work well in 
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classifying ADHD and BPD as separate disorders. However, given the state of 
knowledge, treatments for both disorders in comorbid cases should be considered at 
the same time. Further research is needed to better understand the effects of 
treatments in the comorbid group. 
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4.1 Abstract 
Attention-deficit/hyperactivity Disorder (ADHD) and borderline personality 
disorder (BPD) have overlapping symptoms that make differential diagnosis 
challenging. We previously proposed that excessive spontaneous mind wandering 
(MW) reflects a measurable component of psychopathology that might distinguish 
ADHD from other psychiatric conditions.  
Using a questionnaire measure of excessive MW and a more objective experience 
sampling method, we investigated different aspects of MW in daily life, in 28 ADHD, 
19 BPD, 22 comorbid ADHD/BPD, and 29 control female participants. 
The ADHD, BPD and comorbid ADHD/BPD groups all reported heightened 
frequency and intensity of MW compared to controls. However, no differences were 
found between the clinical diagnoses. When depression and anxiety were controlled 
for, significant differences only persisted between controls and ADHD, who also 
showed significantly elevated intensity of MW compared to BPD and comorbid 
ADHD/BPD. We found no MW instability differences amongst clinical cases as well 
as cases versus controls. Negative content of MW was higher in BPD and comorbid 
ADHD/ DPB  compared to controls, whereas no differences appeared between 
ADHD and controls. When controlling for depression and anxiety, the differences 
between BPD and comorbid ADHD/BPD and controls dissipated. 
Excessive spontaneous MW was found to be a transdiagnostic process present in 
both ADHD and BPD. Yet, the underlying mechanisms of this subjective experience 
may be driven by different processes. The association of anxiety and depression with 
MW in BPD but not ADHD should be further explored in the context of 
understanding the heterogeneity of excessive spontaneous MW. 
4.2 Introduction 
Disentangling the similarities and differences between attention-deficit/hyperactivity 
disorder (ADHD) and borderline personality disorder (BPD) is a question that 
frequently arises in clinical practice (Moukhtarian, Mintah, Moran, & Asherson, 
2018; Xenaki & Pehlivanidis, 2015). High comorbidity of around 20% between the 
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disorders (Ferrer et al., 2010)  and overlap of key clinical features (Matthies & 
Philipsen, 2014; Philipsen, 2006), has led to questions around the distinction between 
ADHD and BPD (Xenaki & Pehlivanidis, 2015). Importantly, current evidence on 
treatments diverge, since drug treatments in the form of stimulants or atomoxetine 
are effective in the treatment of ADHD (Castells et al., 2011; Cunill, Castells, Tobias, 
& Capellà, 2013), whereas to date, drug treatments for BPD have yet to demonstrate 
evidence of effectiveness, making this an important ongoing area of clinical enquiry 
(NICE, 2009). 
Although the diagnosis of ADHD relies on the presence of impairing levels of 
inattention and/or hyperactivity/impulsivity, associated features of ADHD show 
considerable overlap with the symptoms used to define BPD (Philipsen, 2006; 
Philipsen et al., 2009). Emotional dysregulation, poor impulse control and unstable 
interpersonal relationships are core features of BPD which are commonly seen in 
individuals with ADHD (Asherson et al., 2014; Moukhtarian et al., 2018; Philipsen, 
2006). These common features can hamper the differential diagnosis process and 
represent a significant risk of misdiagnosis, leading to individuals not receiving 
optimal treatments for their clinical condition (Asherson et al., 2014). 
One approach to this problem is to focus on aspects of psychopathology that might 
distinguish ADHD and BPD. Regarding ADHD, we previously found that excessive 
spontaneous mind wandering (MW) is strongly associated with ADHD, and 
proposed that this form of MW reflects a measurable component of psychopathology 
that might distinguish ADHD from other psychiatric conditions (Bozhilova, 
Michelini, Kuntsi, & Asherson, 2018; Mowlem et al., 2016). 
MW is a universal phenomenon that takes up around 50% of daily thinking time 
(Smallwood & Schooler, 2015) and occurs when one’s mind drifts away from the 
primary task on-hand and focuses on internal, task-unrelated thoughts and images 
(Smallwood, McSpadden, & Schooler, 2007). Although not all forms of MW reflect 
pathological processes (Seli, Smallwood, Cheyne, & Smilek, 2015), excessive 
spontaneous MW, that is detrimental to performance, has been proposed as a 
possible mechanism underlying many of the symptoms and impairments of ADHD 
(Mowlem et al., 2016). However, excessive spontaneous MW is also known to be 
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associated with other disorders such as anxiety and depression, and may therefore 
reflect a heterogenous transdiagnostic mental phenomena (Christoff, Irving, Fox, 
Spreng, & Andrews-Hanna, 2016; Hoffmann, Banzhaf, Kanske, Bermpohl, & 
Singer, 2016; Ottaviani & Couyoumdjian, 2013; Xu, Purdon, Seli, & Smilek, 2017). 
The first study of MW in ADHD found that the frequency of task-unrelated thoughts 
was higher in college students with a childhood history of ADHD compared to 
controls, using an experience sampling method (ESM) during a sustained-attention 
task (Shaw & Giambra, 1993). Spontaneous MW measured, was also found to be 
higher in students with ADHD compared to controls, and correlated with ADHD 
symptom severity, using a self-report scale of spontaneous MW (Seli et al., 2015). In 
an adult community sample, ADHD symptoms were positively correlated with 
frequency of, and lack of awareness of MW, using both laboratory and daily-life ESM 
measures (Franklin et al., 2014). Moreover, awareness of MW partially mediated the 
relationship between ADHD symptoms and the detrimental impact of MW, 
suggesting that increasing awareness of MW in ADHD might lead to functional 
improvements (Franklin et al., 2014). 
Recently, our group found significantly elevated ratings of MW in ADHD 
participants compared to controls in two independent adult samples, using a measure 
of excessive spontaneous MW: the Mind Excessively Wandering Scale (MEWS) 
(Mowlem et al., 2016). The MEWS is a 15-item self-rated scale, designed to capture 
the subjective accounts of MW by individuals with ADHD: thoughts constantly on 
the go, thoughts that jump and flit from one topic to another, and multiple thoughts 
at the same time. MEWS scores showed high sensitivity (~0.9) and specificity (~0.9) 
for discriminating between ADHD cases and controls and accounted for unique 
variance in self-reported functional impairments. In one sample MEWS scores 
carried the most importance in the model (β=.49), followed by inattention (β=.29) 
and hyperactivity/impulsivity (β=.17), indicating the clinical relevance of MW in 
ADHD to impairment in daily-life (Mowlem et al., 2016).  
Taken together, these findings shed light on the significant association between 
ADHD and MW, suggesting that measures of MW might have utility in the 
diagnostic process. Although these findings confirm sensitivity of MW measures to 
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ADHD, they do not investigate specificity compared to other common psychiatric 
disorders. For example, it is already established that higher levels of MW are 
associated with depression (Hoffmann et al., 2016), and this could be the case for 
other disorders. Nevertheless, we hypothesise that MW in ADHD may have 
distinctive characteristics compared to MW in other disorders, such as depressive 
ruminations, anxious worrying and obsessional thoughts. 
Regarding BPD, we identified only two investigations of MW (Kanske et al., 2016; 
Scheibner, Spengler, Kanske, Roepke, & Bermpohl, 2016). Using an ESM 
assessment of MW during a reaction time task no differences were found in the 
frequency of MW in BPD compared to controls, although BPD cases reported more 
negative thoughts and greater MW instability (Kanske et al., 2016). In contrast, 
another study reported a higher frequency with longer duration of MW in BPD cases 
compared to controls, using an experimenter-prompted mindfulness task (Scheibner 
et al., 2016). Based on these two studies, it is unclear whether there is greater 
frequency or instability of MW in BPD compared to controls. 
Based on the findings to date, we do not know whether excessive MW is a clinical 
feature of BPD, or whether measures of MW can be used to distinguish ADHD from 
BPD. We therefore set out to investigate the frequency of MW in ADHD and BPD 
using two measurement approaches. First using the MEWS self-report scale of 
spontaneous MW, and secondly using ESM measures of MW in everyday life. Based 
on previous findings, we hypothesised that MW would have distinctive 
characteristics in ADHD from that seen in BPD. More specifically, that MW would 
be more heightened in ADHD than BPD, and that the content of MW would reflect 
higher negative valence thoughts in BPD than in ADHD. 
4.3 Methods 
4.3.1 Participants 
98 female participants aged 18–65 years (M=33.4, SD=11.3) were recruited. 
Controls, not meeting criteria for ADHD or BPD, were recruited through 
advertisements in King’s College London, volunteer databases, and within the local 
community. Clinical cases were recruited from ADHD and borderline personality 
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specialist clinics in the South and Midland regions of England. Members of the 
clinical care teams identified potentially eligible participants and referred them to the 
research team. Clinician diagnoses were based on DSM criteria for ADHD and BPD 
(American Psychiatric Association, 2013), and validated for research by members of 
the research team using the Diagnostic Interview for ADHD in Adults (DIVA) 
(Kooij, 2013) and the Zanarini rating scale for Borderline Personality Disorder 
(ZAN-BPD) (Zanarini, 2003) to maintain reliability and consistency of diagnosis 
across the whole sample (see section 2.3.3.1 in chapter 2 for details on diagnostic 
measures). Co-morbidities were excluded using a checklist of common mental health 
conditions by screening clinical case records. Exclusion criteria for the clinical and 
control groups were: male gender; history of bipolar I and II, recurrent depressive 
episodes, and schizophrenia; current Axis I disorders; head injury or neurological 
conditions; IQ<70; and current treatment with psychoactive medication, specifically 
mood stabilisers and/or anti-psychotics (except concomitant medication for non-
recurrent depression1). Participants on stimulant medication for ADHD were asked 
to come off this medication for 48 hours before the baseline assessment and the 
following five days during ESM. Due to the frequent drug and alcohol use in ADHD 
(Bernardi et al., 2012; Fayyad et al., 2007; Kessler et al., 2006) and BPD (Fyer, 
Frances, Sullivan, Hurt, & Clarkin, 1988; Zanarini et al., 1998) populations, we 
excluded individuals with addiction disorders, but not for elevated alcohol and drug 
use (see section A in supplementary 4 for details). 
                                                 
1 n=31 clinical cases were on concomitant anti-depressants, which constitutes around 45% of the 
clinical sample. To run sensitivity analyses without these cases, our clinical sample size would greatly 
decrease (ADHD= 20, BPD=4, ADHD/BPD= 14), making between group comparisons unmeaningful. 
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4.3.2 Materials and procedure  
4.3.2.1 Symptom measures 
Self-reported excessive MW was assessed using the .SWEM  
The MEWS is a self-rated scale measuring severity of excessive mind  
wandering. It consists of 15 items rated on a 4-point Likert-scale (0=not at all to 
3=nearly all the time or constantly) (Mowlem et al., 2016). 
Comorbid depression and anxiety was measured by the Brief Symptom Inventory 
(BSI) (Derogatis, 1993). The BSI is a self-rated measure consisting of 53-items 
evaluating psychological distress and psychiatric disorders in nine domains including 
depression and anxiety on a 4-point Likert-scale (0=not at all to 3=extremely). 
Intellectual function (IQ) was assessed using the Wechsler Abbreviated Scale of 
Intelligence- Second edition (WASI-II). Two subtests (vocabulary and matrix 
reasoning) of the WASI-II were administered to derive an estimate of IQ (Wechsler, 
2011). 
4.3.2.2. Experience sampling of mind wandering 
Experience sampling of MW was carried out eight times daily, across five 
consecutive days. We used an iOS app called MoodMapper, designed for the 
investigation of emotional dysregulation and MW by co-authors CR and PA. 
MoodMapper was uploaded onto Apple iPods with all other functions disabled. 
Signals for the onset of each monitoring period were provided by Vibralite 12 
wristwatches that were synchronised with the iPods, giving silent vibration signals 
eight times a day, at the onset of each rating period. Participants were instructed to 
complete each rating based on the time-period just before the signal. Following the 
protocol of Skirrow et al. (2014), signals occurred following a pseudorandomised 
schedule, with a minimum inter-rating interval of 65 minutes and a maximum 
interval of 135 minutes (around 10 hours of data collection each day). Participants 
started the ESM phase the day after their research appointment. Start and end times 
were the same each day. 
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Several steps were implemented to promote compliance and were incorporated into 
the testing protocol, including telephone calls to prompt participants when they were 
required to start monitoring, a follow-up call during the monitoring week, providing 
a ‘mood monitoring hotline’ telephone number and e-mail address, and an 
instruction leaflet. 
ESM ratings focused on three parameters of daily subjective MW experience: (1) 
intensity of MW, (2) instability of MW over time, and (3) content of MW (something 
pleasant/unpleasant). The use of ratings eight times per day over five days enabled 
an evaluation of the dynamic process of MW, capturing changes in MW over time. 
MoodMapper employed a total of seven MW questions (see Table 4.1 for details): 
five items that used a continuous visual analogue scale with ratings ranging from 0 
(not at all) to 100 (extremely) and two categorical items. 
Table 4.1 Description of MW items in the MoodMapper 
Items Description Scoring 
Item1 How much is your mind on what you are 
doing or elsewhere NOW? 
0………………...100 
Item2 Were you thinking about many different 
things at once NOW? 
0………………...100 
Item3 How often do new thoughts keep popping 
into your head NOW? 
0………………...100 
Item4 How hard is it to stick your thoughts to one 
thing at a time? 
0………………...100 
Item5 My mind just goes-I cannot switch it off 0………………...100 
Item6 What are you thinking about NOW? a. What I am doing 
b. Daydreaming about something else 
c. My mind drifted off and I can’t 
remember 
Item7 Are you thinking about something other 
than what you are doing NOW? 
a. No 
b. Yes, daydreaming about something 
pleasant 
c. Yes, daydreaming about something 
unpleasant 
d. Yes, daydreaming about something 
neutral 
e. Yes, daydreaming but can’t 
remember 
4.3.2.3 Pre-processing of ESM data 
Data inspection was completed before analyses to check for distributions, outliers 
and implausible data. All reports not completed within 16 minutes after the vibration 
signal were excluded from analyses. Compliance rates for each participant were 
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obtained by identifying the proportion of monitoring instances (maximum 40: eight 
ratings per day, over five days) completed within the 16-minute window. In line with 
previous studies (Simons et al., 2009; Skirrow et al., 2014), participants with an 
overall compliance rate less than 40% were excluded from the analyses (n=7).  
To obtain a measure of MW variability, we calculated squared successive differences 
(SSD), a well-established procedure in experience sampling studies (Ebner-Priemer 
et al., 2007), for each of the continuous MW items. SSD was calculated by taking the 
squared value of the difference between successive responses: SSD=(ti-ti-1)
2. The SSD 
emphasizes larger changes (Trull et al., 2008) and incorporates aspects of amplitude 
(the degree of change), frequency (the rate of change) and temporal dependency (the 
sequence in which reports are made), and is robust to systematic time trends in time 
series data (Jahng, Wood, & Trull, 2008). Further details on the pre-processing of 
ESM data are provided in section 2.6.2 in chapter 2. 
4.3.3 Statistical analyses 
Analyses were carried out in SAS University edition- virtualbox and SPSS 24. The 
significance level α was set at 0.05 (two-tailed). In our multilevel models, adjustments 
per item for multiple testing contrast tests were made by applying Bonferroni and 
Bonferroni-Holm corrections. However, no adjustment was reported for multiple 
measures of MW as these were highly correlated (see section B in supplementary 4). 
Mean ratings were computed for questionnaire based self-report measures and 
compared between groups. For simple group comparisons, normality of data was 
assessed graphically by examining histograms and QQ plots, and with the Shapiro-
Wilk statistic. Parametric and non-parametric tests were used, as appropriate. 
For analysis of the ESM data, multilevel models were used to take into account 
correlated observations nested within individuals, and perform well with missing 
data (Jahng et al., 2008). Instead of the conventional predefined diagnostic group 
comparisons, we used two new binary categorical grouping variables indicating the 
presence or absence of ADHD and BPD diagnoses separately for each individual.  
We used these new variables as predictors in the analyses of a 2x2-model with two 
main effects of ADHD and BPD and the interaction ADHD*BPD (assuming non-
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additivity of the ADHD and BPD effects). We then investigated differences across 
diagnoses by contrasts according to the a priori hypotheses expressed above: (1) 
intensity of MW using raw data, and (2) instability of MW ratings using SSDs. 
Normally distributed data were analysed with a linear mixed model with a random 
intercept (SAS procedure MIXED). SSDs follow a χ2 distribution, which is a special 
case of the gamma distribution and were analysed with a series of generalised 
multilevel models with gamma distributions and log links (SAS procedure 
GLIMMIX). Categorical data exploring frequency of MW occurrence, MW 
awareness and content of MW were analysed using multilevel logistic regression 
models with a binary distribution in the SAS procedure GLIMMIX. 
As MW has been previously associated with mood disorders, such as depression, 
anxiety (Christoff et al., 2016; Hoffmann et al., 2016; Xu et al., 2017), and 
unhappiness (Killingsworth & Gilbert, 2010), and given the significant co-occurrence 
of comorbid depression and anxiety in both ADHD and BPD populations (Cumyn, 
French, & Hechtman, 2009; Zanarini et al., 1998), we explored potential 
confounding effects of depressive and anxious symptomatology on MW; where 
significant bivariate associations were detected, models were adjusted accordingly. 
4.3.4 Ethical standards 
All participants gave full informed consent. The National Research Ethics Service 
Committee London – London Bridge, granted research ethics approval for this study 
(reference: 15/LO/1280). 
4.4 Results 
4.4.1 Sample characteristics and compliance 
The sample consisted of 98 participants: 28 participants with ADHD 
(Mage=38.2, SD=11.7), 19 with BPD (Mage=35.4, SD=11.4), 22 with comorbid 
ADHD/BPD (Mage=33.8, SD=13.8), and 29 controls (Mage=27.1, SD=5.2). There 
was a statistically significant group differences on age, X2(3) = 14.18, p=.003 and IQ, 
F (3,93) = 4.6. p=.005 (ADHD: M=106.5, SD=14.2; BPD: M=97, SD=13.8; 
ADHD/BPD: M=97.7, SD=12.4; controls: M=107.2, SD=9.2). Both age and IQ 
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were initially controlled for in subsequent analyses but did not have a significant 
effect in the models. Therefore, we reported the models by excluding these covariates. 
The groups did not show a difference in the compliance rate of ESM ratings: 
percentage of valid completion of ESM ratings (X2(3) =.12, p=.989) with a mean of 
74.8% and SD of 14.9 across the whole sample. 
4.4.2 Mind Excessively Wandering Scale 
The non-parametric Kruskal-Wallis test showed a significant effect of group on the 
MEWS, X2(3) = 58.06, p<.001. Bonferroni adjusted post-hoc tests revealed that 
controls (mean rank= 16.2) reported significantly less MW, p<.001, than ADHD 
(mean rank=66.7), BPD (mean rank=56.4) and comorbid ADHD/BPD (mean 
rank=65.4). However, there were no significant differences between clinical groups 
(p=1). When adjusting for BSI scores of anxiety and depression, differences only 
between ADHD and comorbid ADHD/BPD remained non-significant (p=.558). 
4.4.3 Group differences on ESM ratings 
4.4.3.1 Intensity 
For the continuous measures of MW, multilevel models revealed significant 
interaction effect of ADHD*BPD (p<.01) for all five items with significantly elevated 
intensity of MW in all clinical diagnoses compared to controls, when no adjustments 
were made for covariates (see model 1, Table 4.2). When adjustments were made for 
BSI anxiety and depression scores, models also revealed significant interaction effect 
of ADHD*BPD (p<.01) for all five items but there only remained significant 
differences between controls and ADHD for all the items except item-5 (see model 
2, Table 4.2) (see section C in supplementary 4 for results of the interactions per item). 
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Table 4.2 Differences between diagnostic groups and control group on MW intensity as 
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Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for BSI anxiety and depression scores 
 
Multilevel models revealed no significant differences between clinical diagnoses on 
intensity of MW, when no adjustments were made for covariates (see model 1, Table 
4.3). When adjustments were made for the BSI anxiety and depression scores, where 
only anxiety had a significant main effect in the model, significant differences 
between ADHD and BPD, plus ADHD and comorbid ADHD/BPD diagnosis were 
revealed on items 3 and 4, as well as between ADHD and BPD on item 2, whereby 
the ADHD group had heightened reports of MW intensity compared to BPD and 
comorbid ADHD/BPD (see model 2, Table 4.3). There were no significant 
differences between BPD and comorbid ADHD/BPD diagnoses, even after adjusting 
for anxiety and depression (see section D in supplementary 4 for estimated means). 
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Table 4.3 Between-diagnoses differences on MW intensity as estimated by multilevel 
modelling 
Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for BSI anxiety and depression scores 
 
4.4.3.2 Instability 
Multilevel models revealed a significant interaction effect of ADHD*BPD (p≤.01) 
only for item-5 with (F (1, 92.82) = 4.96, p=.028) and without (F (1, 91.58) = 4.87, 
p=.030) adjustment for anxiety and depression. Contrast tests showed there were no 
significant differences between clinical diagnoses and controls on items 1, 2, 3, and 4 
(see Table 4.4). Controls reported significantly less instability of MW rated on item-
5 compared to all clinical diagnoses (p<.05). Despite item-5 being highly correlated 
with all other ESM items (see section B of supplementary 4 for inter-item 
correlations), the significant difference could still reflect a type II error. There were 
no between-diagnoses differences found on all items (see section E of supplementary 
4) for instability of MW. All groups showed similar levels of instability. Anxiety and 
depression had no effect in the instability models and the adjusted results are 
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Table 4.4 Differences between diagnostic groups and control group on MW instability as 
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4.4.3.3 Frequency of occurrence, awareness and content of MW 
For the categorical measure of the frequency of MW occurrence (see item 6 in Table 
4.1), multilevel logistic regression models revealed a significant interaction effect of 
ADHD*BPD (F (1, 80.66)= 6.49, p=.013) with all clinical diagnoses reporting 
greater frequency of MW compared to controls (p<.001), with an OR2 of 3.9 (CI:1.7- 
9.3) for BPD diagnosis versus control, 3.9 (CI:1.8- 8.3) for ADHD diagnosis versus 
control and 5.2 (CI:2.3- 11.6) for comorbid ADHD/BPD diagnosis versus control. 
However, when the models were adjusted for anxiety and depression, despite the 
significant interaction effect of ADHD*BPD (F (1, 79.73)= 5.08, p=.027), significant 
differences between controls and BPD diagnosis (p=.142) as well as controls and 
comorbid ADHD/BPD diagnosis dissipated (p=.142), and only the ADHD 
diagnosis still reported more frequent MW compared to controls (p=.005), with an 
OR of 2.9 (CI:1.2- 6.7). However, there were no differences in the frequency of MW 
occurrence among clinical diagnoses, even after controlling for the covariates (p=1). 
When participants reported that their minds were wandering, we investigated the 
extent to which they were aware of this phenomenon (see item 6 in Table 4.1). There 
                                                 
2 OR: Odds ratio 
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was no significant interaction effect of ADHD*BPD with (p=.387) and without 
(p=.466) adjusting for anxiety and depression on awareness of MW. Contrast tests 
showed that there were significantly elevated rates of MW without awareness only 
in the comorbid ADHD/BPD diagnosis compared to controls with (p=.009; OR=.1; 
CI: .01-.7) and without (p=.002; OR=.2; CI: .01-.7) controlling for anxious and 
depressive symptomatology. However, there were no differences in MW awareness 
among clinical diagnoses, even after controlling for the covariates (p>.05). 
Regarding the content of MW (see item 7 in Table 4.1), our models revealed non-
significant interaction effects of ADHD*BPD with (p=.760) and without (p=.497) 
adjusting for anxiety and depression. Contrast tests revealed significantly elevated 
rates of MW about ‘something unpleasant’ in the BPD (p=.017; OR=.3; CI: .1-.9) 
and comorbid ADHD/BPD (p=.017; OR=.3; CI: .1-.9) diagnosis compared to 
controls, whereas no differences were seen between ADHD and controls (p=.806). 
When the multilevel logistic models were adjusted for anxiety and depression, these 
differences between controls and BPD diagnosis (p=1), as well as controls and 
comorbid ADHD/BPD diagnosis (p=1) disappeared. However, no differences were 
found in the proportion of MW about “something unpleasant” between clinical 
diagnoses (p>.05), even after accounting for anxiety and depression (p=1). 
4.5 Discussion 
The main aim of this study was to investigate similarities and differences in measures 
of MW in ADHD, BPD, comorbid ADHD/BPD and controls. We first used a rating 
scale measure of excessive MW developed by our group and shown to be sensitive to 
the ADHD diagnosis. We then applied a more objective method, ESM, to investigate 
different aspects of MW in daily life: examining heightened frequency, intensity and 
instability of MW. We further investigated the proportion of MW with and without 
awareness (meta-awareness), and the proportion of negative thought content during 
periods of MW with awareness. 
Overall, we found heightened levels of MW in all the clinical diagnoses compared to 
controls using both the MEWS scale of excessive spontaneous MW, and ESM 
measures of MW intensity. However, when controlling for anxiety and depression 
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symptoms, the differences between controls and BPD diagnosis, as well as between 
controls and comorbid ADHD/BPD diagnosis dissipated, with only ADHD 
diagnosis showing significantly elevated MW intensity compared to controls.  
Consistent with these effects, we found no differences in MW intensity between the 
clinical diagnoses. However, after controlling for anxiety and depression symptoms, 
ADHD diagnosis showed significantly elevated intensity of MW compared to BPD 
and comorbid ADHD/BPD on most items, while there were no differences between 
BPD and comorbid ADHD/BPD diagnoses.  
The results from the categorical variable exploring frequency of MW occurrence 
supported these findings. While all three clinical diagnoses reported more frequent 
MW than controls, the significance only persisted between controls and the ADHD 
diagnosis, but not BPD nor comorbid ADHD/BPD, when symptoms of depression 
and anxiety were controlled for. 
The absence of MW instability differences amongst clinical cases as well as cases 
versus controls suggests that MW reflects a stable phenomenon over time, 
irrespective of the presence or absence of a clinical diagnosis. While this might be 
explained by a relatively low sampling frequency in this study, these findings suggest 
that mean differences in the frequency and intensity of MW, rather than instability, 
characterise pathological forms of MW. 
With regard to ADHD, these findings suggest that MW (independent of anxiety and 
depression) is a core characteristic of the disorder, supporting the view that MW 
reflects a core process in ADHD (Bozhilova et al., 2018). This is in line with previous 
findings of elevated MW in ADHD compared to controls (Mowlem et al., 2016). 
Following the findings from Van den Driessche et al. (2017) we also hypothesised 
that during periods of MW, there would be a greater proportion of MW without 
awareness associated with the ADHD diagnosis. However, we only found that the 
comorbid ADHD/BPD diagnosis was associated with a greater proportion of MW 
without awareness compared to controls, potentially reflecting greater severity of 
MW in the comorbid ADHD/BPD diagnosis. This may arise since MW without 
awareness is thought to reflect a more severe form of MW, with greater disruption of 
the neural regulation processes involved (Bozhilova et al., 2018). 
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Finally, the data supported the hypothesis that in ADHD the content of MW would 
reflect the same proportion of pleasant to unpleasant thoughts as that seen in controls. 
This is in line with the clinical observation that while the form of thought (i.e. 
excessive MW) may differ in ADHD, content of thought is comparable to that seen 
in most other people who do not have a mental illness (Asherson, 2005). 
The finding of similar levels of MW in BPD to that seen in ADHD was unexpected, 
raising the possibility that excessive MW leading to inattentiveness may be a greater 
problem in the daily lives of people with BPD than generally recognised. However, 
in BPD the association with MW was driven by anxious and depressive symptoms, 
suggesting that excessive MW may be secondary to co-occurring anxiety and 
depressive symptoms. This was further supported by the finding that without 
adjusting for anxiety and depression scores, MW about something unpleasant was 
higher in BPD and comorbid ADHD/BDP compared to controls, whereas no 
differences appeared between ADHD and controls. However, when controlling for 
anxiety and depression symptoms the differences between BPD and comorbid 
ADHD/BPD and controls dissipated. This suggests that MW about something 
unpleasant may reflect anxious thoughts or depressive ruminations in BPD, but not 
in ADHD. However, the lack of significance in the content of MW between the 
clinical diagnoses reduces confidence in this conclusion, which requires further 
investigation.   
Our finding of excessive MW in BPD differed from a previous report which found 
no increase in the frequency of MW in BPD during a choice reaction time task 
(Kanske et al., 2016). This might be explained by using ESM in daily life rather than 
during a laboratory computer task or could be related to greater levels of anxiety and 
depression in our sample. 
Overall our results show that although excessive MW is common in both ADHD 
and BPD, the source of MW may differ. For example, being related to different 
triggers and internal or external mechanisms. A recent review hypothesises that in 
ADHD, excessive spontaneous MW may reflect a core problem related to a failure 
of the default mode network (DMN) deactivation during task conditions, reflecting 
dysfunctional interactions between DMN and salience and cortical control networks 
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(Bozhilova et al., 2018). Such heightened DMN activity may lead to periods of 
spontaneous MW that interfere with attention to external task, underlying the 
symptoms and impairments of ADHD. 
In contrast, social threat hypersensitivity is a core characteristic of BPD patients, who 
show heightened attention to perceived threat (Bertsch et al., 2013). Therefore, we 
can speculate that the combination of a higher tendency to overestimate social threat 
from ambiguous cues, together with difficulties in relational functioning (Kaiser, 
Jacob, Domes, & Arntz, 2017), increases feelings of resentment and anxiety leading 
to alternative forms of MW such as anxious worrying and depressive ruminations. 
This is consistent with higher levels of negative thoughts during periods of MW in 
BPD seen in this study, and the high levels of anxiety and depressive symptoms seen 
in people with BPD (Stepp, Scott, Jones, Whalen, & Hipwell, 2016). 
Although we have drawn attention to differences in the characteristics of MW in 
ADHD and BPD, the overall conclusion is that excessive MW is seen equally in both 
disorders. This is not entirely surprising since there are brain structural and functional 
commonalities between ADHD and BPD in the salience and executive control 
networks (Xenaki & Pehlivanidis, 2015) and previous studies report similar types of 
altered functioning of the DMN both in ADHD (Fassbender et al., 2009; 
Sidlauskaite, Sonuga-Barke, Roeyers, & Wiersema, 2015) and BPD (Wolf et al., 
2011; Yang, Hu, Zeng, Tan, & Cheng, 2016). This may explain excessive MW in 
both disorders since the degree of DMN deactivation has been proportionately linked 
to the frequency of self-generated task-unrelated thoughts (Christoff et al., 2016; 
Kucyi, Esterman, Riley, & Valera, 2016; Smallwood, Brown, Baird, & Schooler, 
2012). 
The relationship between increased spontaneous MW and ADHD symptomatology 
is now well established in the literature (Franklin et al., 2014; Mowlem et al., 2016; 
Seli et al., 2015). Regarding BPD, in addition to the potential functional alterations 
of DMN connectivity during resting state similar to ADHD (Wolf et al., 2011; Yang 
et al., 2016), previous research shows that individuals with BPD often cope with their 
intense negative emotions by suppressing them (Scheibner et al., 2016). Cognitive 
suppression of intrusive and unwanted thoughts or images that usually involve a high 
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emotional burden (Wegner & Zanakos, 1994), paradoxically, would often result in 
greater access to such thoughts (Wegner & Erber, 1992). In addition the tendency to 
suppress these thoughts has been associated with increased sympathetic activation, 
increased anxiety and depression, and an increased risk of emotional disturbance 
(Wenzlaff & Wegner, 2000). Consequently, it seems plausible to assume that this 
same phenomenon is partially contributing to MW in BPD. 
This study was the first to compare ADHD and BPD for measures of MW. Although 
we used multiple measures of MW and included carefully selected and diagnosed 
clinical groups, there are several limitations to consider. First, the sample was 
comprised of females only. This has the advantage that we did not have to account 
for potential sex differences in our analyses, but also means that the findings cannot 
be generalised to males. Considering excessive spontaneous MW as a core 
characteristic of ADHD, we should not ignore the possibility that a different pattern 
of MW may be found for females and males. In BPD, women have been reported to 
ruminate more than men (Johnson & Whisman, 2013). Further studies are required 
to confirm these findings in males.   
Depression and anxiety were measured by the BSI, a self-report scale, which has 
varied evaluations about its validity. Previous confirmatory factor analyses have 
shown high intercorrelations among the BSI subscales, suggesting that the BSI could 
be a better general indicator of psychopathology rather than a screening tool for each 
of the subscales separately (Boulet & Boss, 1991; Wang et al., 2010). We should 
therefore consider this limitation before drawing strong conclusions about the 
relationship of MW and anxiety and depression in BPD.  
Despite having an acceptable compliance rate for the ESM ratings, further studies 
exploring the specificity of MW in ADHD and BPD using an experience sampling 
approach could benefit from larger sample sizes. 
Regardless of these limitations, our findings suggest that excessive spontaneous MW 
is a transdiagnostic process present in both ADHD and BPD. Yet, different 
processes may drive the underlying mechanisms of this subjective experience. 
Research on the specific cognitive and neurobiological mechanisms associated with 
MW should be investigated both in ADHD and BPD, to explain the underlying 
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causes of the clinical overlap between ADHD and BPD. The strong association of 
anxiety and depression with MW in BPD only should be further explored in the 
contex fo t  delineating different aetiological subtypes of MW. An analogy is fever, 
 hcihw like MW is a symptom seen across conditions but reflecting different
 gniylrednu specific causes. This analogy could be further extended to treatment of
 dna WM related impairments. It has been suggested that treatment of ADHD with 
methylphenidate might be mediated by reductions in MW (Mowlem et al., 2016). 
Moreover, it is assumed that methylphenidate improves focus and enhances 
executive resources, as well as enhances task-related DMN deactivation (Van den 
Driessche et al., 2017), which in turn could reduce MW. Whether methylphenidate 
would reduce excessive MW in other conditions such as BPD is however entirely 
unknown, requiring further studies. Thus, further critical work is required to 
disentangle the relationship between ADHD and BPD, leading to more accurate 
diagnoses and, targeting of treatments. 
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Chapter 5: A comparative investigation of emotional dysregulation in 
ADHD and borderline personality disorder using an experience sampling 
approach  
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5.1 Abstract 
Emotional dysregulation is a core diagnostic symptom in borderline personality 
disorder (BPD) and has been described as frequently co-occurring with attention-
deficit/hyperactivity disorder (ADHD). The current study attempted to 
qualitatively distinguish ADHD and BPD on the dynamic construct of emotional 
changes by using ambulatory monitoring of negative and positive emotions (sad, 
irritable, angry, happy and excited) and retrospective measures in adult females 
with ADHD, BPD, comorbid ADHD/BPD and healthy controls. 
Individuals with ADHD and BPD reported some differences in the intensity and 
instability of negative emotions, which were fully accounted for by symptoms of 
depression and anxiety. Neither the increased intensity nor instability in emotions 
in the clinical diagnoses could be fully accounted for by increased frequency and 
impact of bad events, reflecting both a reactive and an endogenously driven 
component of emotional dysregulation in both ADHD and BPD. In line with 
previous studies using ambulatory assessments in psychiatric populations, small to 
moderate correlations were found between indices of emotional dysregulation from 
ambulatory assessment and those from retrospective measures. Findings suggest 
that ambulatory monitoring can provide conclusions, which are not equivalent but 
complementary to rating scale measures. 
This study supports the notion that emotional dysregulation is a transdiagnostic 
clinical symptom present in both ADHD and BPD and could not be used to 
distinguish between the disorders.  
5.2 Introduction 
The differential diagnosis of attention-deficit/hyperactivity disorder (ADHD) and 
borderline personality disorder (BPD) is important for the accurate treatment and 
management of both conditions. Yet, overlapping symptoms, notably symptoms of 
emotional dysregulation, can make differentiation of the conditions challenging. 
According to the DSM-5, emotional dysregulation reflects a core symptom domain 
in the diagnostic classification of BPD, whereas in ADHD it is recognised as an 
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associated feature supporting the diagnosis (American Psychiatric Association, 
2013). 
Emotional dysregulation is a dimensional construct (Shaw, Stringaris, Nigg, & 
Leibenluft, 2014) and is characterised by problems with temper control (feelings of 
irritability and frequent outburst of short duration), emotional over-reactivity 
(diminished ability to handle typical life stresses, resulting in frequent feelings of 
being hassled and overwhelmed), and mood lability (short and unpredictable shifts 
from normal mood to depression or mild excitement) (Reimherr et al., 2005).  
Emerging evidence shows that emotional dysregulation is present in 72–90% of 
adults with ADHD, and independently of core symptoms of ADHD predicts 
impairments in social, educational and occupational domains (Asherson, 2005; 
Skirrow et al., 2014), and responds to treatment within the same time-frame as core 
ADHD symptoms in adults (Rosler et al., 2010). In contrast, emotional 
dysregulation is one of the core symptom domains of individuals with BPD, who 
nearly always suffer from severe persistent affective instability, inner tension and 
difficulty controlling emotions such as anger (American Psychiatric Association, 
2013).  
Phenomenologically, emotional dysregulation is a complex construct, with shared 
characteristics in both ADHD and BPD, particularly pertaining to feelings of 
heightened and unstable reactivity of mood, and difficulty controlling anger 
(criterion six and eight for BPD diagnosis respectively) (Moukhtarian, Mintah, 
Moran, & Asherson, 2018). It remains unclear whether the type of emotional 
dysregulation seen in ADHD is qualitatively similar or different from that seen in 
BPD (Moukhtarian et al., 2018).  
One way to investigate this dynamic and time-dependent process over time 
(Carpenter & Trull, 2013) is by ambulatory assessments, a gold standard method 
that assesses this longitudinal within-individual changing (i.e. direct measure of 
instability) phenomenon (Ebner-Priemer & Sawitzki, 2007; Solhan, Trull, Jahng, & 
Wood, 2009). Ambulatory assessments are repeated assessments over time that 
include a range of methods to study individuals’ affective states, behaviours or 
physiological processes in their natural environment (Santangelo, Bohus, & Ebner-
Emotional Dysregulation in ADHD and BPD 
112 
Priemer, 2012; Trull & Ebner-Priemer, 2014). Ambulatory assessment, diary 
methods, ecological momentary assessment or experience sampling method (ESM)  
are different terms often used interchangeably in the literature (Trull & Ebner-
Priemer, 2014). They all encompass methods that can provide multiple assessments 
of mood per day over several days measuring change of affect from one moment to 
the next, yielding to intensive longitudinal data (Carpenter & Trull, 2013). In this 
study, the method will be referred to as ESM. 
By providing real-time assessments, ESM minimises retrospective and heuristic 
biases (Ebner-Priemer et al., 2006; Santangelo et al., 2012). In fact, it is suggested 
that the recollection of emotional situations are heavily influenced by the most 
intense point of the event and the end-point state, known as the ‘peak-end’ rule 
(Santangelo et al., 2012). In disorders like BPD, where a symptom is defined by 
rapid swings in mood, once-a-day diary entries or even retrospective questionnaire 
entries don’t take into account the timely nature of the data nor the affective 
changes within the day (Santangelo et al., 2012). In addition, ESM assessments 
take place in people’s natural environments where assessments are more 
ecologically valid and therefore general si able to real life, as opposed to 
questionnaire data collected in artificial laboratory or clinical settings (Carpenter & 
Trull, 2013; Santangelo et al., 2012). Finally, data based on clinical interviews are 
often dependent on the skills of the interviewers or raters; another bias issue not 
seen in ESM studies (Trull & Ebner-Priemer, 2014). 
Ambulatory assessments have been used to measure unstable emotions and a 
variety of clinical conditions and symptoms in different psychiatric illnesses, 
including negative affect in depressive disorders (Chepenik et al., 2006), depressive 
symptoms in bipolar disorder (Bauer et al., 2007), affective instability in bulimia 
nervosa and post-traumatic stress disorder (Santangelo et al., 2014), affective 
intensity and instability in ADHD (Skirrow et al., 2014) and distress in BPD 
(Ebner-Priemer, Kuo, et al., 2007) among others. 
To date, only one ESM study has investigated the dynamics of emotional 
dysregulation in adults with ADHD (Skirrow et al., 2014). Compared to controls 
(n= 47), patients with ADHD (n= 41) showed significantly increased instability of 
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irritable, frustrated and angry and increased intensity of irritable and frustrated. They 
also showed greater reactivity of negative emotions, such as anger, to ‘bad’ life 
events. In addition, compared to controls, patients with ADHD showed no 
differences in the intensity and instability of positive emotions (happy, excited). 
This study included only males and specifically excluded patients with comorbid 
conditions (Skirrow et al., 2014), hence attributing the heightened mood 
dysregulation to the presence of ADHD only. 
In BPD, several ESM studies have been reported investigating emotional 
dysregulation. Below is a brief summary of the most recent findings. 
In one study of 50 individuals with BPD and 50 psychiatrically healthy female 
controls, affective instability was assessed every 10-20 minutes during the waking 
hours of a 24-hour period (Ebner-Priemer, Kuo, et al., 2007; Ebner-Priemer et al., 
2008; Ebner-Priemer et al., 2006; Ebner-Priemer, Welch, et al., 2007; Reisch, 
Ebner-Priemer, Tschacher, Bohus, & Linehan, 2008). The BPD group showed 
heightened affective instability (emotions including happy, anxious, angry, sad, 
disgust) characterised by rapid fluctuations from positive valence mood to 
negative valence mood compared to controls. BPD patients also displayed greater 
frequency and intensity of negative emotions compared to controls. However, no 
group differences were seen in the intensity of positive emotions. Moreover, when 
comparing retrospective questionnaire ratings to ESM ratings, results showed that 
the BPD group overestimated emotions with negative valence and underestimated 
emotions with positive valence when using rating scales data, yrartnoc  to the 
control group who did the opposite. 
In another all-female study comparing 76 outpatients with BPD and 50 controls 
with a depressive disorder, affective states were recorded using ESM six tim se  a day 
over a 28-day period (Jahng et al., 2011; Jahng, Wood, & Trull, 2008; Solhan et al., 
2009; Trull et al., 2008). Overall, results indicated greater instability over time for 
fear, hostility and sadness in the BPD group only. Results also showed an increased 
long-term (between-day) and short-term (within-day) instability of negative affect in 
BPD compared to patients with a depressive disorder. 
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In a female-only study using a paper-and-pencil diaries and an event-contingent 
sampling strategy over a 20-day period, authors reported heightened instability in 
pleasant affect (happy, pleased, fun, joyful) for patients with BPD (n=38) compared 
to healthy controls (n=44), but interestingly no group differences in the instability of 
negative affect (anxious, frustrated, angry, unhappy, sad) (Russell, Moskowitz, 
Zuroff, Sookman, & Paris, 2007; Sadikaj, Russell, Moskowitz, & Paris, 2010). 
Finally, in a more recent study, Santangelo et al. (2014) investigated the specificity 
of affective instability in BPD (n=43), compared to posttraumatic stress disorder 
(PTSD) (n=28), bulimia nervosa (n=20), and healthy controls (n=28), 
approximately every 15 minutes for 24-hours. Findings showed that affective 
instability was equally heightened in all patient groups (Santangelo et al., 2014). 
Contrary to Santangelo et al., Scheiderer et al. (2016) employed ESM six times a 
day over a 28-day period and found significant differences in the instability of 
negative affect across the BPD with and without PTSD (n=78), and psychiatric 
comparison groups of major depressive disorder (n=50).  
To date, the empirical findings from the above-mentioned ESM studies show some 
inconsistencies because of various methodological and statistical differences. 
However, overall, they point to heightened instability of negative emotion reported 
by both retrospective scales and ESM methods for both BPD and ADHD. 
Although a strong relationship between ADHD and BPD pertaining to overlapping 
symptoms of emotional dysregulation has been established using retrospective 
measures (Bernardi et al., 2012; Cumyn, French, & Hechtman, 2009; Ferrer et al., 
2010; Jacob et al., 2007; Philipsen et al., 2008; Speranza et al., 2011), no direct 
comparison has assessed the overlapping dynamic construct of emotional 
dysregulation using ESM in naturalistic settings. 
The present study investigat de  the dynamics of positive and negative emotions, and 
the occurrence and impact on mood of bad social and functional events (described 
in section 5.3.2.2), captured by ESM eight times a day, over five days in adult 
females with ADHD, BPD, comorbid ADHD/BPD, and psychiatrically healthy 
controls. By taking an exploratory approach, I investigated whether there were any 
differences in the intensity and instability of positive and negative emotions in 
ADHD and BPD, first using retrospective questionnaire-based data, and secondly 
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using ESM measures of mood in everyday life. I also hypothesised that reactivity of 
negative mood will predominantly be influenced by bad social events (i.e. involving 
other people or events in social situations) in BPD, whereas in ADHD, negative 
mood will be impacted more frequently by bad functional events (i.e. in relation to 
practical and everyday life tasks). Finally, to examine the strength of association 
between ambulatory assessments of emotions with more conventional retrospective 
self-report measures of emotional dysregulation, I cross-validated the two measures 
to establish whether the scales reflect the same construct as the ESM data.  
5.3 Methods 
5.3.1 Sample 
98 female participants aged of 18-65 years (M=33.4, SD=11.3) were recruited for 
this study. Controls, not meeting criteria for ADHD or BPD, were recruited 
through advertisements in King’s College London, volunteer databases, and within 
the local community. Clinical cases were recruited from ADHD and borderline 
personality specialist clinics in the South and North London and Midland regions 
of England. Members of the clinical care teams identified potentially eligible 
participants and referred them to the research team. Clinician diagnoses were based 
on DSM criteria for ADHD and BPD (American Psychiatric Association, 2013), 
and validated for research by members of the research team using the Diagnostic 
Interview for ADHD in Adults (DIVA) (Kooij, 2013) and the Zanarini rating scale 
for Borderline Personality Disorder (ZAN-BPD) (Zanarini, 2003) to maintain 
reliability and consistency of diagnosis across the whole sample (see section 2.3.3.1 
in chapter 2 for details on clinical diagnosis). Co-morbidities were excluded using a 
checklist of common mental health conditions by screening clinical case records. 
Exclusion criteria for the clinical and control groups were: male gender; history of 
bipolar I and II, recurrent depressive episodes, and schizophrenia; current Axis I 
disorders; head injury or neurological conditions; IQ<70; and current treatment 
with psychoactive medication, specifically mood stabilisers and/or anti-psychotics 
(except concomitant medication for non-recurrent depression). Participants on 
stimulant medication for ADHD were asked to come off this medication for 48 
hours before the baseline assessment and the following five days during experience 
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sampling. Due to the frequent drug and alcohol use in ADHD (Bernardi et al., 
2012; Fayyad et al., 2007; Kessler et al., 2006) and BPD (Fyer, Frances, Sullivan, 
Hurt, & Clarkin, 1988; Zanarini, Gunderson, Frankenburg, & Chauncey, 1989) 
populations, I excluded individuals with addiction disorders, but not for elevated 
alcohol and drug use (see section 2.4.1.6 in chapter 2 for more details, and section 
A in supplementary 5 for sensitivity analyses). 
5.3.2 Measures 
5.3.2.1 Symptom measures 
Emotional dysregulation was assessed using one self-rated questionnaire and one 
investigator-rated interview scale; the Affective Lability Scale- Short form (ALS-SF- 
Appendix 3) (Oliver & Simons, 2004) and the Wender-Reimherr Adult Attention 
Deficit Disorder Scale- Emotion dysregulation subscale (WRAADDS-EDS- 
Appendix 5) (Wender, 1995) respectively. Comorbid depression and anxiety were 
measured by the Brief Symptom Inventory (BSI) (Derogatis, 1993). All scales are 
described in detail in chapter 2 (section 2.4.1.1). Intellectual function (IQ) was 
assessed using the Wechsler Abbreviated Scale of Intelligence- Second edition 
(Wechsler, 2011). 
5.3.2.2 Experience sampling of emotions 
Experience sampling of emotions was carried out eight times daily, across five 
consecutive days. We used an iOS app called MoodMapper, designed for the 
investigation of emotional dysregulation and mind wandering in ADHD. 
MoodMapper was uploaded onto Apple iPods with all other functions disabled. 
Signals for the onset of each monitoring period were provided by ‘Vibralite 12’ 
wristwatches that were synchronised with the iPods, giving silent vibrations signals 
eight times a day, at the onset of each rating period. Participants were instructed to 
complete each rating based on the time-period just before the signal. Signals 
occurred following a pseudorandomised schedule, with a minimum inter-rating 
interval of 65 minutes and a maximum interval of 135 minutes (around 10 hours of 
data collection each day). The rationale for using 8 times per day assessment over 
five days stems for the notion that emotions are transient and short-lasting 
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phenomena, and affective instability usually occurs within hours and not between 
days. Therefore, intervals that are too long might fail to detect natural changes, 
exclude important events, and even contribute to biased recollection. On the other 
hand, very short intervals could increase the burden placed on participants. There is 
in fact no general convention for time-based designs established to date (Ebner-
Priemer & Sawitzki, 2007). Therefore, a similar protocol to that successfully 
implemented by Skirrow et al. (2014) in their study of adult men with ADHD and 
controls was followed. Participants started the ESM phase the day after their 
research appointment. Start and end times were the same each day. Several steps 
were implemented to promote compliance and were incorporated into the testing 
protocol, including telephone calls to prompt participants when they were required 
to start monitoring, a follow-up call during the monitoring week, providing a ‘mood 
monitoring hotline’ telephone number and e-mail address, and an instruction 
leaflet. 
ESM ratings of mood were based on three parameters: (1) intensity of positive and 
negative mood, (2) instability of positive and negative mood, and (3) impact of bad 
events on negative mood. Items included emotions frequently associated with 
ADHD and BPD in the literature. MoodMapper employed a total of eight 
questions (see Table 5.1 for details): Six items used a continuous visual analogue 
scale with ratings ranging from 0 (not at all) to 100 (extremely), and two were 
categorical items.
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Table 5.1 Moodmapper mood items with descriptions 
Items Description Scoring 
Item1- Happy How happy do you feel now? 0………………...100 
Item2- Excited How excited do you feel now? 0………………...100 
Item3- Sad How sad do you feel now? 0………………...100 
Item4- Irritable How irritable do you feel now? 0………………...100 
Item5- Angry How angry do you feel now? 0………………...100 
Item6 Did any bad thing happen to you 
in the past hour? 
1. No 
2. Argument 
3. Lost something 
4. Late/missed something I wanted 
5. Told off 
6. Punished 
7. Hurt/accident/pain 
8. Annoyed by someone 
9. Bullied 
10. Failed something 
11. Need to do something I dislike 
12. Other 
Item7 Did any good thing happen to 
you in the past hour? 
1. No 
2. Doing something well 
3. Compliments 
4. Rewarded 
5. Being in good company 
6. Doing something I like 
7. Other 
5.3.2.3 Pre-processing of ESM data 
Data inspection was completed before analyses to check for distributions, outliers 
and implausible data. Allowing a choice in the self-selection of monitoring 
instances runs the risk of introducing each participant’s bias in selecting some 
instances and overlooking others (Bolger, Davis, & Rafaeli, 2003). Therefore, to 
reduce this bias, all reports not completed within 16 minutes after the vibration 
signal were excluded from analyses (Skirrow et al., 2014; Solhan et al., 2009). 
Compliance rates for each participant were then obtained by identifying the 
proportion of monitoring instances (maximum 40: eight ratings per day, over five 
days) completed within the 16-minute window. In line with previous studies 
(Simons et al., 2009; Skirrow et al., 2014), participants with an overall compliance 
rate less than 40% were excluded from the analyses (n=7). 
To obtain a measure of emotio i lan nstability, squared successive difference (SSD) for 
each item was calculated by taking the squared value of the difference between 
successive responses: SSD= (ti-ti-1)
2. SSD emphasizes larger changes (Trull et al., 
2008) and incorporates aspects of amplitude (the degree of change), frequency (the 
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rate of change) and temporal dependency (the sequence in which reports are made), 
and is robust to systematic time trends in time series data (Jahng et al., 2008). Mean 
SSD (MSSD) was calculated by averaging SSDs within each day and then 
averaging across days (Solhan et al., 2009). 
Finally, multiple choice answers for the bad events question (see item 6 in Table 
5.1) were grouped into two categories; (1) bad social: argument, told off, punished, 
annoyed by someone, bullied, which were events involving other people, and (2) 
bad functional: lost something, late/missed something I wanted, hurt/accident/pain, 
failed something, need to do something I dislike, which were events relating to 
everyday life situations and involving the subject only. 
5.3.3 Statistical analysis 
Analyses were carried out in SAS university edition- virtualbox and SPSS 24. The 
significance level α was held at .05 (two-tailed). In the multilevel models, 
adjustments per item for multiple testing contrast tests were made by applying 
Bonferroni and Bonferroni-Holm corrections. Adjustments across items were made 
for two independent sets of tests, as positive items (happy and excited), as well as 
negative items (sad, irritable and angry) were highly correlated, r=.80 and .70 to .80 
respectively. The Bonferroni adjusted p for the multilevel analyses was therefore set 
at .025. 
Mean ratings were computed for each questionnaire-based measure and compared 
between groups. For simple group comparisons, normality of data was assessed 
graphically by examining histograms and QQ plots, and with the Shapiro-Wilk 
statistic. Parametric and non-parametric tests were used, as  
appropriate. 
For analysis of the ESM data, multilevel models were used to take into account 
correlated observations nested within individuals. These models perform well with 
missing data (individuals with a greater number of valid reports contribute more to 
the estimation of group means) (Jahng et al., 2008). Analyses investigated group 
differences in a 2x2-model (ADHD*BPD, assuming non-additivity of the ADHD 
and BPD effects), followed by contrasts according to the a priori hypotheses: (1) 
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intensity of emotions using raw data and (2) instability of emotions using SSDs. 
Normally distributed data were analysed with a linear mixed model with a random 
intercept (SAS procedure MIXED). SSDs follow a χ2 distribution, which is a special 
case of the gamma distribution and were analysed with a series generalised 
multilevel models with gamma distributions and log links (SAS procedure 
GLIMMIX).  
Additional models that specified a diagnosis-by-event interactive effects investigated 
whether diagnosis (ADHD and BPD) has an influence on how bad social and 
functional events impact negative mood. 
Lastly, using Spearman’s correlations a cross-validation of retrospective self-report 
measures of emotional dysregulation using mean scores of the ALS-SF and 
WRAADDS-EDS with mean instability scores (i.e. MSSD) of each ESM item was 
carried out. 
Given the significant co-occurrence of comorbid depression and anxiety in both 
ADHD (Cumyn et al., 2009) and BPD (Zanarini et al., 1989) populations, potential 
confounding effects of depressive and anxious symptomatology on mood was 
explored; and where significant effects were detected, models were adjusted 
accordingly. 
It should be noted that 31 clinical cases were on concomitant anti-depressants, 
which constitutes around 45% of the clinical sample. To run the main analyses 
without these cases, the clinical sample size would greatly decrease (ADHD= 20, 
BPD=4, ADHD/BPD= 14), making between group comparisons unmeaningful. 
Therefore, I did not run any sensitivity analyses with the exclusion of these cases. 
5.3.4 Ethical standards 
The National Research Ethics Service Committee London – London Bridge, 
granted research ethics approval for this study (reference: 15/LO/1280). All 
subjects participating in the study gave full informed consent. 
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5.4 Results 
5.4.1 Participant characteristics and compliance 
The sample consisted of 98 females between the ages of 18-65 years (Mage=33.42, 
SD=11.35), including 28 participants with ADHD, 19 with BPD, 22 with comorbid 
ADHD/BPD and 29 psychiatrically healthy controls. The groups significantly 
differed on age, X2(3) = 14.53, p=.002 (ADHD: M= 38.21, SD=11.67; BPD: M= 
35.45, SD=11.09; ADHD/BPD: M= 33.77, SD=13.80; controls: M= 27.14, 
SD=5.17), and IQ, F (3,93) = 4.6. p=.005 (ADHD: M=106.54, SD=14.19; BPD: 
M=97.75, SD=13.81; ADHD/BPD: M=97.71, SD=12.37; controls: M=107.21, 
SD=9.21). Both age and IQ were initially controlled for in subsequent analyses but 
did not have significant effects in the models. Therefore, I reported the models by 
excluding these covariates. The groups did not show a difference in the compliance 
rate of ESM ratings: percentage of valid completion of ESM assessments (X2(3) 
=.12, p=.989) with a mean of 74.8% and SD of 14.9 across the whole sample. 
5.4.2 Retrospectively measured emotional dysregulation 
Non-parametric Kruskal-Wallis tests revealed significant group differences in 
retrospective questionnaire-based emotional dysregulation (X2(3) = 52.22, p< .001 
for the ALS-SF, and X2(3) = 68.81, p< .001 for the WRAADDS-EDS). 
Post-hoc tests showed significant elevated self-ratings of emotional dysregulation in 
ADHD, BPD and comorbid ADHD/BPD compared to controls on both scales 
(p<.001). The clinical groups reported equally elevated ratings of emotional 
dysregulation on the ALS (p>.05). Regarding the WRAADDS-EDS, the BPD 
group showed similar ratings as the ADHD and comorbid ADHD/BPD groups (p> 
.05), but the comorbid ADHD/BPD group reported small but significantly elevated 
ratings compared to the ADHD group (p=.026) (see Figure 5.1). 


























Figure 5.1 Mean scores comparisons in retrospective emotional dysregulation scales.  
Note: Error bars represent standard errors 
5.4.3 Real-time emotional changes 
5.4.3.1 Intensity 
Multilevel models revealed a non-significant interaction effect of ADHD*BPD on 
all items, in unadjusted models (Model 1) and adjusted models for anxiety and 
depression (Model 2). 
Post-hoc comparisons (see Table 5.2) revealed that the control group reported 
significantly higher intensity of happy, and significantly lower intensity of all 
negative emotion items (sad, irritable and angry) than the BPD and comorbid 
ADHD/BPD diagnoses (p<.001) (Model 1). When models were adjusted for 
anxiety and depression (Model 2), the significant differences between the controls 
and BPD as well as controls and ADHD/BPD dissipated. The control group also 
reported significantly elevated intensity of excited compared to the BPD diagnosis 
(p=.011) only. All comparisons were robust to Bonferroni correction (adjusted 
p=.025). 
No differences were seen between controls and the ADHD diagnosis for the 
intensity of positive emotion items (happy, excited) and angry with and without 
controlling for anxiety and depression. The ADHD diagnosis compared to controls 
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showed heightened intensity of sad and irritable in the unadjusted models (Model 1). 
In the adjusted models (Model 2), significant differences only remained for irritable 
(p=.038), which was however not robust to Bonferroni correction (p=.025). 
 
Table 5.2 Differences between diagnostic groups and control group on mood intensity as 





No diagnosis vs 
ADHD diagnosis 
No diagnosis vs 
BPD diagnosis 














































































































Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for BSI anxiety and depression scores 
 
Post-hoc comparisons (see Table 5.3) showed no group differences in the intensity 
of all positive and negative emotion items (happy, excited, sad, irritable, and angry) 
between BPD and comorbid ADHD/BPD diagnoses with and without controlling 
for anxiety and depression.  
The ADHD diagnosis showed significantly higher intensity of happy, and a 
significantly lower intensity of sad and angry compared to the BPD and comorbid 
ADHD/BPD diagnoses. All comparisons, except for angry, were robust to 
Bonferroni correction p=.025. These significant differences dissipated when models 
were adjusted for anxiety and depression (Model 2). 
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Table 5.3 Between-diagnoses differences on mood intensity as estimated by multilevel 
modelling 
Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for BSI anxiety and depression scores 
 
5.4.3.2 Instability 
Multilevel models revealed a non-significant interaction effect of ADHD*BPD on 
all items, in unadjusted (Model 1) and adjusted (Model 2) models for depression 
and anxiety. 
There were some differences between the control and BPD diagnosis (see Table 
5.4), as well as controls and the comorbid ADHD/BPD diagnosis (Model 1) in the 
instability of positive and negative emotion items, of which only sad between 
controls and the BPD diagnosis, and all the negative emotion items between 
controls and comorbid ADHD/BPD diagnosis were robust to Bonferroni 
adjustment (p=.025). All significant differences dissipated when controlling for 
anxiety and depression (Model 2). 
Post-hoc tests revealed no significant differences between controls and the ADHD 
diagnosis with and without controlling for depression and anxiety on the instability 





ADHD diagnosis vs 
BPD diagnosis 
ADHD diagnosis vs 
ADHD/BPD 
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instability of sad and irritable compared to controls (Model 1). When models were 
adjusted for anxiety and depression, these significant differences dissipated (Model 
2). Comparisons were robust to Bonferroni correction (p=.025). 
 
Table 5.4 Differences between diagnostic groups and control group on mood instability as 





No diagnosis vs 
ADHD diagnosis 
No diagnosis vs 
BPD diagnosis 














































































































Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for BSI anxiety and depression scores 
 
In the comparison of the clinical diagnoses of ADHD, BPD and comorbid 
ADHD/BPD, there were no differences in the instability of all positive and 
negative emotion items (see Table 5.5). Anxiety and depression had no effect in the 
instability models when comparing clinical diagnoses and the adjusted results are 
therefore not presented below. 
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5.4.4 Visualising emotions 
Figure 5.2 shows a 3-dimensional representation of the data (covering subject, time 
and intensity) for the emotion ratings of irritable over the 5-day ambulatory 
monitoring period. Each horizontal row represents a participant, each square 
corresponds to a single report and the colour shade denotes the level of irritability 
(with darker squares indicating higher ratings). Variability in the length of 
individual bars indicates differences in compliance. The frequency and fast 
changing intensity seen in the lower three portions of the figure represents the 
within-subject variability in individuals with ADHD, BPD and ADHD/BPD 
respectively, and the darker shade overall suggests a greater proportion of higher 
ratings of irritable. 
The figure also illustrates differences in intra-individual variability within groups, 
with a few individuals with ADHD and BPD showing more similar patterns to 
those of controls, and a few controls showing more similar patterns to those seen in 
ADHD and BPD. 
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The heatmap reveals observable differences among the patient groups and healthy 
controls. All three patient groups showed higher intensity of irritable (i.e., more dark 
squares) and more changes over time (i.e., more colour changes across ratings) than 
healthy controls. However, the clinical groups cannot be distinguished from one 
another regarding the frequency of high irritable ratings (i.e., the number of dark 
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5.4.5 Bad social and functional events 
Controls reported significantly less bad social and bad functional events compared to 
all three clinical groups (p<.05). The ADHD, BPD and comorbid ADHD/BPD 
groups did not differ significantly on the frequency of reported bad events (p>.05) 
(See Figure 5.3). 
Figure 5 3.  Frequency of bad events 
 
The contribution of reported bad social and bad functional events in the intensity and 
instability of sad, irritable and angry were investigated below. First, multilevel 
models were run to investigate the relative contribution of bad events as predictors 
in the models, and secondly additional models were run to investigate the 
interaction of diagnosis (ADHD and BPD) and bad events on emotions. 
Main effects from the multilevel models indicated that across the whole sample, bad 
social and bad functional events both have a significant main effect on the intensity 
and instability of negative emotion items (sad, irritable and angry; p<.001).  
Results also showed that after the inclusion of bad social (Model 3) and bad functional 
(Model 4) events in the multilevel models of intensity and instability of emotions, 
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was seen as in the models without these predictors (See Tables 5.6 and 5.7 for bad 
social events, and Tables 5.8 and 5.9 for bad functional events). 
 
Table 5.6 Between-diagnoses differences on the effect of bad social events on mood 
intensity 
Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for depression, anxiety 
Model 3: Multilevel models adjusted for depression, anxiety and bad social events 
 
Table 5.7 Between-diagnoses differences on the effect of bad social events on mood 
instability 
Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for depression, anxiety 
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Table 5.8 Between-diagnoses differences on the effect of bad functional events on mood 
intensity 
Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for depression, anxiety 
Model 4: Multilevel models adjusted for depression, anxiety and bad functional events 
 
Table 5.9 Between-diagnoses differences on the effect of bad functional events on mood 
instability 
Model 1: Multilevel models unadjusted 
Model 2: Multilevel models adjusted for depression, anxiety 
Model 4: Multilevel models adjusted for depression, anxiety and bad functional events 
 
Further models investigating the impact of diagnosis on the interaction of bad 
events on mood revealed that diagnosis does not have a significant effect (p>.05) on 
the impact of bad functional events on the intensity of sad and irritable, when 
comparing ADHD and BPD diagnoses. On the other hand, diagnosis had a 
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the BPD diagnosis reported higher intensity of angry than the ADHD diagnosis 
(p=.003). Results were similar in models controlling for anxiety and depression 
symptoms. 
Regarding bad social events, diagnosis had no significant effect on the impact of bad 
social events on the intensity of sad and angry, when comparing ADHD and BPD 
diagnoses. While a significant effect of diagnosis on the event-by-irritable interaction 
was seen, whereby the ADHD diagnosis reported higher intensity of irritable than 
the BPD diagnosis (p=.010). When controlling for depression and anxiety 
symptoms, findings are similar for sad and angry, and a more robust significance 
value is depicted for irritable (p=.001). 
Diagnosis-by-event interaction models on the instability of negative emotions items 
were all non-significant.  
5.4.6 Relationship of experience sampling data and retrospective 
measures of emotional dysregulation 
Bivariate correlations between total mean scores obtained from the ALS and 
WRAADDS-EDS and mean ratings of mood instability (i.e. MSSD) from ESM 
assessments confirmed significant small to moderate associations between the two 
types of measures across the whole sample (see Table 5.10). Correlations became 
non-significant when investigated in the control participants and the clinical cases 
separately. This most likely reflects the generally lower levels of reported emotional 
dysregulation in both the retrospective and ambulatory monitoring measures in the 
control group, and the higher levels in the clinical groups, leading to less variation 
in the data when investigated in the groups separately, as opposed to the 
investigation across the whole sample. 
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Table 5.10 Correlation coefficients for relationship between retrospective measures and 
mean instability from ESM data of emotional dysregulation across the whole sample 
MSSD ALS WRAADDS-EDS  
Happy .36* .33* 
Excited .18 .17 
Sad .37* .37* 
Irritable .30* .33* 
Angry .46* .50* 
Correlation is significant at the .01 level (2-tailed).  
5.4.7 Relationship between BSI scores of depression and anxiety and 
measures of emotion instability 
Given the significant effect of depression and anxiety symptoms in measures of 
emotion instability, Table 5.11 shows the correlations between BSI scores of 
depression and anxiety, retrospective and ESM measures of emotion instability. 
Apart from instability of excited, retrospective and ESM measures of emotion 
instability show moderate to strong correlations with BSI scores of anxiety and 
depression. 
Table 5.11 Correlation coefficients for relationships between MSSDs and retrospective 
measures of emotion instability with BSI scores of depression and anxiety across the whole 
sample 
MSSD BSI_Depression BSI_Anxiety 
Happy .28* .29* 
Excited .02 .08 
Sad .40* .41* 
Irritable .33* .37* 
Angry .52* .57* 
ALS .65* .76* 
WRAADDS-EDS .68* .76* 
Correlation is significant at the .01 level (2-tailed).     
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5.5 Discussion 
The main aim of this study was to assess the similarities and differences in 
measures of emotional dysregulation in adults with ADHD, BPD, comorbid 
ADHD/BPD and controls using ambulatory monitoring and retrospective 
questionnaire measures. 
5.5.1 The dynamic changes of emotions 
Regarding retrospective questionnaire measures, the clinical diagnoses reported 
significantly heightened levels of emotional dysregulation compared to controls, yet 
no distinctive differences were detected between the diagnoses on these measures. 
Regarding ESM measures of emotional dysregulation, the BPD and comorbid 
ADHD/BPD diagnoses displayed differences in the intensity and instability of 
positive and negative emotion items compared to controls. Consistent with these 
findings, the ADHD diagnosis showed heightened intensity and instability of sad 
and irritable compared to controls. 
On the other hand, no differences were seen between the ADHD diagnosis and 
controls on the intensity and instability of positive emotion items and angry. This 
suggested that emotions of happy, excited and angry are similarly expressed in 
controls and ADHD. The findings supported the clinical descriptions in the 
literature of emotional dysregulation in these clinical populations, including 
“definite shifts from normal mood to depression or mild excitement” (Reimherr et 
al., 2005, p.125), and “rapid shifts into depression and excitability” (Asherson, 
Chen, Craddock, & Taylor, 2007, p.7) in  ADHD, and “rapid changes in mood” 
(Carpenter & Trull, 2013, p.3), and “high levels of negative affect, lower levels of 
positive affect, and more instability if negative affect” (Trull, 2018, p.2) in BPD. 
Finally, results from the models investigating differences in the intensity of 
emotions between the clinical diagnoses indicated some differences with ADHD 
showing less intensity of negative emotions than BPD. No differences in the 
instability of positive and negative emotions were seen between the clinical 
diagnoses. 
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All the above-mentioned significant case-control differences, as well as differences 
seen between the ADHD and BPD diagnoses w ere accounted for by  
symptoms of anxiety and depression of the BSI. 
Overall, findings of this study suggest that intensity and instability of positive 
emotions are not able to distinguish between individuals with ADHD and controls, 
contrary to clear differences between controls and BPD populations. Additionally, 
emotional dysregulation cannot seem to distinguish between ADHD and BPD. 
Anxiety and depression seem to be strongly associated with intensity and instability 
of emotions in ADHD and BPD, potentially being markers of this dynamic 
phenomenon. 
5.5.2 Bad events 
ADHD and BPD have both been associated with greater adversity and acute 
stressful situations in everyday life (Bourvis, Aouidad, Cabelguen, Cohen, & 
Xavier, 2017; van der Meer et al., 2014), which raises the question whether 
emotional dysregulation is simply a reaction to the greater number of adverse 
situations in daily life and whether emotional dysregulation in ADHD and BPD 
differ by the type of adverse events (functional versus social). 
Overall, all three clinical diagnoses reported a higher number of bad events 
compared to controls, whilst not differing between each other. 
Both bad social and bad functional events had a significant effect on the intensity 
and instability of negative emotions, yet covariation for the effect of these bad 
events did not eliminate or generate any group differences. The models controlling 
for these bad events only slightly changed still reflecting the same pattern of results 
of that seen without the covariate. In line with the findings in adult males with 
ADHD of Skirrrow et al. (2014), this could indicate that heightened intensity and 
instability of negative affect has both a reactive and an endogenously driven 
component in both ADHD and BPD, and differences between the groups are not 
accounted for by differences in the frequency of reported bad events. Similar 
findings in depres nois nwohs evah  that although reactions to significant  
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external events contribute to emotional instability, they do not fully explain the 
levels of emotional instability in major depressive disorder (Thompson et al., 2012). 
Regarding differences between ADHD and BPD on the type of bad events, for most 
of the emotions the type of event (social or functional) had the same effect for both 
ADHD and BPD diagnoses. The exceptions were that the ADHD diagnosis 
reported higher intensity of irritable in the presence of bad social events, whilst the 
BPD diagnosis reported higher intensity of angry in the presence of bad functional 
events. These two isolated findings were not however expected, are hard to explain, 
and should therefore be treated with caution. 
Overall, the findings on bad events do not support the initial hypothesis of 
emotional dysregulation being triggered more frequently by bad social events in 
BPD, as opposed to bad functional events in ADHD, overall indicating that type of 
events doesn’t distinguish the disorders. This could be due to the 
pseudorandomised sampling strategy of the ESM data which may not have been 
adequate to investigate the effects of adverse life events on negative emotions. An 
event-contingent paradigm in future research, where reports are provided when 
experiencing certain environmental events, as opposed to predefined schedule, 
could be more appropriate to test the reactivity model of emotional dysregulation 
(Trull et al., 2008). 
5.5.3 Relationship between retrospective questionnaires and prospective 
ambulatory monitoring 
The limited association as shown by the relatively low correlations between the 
questionnaire measures and ambulatory assessment measures of emotional 
dysregulation across the control and clinical samples together, suggests only a small 
to moderate concordance between these two types of measures. These findings are 
in line with previous research in ADHD (Skirrow et al., 2014), bulimia nervosa 
(Anestis et al., 2010) and personality disorders (Solhan et al., 2009), where weak 
associations in such comparisons were also seen. Given the dynamic nature of 
emotions on one hand, and the recall bias associated with retrospective measures 
on the other hand, overall, these results indicated that whilst these measures can be 
considered complementary, they may not be considered equivalent. 
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5.5.4 Strengths and limitations  
This study was the first to compare ADHD and BPD for measures of emotional 
dysregulation using a prospective ESM approach, with high sampling frequency 
and time-sensitive instability indices (Santangelo et al., 2014). Despite using 
multiple measures of emotional dysregulation and including carefully selected and 
diagnosed clinical cases, the findings should be considered in light of several 
limitations. 
The moderate compliance rate obtained in this study was low compared to previous 
studies in BPD and depression, with rates around 90% and above (Ebner-Priemer, 
Welch, et al., 2007; Solhan et al., 2009), yet was more closely in line with other 
ESM studies in outpatients with schizophrenia (69%; Granholm, Loh, & 
Swendsen, 2008), adult men with ADHD (64%; Skirrow et al., 2014), and healthy 
adolescents (71%; Hedeker, Mermelstein, Berbaum, & Campbell, 2009). 
Additional limitations concern the general sample demographics. Results may not 
be generalised beyond the specific demographic and diagnostic groups utilised in 
this study, which included only females from outpatient ADHD and BPD specialist 
clinics. Yet, this had the advantage of not accounting for potential sex differences in 
the analyses. Results from the comparisons between the ADHD diagnosis and 
controls were similar with the findings of Skirrow et al. (2014) in adult men with 
ADHD and without other comorbidities, who showed increased instability of 
irritable and angry and no differences in the intensity and instability of positive 
emotions compared to controls. On the other hand, to the best of my knowledge, 
no studies of ESM have been conducted in males with BPD. Two ESM studies in 
BPD initially recruited six (Jahng et al., 2011) and two (Russel et al. 2007) males 
respectively into their samples, but subsequently had to exclude them from 
analyses, as the number was not sufficient for the examination of sex differences. 
Therefore, future studies are required to confirm the findings reported here in males 
with BPD. 
In this study, care was taken to exclude individuals with comorbid major depressive 
disorders and anxiety disorders. Yet, all three clinical groups showed equally 
heightened symptoms of depression and anxiety compared to controls, and 
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significant differences between diagnoses in measures of emotional dysregulation 
were all accounted for by these depressive and anxious symptomatology. Emotional 
dysregulation seems to have a similar relationship to depression and anxiety in both 
ADHD and BPD, further suggesting that the type of emotional dysregulation is 
similar in the two disorders. Therefore, it seems plausible that anxious and depressive 
symptoms have a marked effect on emotional dysregulation, and their close 
association with intensity and instability of emotional dysregulation could mean that 
they might all reflect a single underlying construct. This was in line with the findings 
of Skirrow at al. (2014), where comorbid depression and anxiety disorders were 
systematically excluded in men with ADHD, yet high subthreshold depressive 
symptoms were present in the sample, and comparable results to this study of 
emotional intensity and instability were seen. Of note, the depression and anxiety 
subscales of the BSI have been shown to have good predictive ability for DSM-IV 
diagnoses of depression and anxiety (Petkus et al., 2009), yet were recommended not 
to be relied upon as an alternative to diagnosis (Recklitis, Blackmon, & Chang, 2017). 
Future studies should address the underlying mechanisms of depression and anxiety, 
how they relate to emotional dysregulation and their potential implications on 
treatment outcome. 
The nature of self-reported assessments in all measures used in this study should be 
considered when interpreting the results. Whether retrospectively assessed in 
questionnaire measures, or prospectively in ESM measures, reports were based on 
the subjective view of the individuals of their affective states. Additionally, it will 
remain unknown whether the extreme mood changes were triggered by the reported 
bad events, or whether they were over-reported and influenced by these bad events. 
Future investigations of ADHD and BPD using ESM approach could additionally 
incorporate more objective physiological measures (e.g. heart rate, breathing, 
arousal), which will reflect emotional reactivity and instability more accurately 
(Alpers, 2009), and/or employ more complex network analyses, which is an 
empirical approach when investigating interactive components (Bringmann et al., 
2016; Hasmi et al., 2017). 
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5.5.5 Conclusions 
The current study employed ambulatory assessmen st  to qualitatively characterise the 
intensity and instability in emotions experienced by adult females with ADHD and 
BPD over a period of five days. Real-life assessments of emotions showed 
complementary findings to data of retrospectively reported emotional 
dysregulation. The lack of specificity in the intensity and instability of negative 
affect in ADHD and BPD was not entirely surprising, and were line with unspecific 
patterns of emotional dysregulation also reported in bulimia nervosa, posttraumatic 
stress disorder, depression, anxiety disorders and bipolar disorder (Santangelo et al., 
2014). Notably, differences in intensity and instability of mood could not be 
accounted for by the presence and impact of bad negative events in ADHD or BPD. 
Despite the fact that BPD is the only disorder where emotional dysregulation is a 
diagnostic criterion, results in this study showed similar patterns of heightened 
instability in ADHD as well. Findings further support the notion that emotional 
dysregulation is a transdiagnostic clinical symptom of several psychiatric 
conditions and could not be used to distinguish between disorders.  
Promising avenues for future research include to statistically model the dynamic 
interplay between affect and self-esteem to discriminate between transdiagnostic 
and disorder-specific mechanisms as previous findings have shown that individuals 
with unstable self-esteem could be more reactive to daily events (Greenier et al., 
1999; Meier, Semmer, & Hupfeld, 2009). Additional suggestions by the Research 
Domain Criteria (RDoC; Insel et al., 2010) are to explore overlapping underlying 
mechanisms of emotional dysregulation using dimensions of neurobiology and 
observable behaviour (integrated information from genomics and circuits to 
behaviour and self-reports). 
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adults: A systematic review and meta-analysis 
European Psychiatry 44 (2017) 198–207Review
Effects of stimulants and atomoxetine on emotional lability in adults:
A systematic review and meta-analysis
T.R. Moukhtarian a,1,*, R.E. Cooper a,b,1, E. Vassos a, P. Moran c, P. Asherson a
aKing’s College London, MRC social, genetic and developmental psychiatry centre, Institute of psychiatry, psychology and neuroscience, SE5 8AF London, UK
bNewham centre for mental health, unit for social and community psychiatry, Queen Mary University of London, UK
cCentre for academic mental health, School of social & community medicine, University of Bristol, UK
A R T I C L E I N F O
Article history:
Received 22 March 2017
Received in revised form 8 May 2017
Accepted 11 May 2017








A B S T R A C T
Background: Emotional lability (EL) is an associated feature of attention-deﬁcit/hyperactivity disorder
(ADHD) in adults, contributing to functional impairment. Yet the effect of pharmacological treatments for
ADHD on EL symptoms is unknown. We conducted a systematic review and meta-analysis to examine the
effects of stimulants and atomoxetine on symptoms of EL and compare these with the effects on core
ADHD symptoms.
Methods: A systematic search was conducted on the databases Embase, PsychInfo, and Ovid Medline1
and the clinicaltrials.gov website. We included randomised, double-blind, placebo-controlled trials of
stimulants and atomoxetine in adults aged 18–60 years, with any mental health diagnosis characterised
by emotional or mood instability, with at least one outcome measure of EL. All identiﬁed trials were on
adults with ADHD. A random-effects meta-analysis with standardised mean difference and 95%
conﬁdence intervals was used to investigate the effect size on EL and compare this to the effect on core
ADHD symptoms.
Results: Of the 3,864 publications identiﬁed, nine trials met the inclusion criteria for the meta-analysis.
Stimulants and atomoxetine led to large mean weighted effect-sizes for on ADHD symptoms (n = 9,
SMD = 0.8, 95% CI:1.07 to 0.53). EL outcomes showed more moderate but deﬁnite effects (n = 9,
SMD = 0.41, 95% CI:0.57 to 0.25).
Conclusions: In this meta-analysis, stimulants and atomoxetine were moderately effective for EL
symptoms, while effect size on core ADHD symptoms was twice as large. Methodological issues may
partially explain the difference in effect size. Reduced average effect size could also reﬂect heterogeneity
of EL with ADHD pharmacotherapy responsive and non-responsive sub-types. Our ﬁndings indicate that
EL may be less responsive than ADHD symptoms overall, perhaps indicating the need for adjunctive
psychotherapy in some cases. To clarify these questions, our ﬁndings need replication in studies selecting
subjects for high EL and targeting EL as the primary outcome.
C 2017 Elsevier Masson SAS. All rights reserved.
Contents lists available at ScienceDirect
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jo u rn al h om epag e: h t tp : / /ww w.eu ro p s y- jo ur n al .co m1. Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is a common
neurodevelopmental condition affecting around 5% of children
[1]. Longitudinal follow-up studies show that ADHD frequently
persists into adulthood, either as the full blown disorder, or as
persistent subthreshold levels of symptoms causing impairment
[2,3], with epidemiological surveys suggesting an estimated
prevalence in adults of around 3–4% [4]. Although inattention,
hyperactivity and impulsivity are considered to be the core
symptoms of ADHD [5], emotional lability (EL), characterised by* Corresponding author.
E-mail address: talar_rita.moukhtarian@kcl.ac.uk (T.R. Moukhtarian).
1 Co-ﬁrst authors.
http://dx.doi.org/10.1016/j.eurpsy.2017.05.021
0924-9338/C 2017 Elsevier Masson SAS. All rights reserved.low frustration tolerance, irritability and mood lability, is a
commonly associated feature that causes considerable distress to
individuals and their families [6]. Clinically signiﬁcant levels of EL
are present in around 70–90% of adults with ADHD, and is an
independent predictor of functional impairments beyond those
accounted for by inattention and hyperactivity-impulsivity [7–10].
The importance of EL in adult ADHD was established by Wood,
Wender and colleagues, who were among the ﬁrst to describe the
syndrome and included affective lability, hot temper, and stress
intolerance as core symptoms of the disorder [11,12]. The current
diagnostic and statistical manual of mental disorders (DSM-5)
describes such emotional symptoms as associated features of ADHD
that support the diagnosis [13]. Furthermore, high levels of EL are
also observed in ADHD patients who do not present with co-





(1946 to June week 1, 2015)
Embase
(1974 to June 10, 2015)
PsychInfo
(1806 to June week 2, 2015)
Key Word search: (‘‘affect*’’ or ‘‘oppositional’’
or ‘‘conduct’’ or ‘‘aggression’’ or ‘‘mood’’ or
‘‘emotion*’’ or ‘‘instability’’ or ‘‘lability’’ or
‘‘*regulation’’ or ‘‘bipolar’’) and
(‘‘stimulants’’ or ‘‘*methylphenidate*’’ or
‘‘*amphetamine*’’ or ‘‘*amfetamine*’’ or
‘‘atomoxetine’’) and (‘‘RCT’’ or ‘‘randomized
controlled trial’’ or ‘‘randomised controlled
trial’’ or ‘‘double blind study’’ or ‘‘clinical
trial’’ or ‘‘placebo controlled’’)
Clinicaltrials.gov (‘‘affect*’’ OR ‘‘oppositional’’ OR ‘‘conduct’’
OR ‘‘aggression’’ OR ‘‘mood’’ OR ‘‘emotion*’’
OR ‘‘instability’’ OR ‘‘lability’’ OR
‘‘*regulation’’ OR ‘‘bipolar’’) AND
(‘‘stimulants’’ OR ‘‘*methylphenidate*’’ OR
‘‘*amphetamine*’’ OR ‘‘*amfetamine*’’ OR
‘‘atomoxetine’’)
T.R. Moukhtarian et al. / European Psychiatry 44 (2017) 198–207 of EL with ADHD cannot always be accounted for by the presence of
comorbid disorders such as bipolar or borderline personality
disorders [14].
Debate as to whether EL reﬂects a core domain of ADHD in
adults is ongoing [5,15,16]. In particular it is unclear whether
medications such as stimulants and atomoxetine, used in the
treatment of ADHD, also lead to reductions in EL. Randomized
placebo controlled trials in adults with ADHD conclusively show
that both groups of medications lead to clinically signiﬁcant
reductions in symptoms of ADHD symptoms [9,17–20]. However,
the effects of drugs used to treat ADHD on EL are yet to be
established.
In order to assess the effects of stimulants and atomoxetine on
EL in adults we conducted a systematic review and meta-analysis
of randomised placebo-controlled trials. Our primary aim was to
quantify the effects of stimulants and atomoxetine on EL. Our
secondary aim was to contrast the effects of stimulants and
atomoxetine on EL with the effects on the core ADHD symptoms of
inattention and hyperactivity-impulsivity in the same studies.
2. Methods
We conducted a systematic review and meta-analysis in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [21].
2.1. Search strategy and selection criteria
Studies were included if: (a) they were randomised double-
blind placebo-controlled trials of stimulants or atomoxetine; (b)
participants were adults aged 18–60 years with any mental health
diagnosis associated with EL1; (c) the study measured at least one
outcome of behavioural change related to EL; (d) for each outcome
measure, mean (M) and standard deviation (SD) from baseline and
follow-up for the placebo and active group were reported or
obtained upon contacting the authors. Trials published in
languages other than English were excluded for feasibility reasons
of translation.
A literature search was conducted using pre-speciﬁed search
terms (Table 1) using the following databases: Embase (1974 to
2015 June 10th), PsychInfo (1806 to June week 2, 2015) and Ovid
Medline1 (1946 to June week 1, 2015). Unpublished or ongoing
trials were searched on the clinicaltrials.gov website. Authors were
contacted to request missing data.
In spite of the ofﬁcial systematic search being stopped in June
2015, there were no new clinical trials published meeting the
selection criteria of this systematic review up until 2nd May, 2017.
To assess for the risk of bias, study quality was assessed by two
independent authors (TRM & PM) according to PRISMA guidelines
and the Cochrane Handbook of Systematic Reviews [22] (Tables
2 and 3). TRM and PM then met to discuss assessments and reach a
consensus on study inclusion. Unresolved classiﬁcation of studies
was arbitrated by PA and REC. Studies were classiﬁed overall as
unclear, low or high risk. High risk studies were excluded.
Data extraction was performed by TRM and checked by two
research assistants. The main outcome measures were raw scores
of mean and standard deviation of the pre- and post-treatment
measures of EL and DSM-IV ADHD symptoms for active and
placebo arms. Intent to treat analysis (ITT) was reported. For trials
with a cross-over design, only the initial pre-cross-over data was
included, if available, and treated as a parallel group trial. We used
this rather conservative approach because there was lack of1 ADHD was not speciﬁed as a search term, with the intention of including trials
of stimulants and atomoxetine on EL in non-ADHD populations. However, all
resulting trials were conducted on adults with ADHD.sufﬁcient data to permit analysis of within-individual change (i.e.
correlations of scores between conditions were not given). Missing
data that remained unavailable after contacting authors were not
imputed.
2.2. Outcome measures
Two outcome domains were included in the meta-analysis: EL
and DSM-IV ADHD symptoms. EL was measured using the emotion
dysregulation subscale of the Wender Reimherr Adult Attention
Deﬁcit Disorder Scale (WRAADDS-EDS) [11], which combined
subscales of hot temper, affective lability and emotional over-
reactivity, or the emotion control subscale of the Behaviour Rating
Inventory of Executive Function (BRIEF-A) [23]. ADHD DSM-IV
domains were measured by the investigator-rated, self-rated or
informant-rated Conners Adult ADHD Rating Scale (CAARS) [24],
ADHD- Rating Scale (ADHD-RS) or the investigator rated
WRAADDS [11]. Table 4 contains a detailed list of measures used
in these two domains.
2.3. Data analysis
2.3.1. Statistical analyses
Analyses were performed in STATA 11.2 [25]. An initial analysis
in the full sample across the two domains of EL and ADHD
symptoms was run, following this, subgroup analyses (see below)
were conducted.
We report the SMD calculated as the mean pre-to-post-
treatment change, minus the mean pre-to-post-placebo group
change, divided by the pooled pre-test standard deviation (SD),
with a bias adjustment. The equation for this method is presented
below [26]. Effects sizes were classiﬁed according to Cohen’s d as









nT1ð ÞSD2pre; T þ nC1ð ÞSD2pre; C
nT þ nC2
s
CP ¼ 1 34 nT þ nc2ð Þ1
Table 3
Study quality appraisal.
First Author Reason if not low risk? Other limitations
Reimherr et al. (2007) Random sequence generation: Insufﬁcient information
Allocation concealment: Insufﬁcient information
Blinding of participants and personnel: Procedure unspeciﬁed
Blinding of outcome: Procedure unspeciﬁed
Incomplete outcome data: 6 drop-outs, reasons not stated
N/A
Wender et al. (2011) Allocation concealment: Insufﬁcient information N/A
Reimherr et al. (2005) Random sequence generation: Insufﬁcient information
Allocation concealment: Unspeciﬁed
Blinding participants and personnel: Insufﬁcient information
N/A
Adler et al. (2013) Random sequence generation: Unspeciﬁed
Blinding of outcome assessment: Unspeciﬁed
N/A
Adler et al. (2014) Blinding of outcome assessment: Insufﬁcient information N/A
Rosler et al. (2010) Random sequence generation: Randomised
Allocation concealment: Insufﬁcient information
Blinding of participants: Double-blind
Blinding of outcome assessment: Insufﬁcient information.
N/A
Merchant et al. (2011) Allocation concealment: Unspeciﬁed
Blinding of participants and personnel: Unspeciﬁed
Binding of outcome assessment: Unspeciﬁed
Incomplete outcome data: High drop-out rate with no explanations
N/A
Goto et al. (2011) Random sequence generation: Unspeciﬁed
Allocation concealment: Unspeciﬁed
Blinding of participants and personnel: Insufﬁcient information.
Blinding of outcome assessment: Unspeciﬁed
N/A
Retz et al. (2012) Allocation concealment: Insufﬁcient information
Blinding of participants and personnel: Unspeciﬁed
Binding of outcome assessment: Unspeciﬁed
N/A
Table 2























Reimherr et al. (2007) Unclear Unclear Unclear Unclear Unclear Low N/A Unclear No
Wender et al. (2011) Low Unclear Low Low Low Low N/A Unclear No
Reimherr et al. (2005) Unclear Unclear Unclear Low Low Low N/A Unclear No
Adler et al. (2013) Unclear Low Low Unclear Low Low N/A Unclear No
Adler et al. (2014) Low Low Low Unclear Low Low Low Unclear No
Rosler et al. (2010) Unclear Unclear Unclear Unclear Low Low N/A Unclear No
Marchant et al. (2011) Low Unclear Unclear Unclear Unclear Low N/A Unclear No
Goto et al. (2011) Unclear Unclear Unclear Unclear Low Low N/A Unclear No
Retz et al. (2012) Low Unclear Unclear Unclear Low Low N/A Unclear No
T.R. Moukhtarian et al. / European Psychiatry 44 (2017) 198–207Note. dppc2: standardised mean difference (SMD); Cp: bias
adjustment; M: mean; T: treatment, C: control, Post: post-
treatment, Pre: pre-treatment, SD: standard deviation, n: number
of participants.
Given the between-study heterogeneity in terms of study
design, trial duration, outcome measures and participant characte-
ristics we chose apriori to use random-effects models [28].
A nominal level of signiﬁcance was set at P < .05. The I2 statistic
assessed heterogeneity between studies. Publication bias was
investigated on the basis of funnel plots using Begg & Mazumdar’s
rank correlation approach and the Egger regression asymmetry
test.
2.3.2. Subgroup analyses
Additional analyses were conducted in subsets of the total
sample to investigate the stability of the results to the scale used tomeasure EL (WRAADS-EDS versus BRIEF-A) and the class of study
medication (stimulants versus atomoxetine).
Outcome measure: EL was measured by either BRIEF-A the
emotion control subscale [23] or the WRAADDS-EDS [11]. Analyses
were performed separately on the trials using the BRIEF-A (n = 3)
and WRAADDS-EDS (n = 6).
Medication class: Included trials medicated participants with
either stimulants or atomoxetine. Analyses were conducted
separately on studies which used stimulants (n = 6) and atomo-
xetine (n = 3).
Medication class and outcome measure: To check whether the
medication gave different effect size estimates when controlling
for the EL scale (BRIEF-A or WRAADDS-EDS) used: we compared
the effects of stimulants set against atomoxetine, ﬁrst when EL was
measured by the WRAADDS-EDS and then when it was measured
by the BRIEF-A.
Table 4
Detailed breakdown of behavioural rating scales included in the meta-analysis per study by the two outcome measures.





Reimherr et al. (2007) Emotional lability WRAADDS-EDS Emotional lability 20 20
ADHD symptoms ADHD-RS ADHD DSM-IV domains 20 20
Wender et al. (2011) Emotional lability WRAADDS-EDS Emotional lability 58 57
ADHD symptoms WRAADDS ADHD DSM-IV domains 58 57
Reimherr et al. (2005) Emotional lability WRAADDS-EDS Emotional lability 225 226
ADHD symptoms CAARS- Investigator rated ADHD DSM-IV domains 225 226
Adler et al. (2013) Emotional control BRIEF-A (BRI-emotional control subscale)-
self-report
Emotional lability 79 75
ADHD symptoms CAARS- Informant rated ADHD DSM-IV domains 79 80
Adler et al. (2014) Emotional control BRIEF-A (BRI-emotional control subscale) Emotional lability 161 167
ADHD symptoms CAARS- Investigator rated ADHD DSM-IV domains 192 199
Ro¨sler et al. (2010) Emotional lability WRAADDS-EDS Emotional lability 241 118
ADHD symptoms CAARS- Self report ADHD DSM-IV domains 239 118
Marchant et al. (2011) Emotional lability WRAADDS-EDS Emotional lability 26 33
ADHD symptoms CAARS- Investigator rated ADHD DSM-IV domains 26 33
Goto et al. (2011) Emotional control BRIEF-A (BRI-emotional control subscale)-
self-report
Emotional lability 178 190
ADHD symptoms CAARS- Investigator rated ADHD DSM-IV domains 191 195
Retz et al. (2012) Emotional lability WRAADDS-EDS Emotional lability 84 78
ADHD symptoms CAARS- Self report ADHD DSM-IV domains 83 76
Note. BRIEF-A (BRI) = Behaviour Rating Inventory of Executive Function, behavioural regulation scales (Roth et al., 1996); WRAADDS = Wender-Reimherr Adult Attention
Deﬁcit Disorder Scale (Wender, 1995); CAARS = Conners’ Adult ADHD Rating Scale (Conners, 1998); ADHD-RS = ADHD- Rating Scale
T.R. Moukhtarian et al. / European Psychiatry 44 (2017) 198–207 3. Results
3.1. Selection of studies
The initial database search identiﬁed 3864 unique publications.
403 abstracts were screened against the inclusion criteria, of which
385 were excluded because: the data were already used or
reported in another publication (n = 18); the outcomes were
unsuitable (n = 44); the studies were not randomised controlled
trials (n = 61), failed to report a placebo group (n = 4); were open
label trials (n = 5); used unsuitable medication (medications other
than stimulants or atomoxetine) (n = 14) or population (n = 6);
were not published in English (n = 5); requests for data from
unpublished trials were not returned successfully (n = 24); or the
trial was conducted on children (n = 204). Eighteen full-text
articles were subsequently quality appraised and eight were
excluded because of: an open label design (n = 1), unsuitable
population (n = 2), unsuitable design (n = 2) and unsuitable
outcome (n = 3). Ten studies met the inclusion criteria, but one
of these had to be excluded on the grounds of missing statistics,
leaving nine studies for inclusion in the ﬁnal pool for the meta-
analysis (Fig. 1 and Tables 5–7).
3.2. Quality and characteristics of studies included in qualitative
synthesis
Nine studies were judged to be of sufﬁcient quality and
suitability to be included in the quantitative synthesis (Tables
2 and 3). Randomisation and allocation concealment were
explicitly described in only one study [29]. In the remainders,
this was absent or unclear. Means of blinding the participants,
personnel and outcome assessment were unclear in seven studies,
and were only clearly stated in three studies. In one study, 25.5% of
the initially recruited participants dropped out prior to randomi-
sation and another 12% following randomisation [19], and inanother study, four subjects were eliminated after randomisation
[30], raising concerns about the likelihood of selection bias. Study
characteristics are outlined in Table 5.
3.3. Quantitative meta-analysis
Main effects from the meta-analysis of the nine included
studies are summarised in Fig. 2. A detailed description of these
results is available in Appendix 1.
In adults with ADHD treatment with stimulants (OROS-
methylphenidate, IR-methylphenidate, Lis-dexamphetamine,
methylphenidate-ER, methylphenidate transdermal system) and
atomoxetine had a moderate effect on EL (9 studies, SMD = 0.41;
95% CI: 0.57 to 0.25, z = 5.14, P = 2.7  107) and a large effect
on ADHD symptoms (9 studies, SMD = 0.8; 95% CI: 1.07 to
0.53, z = 5.85, P = 4.9  109). There was evidence of high
heterogeneity in both analyses (X2 = 27.40, I2 = 70.8%, P = 0.001;
X 2 = 72.09, I2 = 88.9%, P < 0.001, respectively). There was no
evidence of publication bias.
3.4. Subgroup analysis
Main effects from the sub-group analyses are shown in
Table 8.
Outcome measure: In the subgroup analysis of studies using the
WRAADDS-EDS as a measure of EL, a higher treatment effect was
found for EL symptoms (6 studies, SMD = 0.54; 95% CI: 0.75 to
0.33, z = 5.02, P = 5.2  107), compared to the treatment effect of
ADHD medication on EL measured by the BRIEF-A (3 studies,
SMD = 0.19; 95% CI: 0.33 to 0.05, z = 2.66, P = 0.008).
Medication class: In the subgroup analysis of stimulants only, a
higher effect size was found on EL symptoms (6 studies,
SMD = 0.57; 95% CI: 0.80 to 0.34, z = 4.90, P = 9.6  107),
compared to the small effect of atomoxetine on EL (3 studies,










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Records identified through  database 
searching  
(n=4605) 
Additio nal  reco rds identi fied 
through other  sources   
(n=2) 
Records  after duplicates  re moved  
(n=3865) 
Records  sc reened  
(n=403) 
Records excluded  
(n=385) 
Full-text articles  excluded, 
with reasons  (n=8) 
Open label  (n=1)   
Unsuitable  population  (n=2) 
Unsuitable design  (n=2) 
Unsuitable outcome (n=3) 
Full-text articles  asse ssed 
for eligibility  
(n=18) 
Studies included  in 
qualitative synthesis   
(n=10) 
Studies included  in 
quantitative synthesis 
(meta-analysis)   
(n=9) 
Statistics not available  (n =1) 
Fig. 1. Prisma ﬂow diagram.
Table 7
Studies excluded at full text stage with reasons (n = 8).
Reason for exclusion Studies
Open label Sobanski et al. (2012)
Unsuitable population Drijgers et al. (2012)
Young et al. (2013)
Unsuitable design Kavoussi et al. (1993)
Du Paul et al. (2012)
Unsuitable outcome Brown et al. (2011)
T.R. Moukhtarian et al. / European Psychiatry 44 (2017) 198–207 We also looked at the effects of stimulants and atomoxetine on
core ADHD symptoms. There was a large treatment effect of
stimulants on core ADHD symptoms (6 studies, SMD = 0.98; 95%
CI: 1.51 to 0.44, z = 3.58, P = 3.4  104) and a moderate to large
treatment effect of atomoxetine (3 studies, SMD = 0.57; 95% CI:
0.68 to 0.45, z = 9.76, P = 1.7  1022).
Medication class and outcome measure: There was a large
treatment effect of stimulants on EL symptoms when the latter wasWender et al. (1985)
Medori et al. (2008)
Statistics not available Adler et al. (2014)Table 6










Trial duration (weeks) 8.9
MPH (daily dose) Ranging from 10 mg to 120 mg/day
ATX (daily dose) Ranging from 40 mg to 120 mg/day
a One study did not specify sex ratio’s and was therefore not included in this
calculation (Marchant et al., 2011).
b One study did not specify the mean age but only gave an age range of the
participants eligible to take part in the trial, therefore not included in this
calculation (Marchant et al., 2011).measured by the WRAADDS-EDS (5 studies, SMD = 0.64; 95% CI:
0.91 to 0.36, z = 4.46, P = 8.2  106).
Atomoxetine had a small effect on EL when this was measured
by the BRIEF-A (2 studies, SMD = 0.15; 95% CI: 0.3 to 0, z = 1.97,
P = 0.049).
4. Discussion
We conducted a systematic review and meta-analysis examin-
ing the efﬁcacy of stimulants (methylphenidate and dexamphe-
tamine/lisdexamfetamine) and atomoxetine on EL in adults. In
addition, we reported on the effects on ADHD symptoms in the
same studies to enable a comparison of medication effects on
ADHD and EL. Overall we found an effect of stimulants and
Fig. 2. Forests plots for meta-analyses across the two main outcome domains ES = Effect size.
Table 8
Subgroup meta-analyses of studies based on: (1) Outcome measure (2) medication class and (3) medication class and outcome measure.
Sub-analyses domain Studies P SMDa 95% CI
1 WRAADDS-EDS 2,3,6–9 5.2  107 0.54 0.75 to 0.33
BRIEF-A-BRI 1,4,5 0.008 0.19 0.33 to 0.05
2 Stimulants on EL 1,2,6–9 9.6  107 0.57 0.80 to 0.34
Atomoxetine on EL 3–5 0.001 0.21 0.34 to 0.08
Stimulants on ADHD 1,2,6–9 3.4  104 0.98 1.51 to 0.44
Atomoxetine on ADHD 3–5 1.7  1022 0.57 0.68 to 0.45
3 WRAADDS-EDS +Stimulants 2,6–9 8.2  106 0.64 0.91 to 0.36
BRIEF-A-BRI + Atomoxetine 4,5 0.049 0.15 0.3 to 0
Studies: 1 = Adler et al. (2013) [31]; 2 = Reimherr et al. (2007) [30]; 3 = Reimherr et al. (2005) [17]; 4 = Adler et al. (2014) [29]; 5 = Goto et al. (2011) [32]; 6 = Wender et al.
(2011) [33]; 7 = Marchant et al. (2011) [19]; 8 = Retz et al. (2012) [18]; 9 = Ro¨sler et al. (2010) [9].
a Negative SMD favours a treatment effect for the active medication (stimulants or atomoxetine); Positive SMD favours a treatment effect for the placebo group.
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T.R. Moukhtarian et al. / European Psychiatry 44 (2017) 198–207 atomoxetine of d = 0.41 (CI: 0.57 to 0.25) for EL symptoms and
d = 0.8 (CI: 1.07 to 0.53) for ADHD symptoms. Our ﬁndings
suggest that medications used to treat ADHD also have a signiﬁcant
effect on EL, although the effect appears to be more modest on EL
compared to the effect on the core ADHD symptoms of inattention
and hyperactivity-impulsivity.
Subgroup analyses indicated that use of the WRAADDS-EDS as
an outcome measure might lead to greater estimates of clinical
effectiveness of ADHD medications on EL than use of the BRIEF-A-
BRI scale. Subgroup analyses also indicated that stimulants might
have a stronger effect on reducing EL symptoms than atomoxetine.
The greater effects of stimulants compared to atomoxetine on EL is
in line with independent ﬁndings from meta-analyses of these
medication on core ADHD symptoms [34,35].
Consistent with this, the greatest effect on EL was found when
analysing the subgroup of 5 studies which examined the effects of
stimulants on EL measured by the WRAADDS-EDS (d = 0.64). These
ﬁndings suggests that the effect sizes on EL found in this meta-
analysis may have been affected by measurement bias or
differences in the effects of medication class (i.e. stimulants
compared to atomoxetine).
In this meta-analysis stimulants and atomoxetine had a two-
fold higher treatment effect on core ADHD than on EL symptoms.
Nevertheless, the moderate treatment effect shows clinically
signiﬁcant improvement in the symptoms of EL. One study that
was included in the qualitative but not the quantitative analysis
also found a signiﬁcant treatment effect of atomoxetine compared
with placebo on EL. Patients receiving atomoxetine had a
signiﬁcant reduction of EL symptoms measured by the BRIEF-A
self-rated and informant-rated scales [36].
There were a number of limitations associated with this
systematic review. First, despite adopting a broad approach towards
the selection of studies, many did not meet the eligibility criteria
and we were only able to include half of those assessed for eligibility
(9 studies) in the meta-analysis. Secondly, there was substantial
heterogeneity with regard to patient groups, assessment measures
(including differences in informant versus self-report vs investiga-
tor-rated measures) and quality of studies and we therefore had to
use random-effects models that produced wide conﬁdence inter-
vals. Thirdly, all the studies included in the meta-analysis relied on
participants who were selected on the grounds of having high levels
of core ADHD symptoms, not EL symptoms and this may have
contributed to the differential effect sizes. No studies of stimulants
or atomoxetine on EL symptoms were found for conditions other
than ADHD, and none of the trials examined the effects of ADHD
medication on EL as a primary outcome. Finally, none of the studies
reported standard deviation of the change (the difference before
and after the intervention) in their effect size calculations [26] and
so we had to rely on the pre-treatment standard deviation in our
calculations. This may also have contributed to an underestimation
of the true effect size associated with EL [37].
Another limitation was in relation to the different duration of
the included trials that may have inﬂuenced the result on EL.
Therefore a meta-regression of trial duration on both ADHD and EL
symptoms has been conducted. However, due to the small number
of studies and heterogeneity of study characteristic, the results
were inadequate.
In conclusion, our ﬁndings indicate that EL in patients with
ADHD can be treated with stimulants or atomoxetine. Although
these medications reduce EL, the effects appear to be modest by
comparison with the effects on the core ADHD symptoms of
inattention and hyperactivity-impulsivity. Our ﬁndings require
replication, particularly in patients selected for high baseline levels
of EL and addressing methodological issues such as measurement
bias and the potential differential effects of stimulants and
atomoxetine.With regard to the clinical implications of our ﬁndings, there
are two main possibilities to consider. First, that EL reﬂects a
heterogeneous domain of psychopathology that results from a
number of distinct processes requiring different treatments, much
in the same way there are different causes for fever or headache. In
this scenario it would be important to distinguish between
stimulant and atomoxetine responsive and non-responsive forms
of EL particularly in ADHD. An alternative explanation is that
stimulants and atomoxetine may have a more modest effect on EL
overall, perhaps indicating the need for additional targeted
psychological treatments in some cases. For example, dialectical
behaviour therapy has proven efﬁcacy in the treatment of
emotional instability in people with borderline personality
disorder [38], and may also have similar effects in ADHD
accompanying pharmacological treatments [39]. Further investi-
gations are required using individual patient level data to address
these questions.
Finally, we did not ﬁnd any studies of ADHD drug treatments in
adult ADHD patients with comorbid conditions in which emotional
symptoms are also prominent. Further studies are therefore
required to clarify the role that stimulants or atomoxetine play in
the treatment of EL in patients with ADHD and co-occurring
conditions such as borderline personality disorder, or bipolar
disorder. Notwithstanding, clinicians should be aware that
symptoms of EL are often reduced when treating patients with
stimluants or atomoxetine who meet diagnostic criteria for ADHD.
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Appendix 1. Detailed description of meta-analyses results
Emotional lability
Nine trials in 2,036 adults with ADHD examined emotional
lability. There was a moderate effect of stimulants and atomoxe-
tine on EL (SMD = 0.41; 95% CI: 0.57 to 0.25, z = 5.14,
P = 2.7  107) with evidence of signiﬁcant high heterogeneity
(X 2 = 27.40, I2 = 70.8%, P = 0.001).
T.R. Moukhtarian et al. / European Psychiatry 44 (2017) 198–207ADHD symptoms
Nine trials in 2,097 adults with ADHD examined combined
ADHD symptoms. There was a large effect of stimulants and
Atomoxetine on core ADHD symptoms (SMD = 0.8; 95% CI: 1.07
to 0.53, z = 5.85, P = 4.9  109) with evidence of high signiﬁcant
heterogeneity (X 2 = 72.09, I2 = 88.9%, P < 0.001).
Emotional lability (WRAADDS-EDS)
Six trials in 1,186 adults with ADHD examined EL using the
emotion dysregulation subscale (EDS) of the WRAADDS. There was
a medium effect of stimulants and ATX on EL (SMD = 0.54; 95%
CI: 0.75 to 0.33, z = 5.02, P = 5.2  107) with evidence of
signiﬁcant heterogeneity (X2 = 18.78, I2 = 73.4%, P = 0.002).
Emotional lability (BRIEF-A-BRI, emotional control sub-
scale)
Three trials in 850 adults with ADHD examined EL using the
emotional control subscale of the BRIEF-A. There was a small
signiﬁcant effect of stimulants and ATX on EL (SMD = 0.19; 95%
CI: 0.33 to 0.05, z = 2.66, P = 0.008) with no evidence of
heterogeneity (X2 = 2.17, I2 = 7.9%, P = 0.337).
Emotional lability (Stimulants)
Six trials in 889 adults with ADHD examined effects of
stimulants on EL. There was a medium to large effects of stimulant
medication on EL (SMD = 0.57; 95% CI: 0.80 to 0.34, z = 4.90,
P = 9.6  107), with evidence of heterogeneity (X2 = 17.76,
I2 = 71.8%, P = 0.003).
Emotional lability (Atomoxetine)
Three trials in 1,147 adults with ADHD examined effects of
Atomoxetine on EL. There was small signiﬁcant effect of ATX on EL
(SMD = 0.21; 95% CI: 0.34 to 0.08, z = 3.25, P = 0.001) with no
evidence of heterogeneity (X2 = 2.42, I2 = 17.3%, P = 0.298).
ADHD symptoms (Stimulants)
Six trials in 889 adults with ADHD examined effects of
stimulants on core ADHD symptoms. There was a large treatment
effect of stimulants on ADHD symptoms (SMD = 0.98; 95% CI:
1.51 to 0.44, z = 3.58, P = 3.4  104), with evidence of
signiﬁcant heterogeneity (X2 = 71.47, I2 = 93%, P < 0.001).
ADHD symptoms (Atomoxetine)
Three trials in 1,228 adults with ADHD examined effects of
Atomoxetine on core ADHD symptoms. There was a moderate to
large treatment effect of ATX on ADHD symptoms (SMD = 0.57;
95% CI: 0.68 to 0.45, z = 9.76, P = 1.7  1022) with no evidence
of heterogeneity (X2 = 0.4, I2 = 0%, P = 0.817).
Emotional lability (WRAADDS-EDS + stimulants)
Five trials in735 adults examined the effects of stimulants on EL
when measured by the WRAADDS-EDS. There was a large
treatment effect of stimulants on EL (SMD = 0.64; 95% CI:
0.91 to 0.36, z = 4.46, P = 8.2  106) with evidence of signiﬁ-
cant heterogeneity (X2 = 17.66, I2 = 77.4%, P = 0.001).
Emotional lability (BRIEF-A + Atomoxetine)
Two trials in 696 adults examined the effects of atomoxetine on
EL when this was measured by the BRIEF-A-BRI. There was a small
treatment effect of ATX on EL (SMD = 0.15; 95% CI: 0.3 to 0,
z = 1.97, P = 0.049), with no evidence of heterogeneity (X2 = 0.56,
I2 = 0%, P = 0.45).
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The overall aim of this thesis was to further our understanding of the association 
between attention-deficit/hyperactivity disorder (ADHD) and borderline personality 
disorder (BPD). This was accomplished by bringing together a diversity of 
methodologies and approaches to investigate some of the key underlying clinical 
features that are seen in both disorders. In this chapter, I provide a brief summary 
and interpretation of the key findings for each chapter separately with respect to the 
thesis aims. I then discuss common emerging themes from this thesis and present 
wider clinical implications along with suggestions for future directions, and finally 
present the main strengths and limitations of the research. 
7.2 Overview of key findings 
To further understand the associations between ADHD and BPD in women, in 
Chapter 3, latent class analysis (LCA) was undertaken on a sample of female 
controls, and selected groups meeting DSM-5 diagnostic criteria for ADHD, BPD 
and comorbid ADHD/BPD. The aim was to validate the classification of the clinical 
cases using an empirical approach to identify exclusive classes differing in profiles of 
adult symptoms of ADHD and BPD. First, the latent classes were examined in 
relation to the DSM-5 classification of ADHD and BPD. Secondly, the latent classes 
and DSM-5 groups were used to explore the sample’s characteristics on various 
measures of psychopathology. The findings showed that the LCA and DSM-5 
diagnostic classification groups cross-validate well, indicating the validity of the 
constructs used. Regarding the phenotypic characteristics of the sample, overall the 
empirical and DSM-5 diagnostic approaches gave comparable results. Emotional 
dysregulation, excessive spontaneous mind wandering, anxiety, childhood 
maltreatment and impairments in various domains of everyday life, all measured by 
retrospective questionnaires, reflected non-specific symptoms, risk factors and 
outcomes that were seen across both disorders and could not be relied upon to 
discriminate ADHD from BPD. Furthermore, the ADHD and BPD groups were not 
completely distinct. Both DSM-5 and LCA classification approaches showed that 
one disorder does not appear without the presence of some of the core symptoms of 





the cluster of several of the core symptoms in each disorder (which were measured 
by the diagnostic interviews of the disorders), and the threshold counts (reflecting 
clinical syndromes rather than symptoms), appear to be specific enough to 
systematically delineate the disorders from one another. 
One methodological limitation of the first study (chapter 3) was the reliance on 
retrospectiv  e rating scale data, which could be prone to a variety of  
recall biases. The second (chapter 4) and third (chapter 5) studies summarised below, 
circumvented these problems by using prospective (real time experience sampling) 
data collection methods. 
Chapter 4 and chapter 5 aimed at investigating excessive spontaneous mind 
wandering, and emotional dysregulation respectively, as two components of 
psychopathology that might distinguish ADHD from BPD. In these studies, an 
experience sampling method (ESM) was used, in which participants rated symptoms 
of mind wandering and emotions eight times daily over a period of five days.   
Chapter 4 reports that similar levels of mind wandering in both ADHD and BPD 
diagnoses are found, suggesting that excessive mind wandering leading to 
inattentiveness may be a greater problem in the daily lives of individuals with BPD 
than generally recognised. Nonetheless, the type of mind wandering in ADHD 
appeared to be distinctive. In ADHD mind wandering seemed to reflect a core 
characteristic of the disorder that was not accounted for by symptoms of anxiety or 
depression, whereas in BPD mind wandering was accounted for by levels of anxiety 
and depressive symptoms.  
In chapter 5, using a similar ESM approach, intensity and instability of positive and 
negative emotions, as well as the influence of daily adverse events on these emotions 
were investigated. ADHD and BPD showed similar levels of emotional instability 
for positive and negative symptoms, and some differences in the intensity of happy, 
sad, and angry. Significant differences between the groups were accounted by the 
level of anxiety and depression symptoms. Additionally, neither the increased 
intensity nor instability of emotions in the clinical diagnoses could be fully accounted 
by increased frequency and impact of bad events, reflecting a reactive and an 





Chapter 6 provided the most conclusive evidence to date that treatment with 
stimulants and atomoxetine has a clinically significant effect on reducing symptoms 
of emotional dysregulation in adults with ADHD. Stimulants (methylphenidate and 
dexamphetamine/lisdexamphetamine) and atomoxetine were moderately effective 
for reducing symptoms of emotional dysregulation, while effect sizes on core ADHD 
symptoms (inattentive and hyperactivity/impulsivity) were twice as large. However, 
cases in these studies were selected for high levels of ADHD symptoms and not 
emotional dysregulation. Furthermore, there was some evidence that effects were 
greater with stimulants than atomoxetine, requiring further investigation. A more 
recent systematic review and meta-analysis, also assessing the effects of ADHD 
medication on symptoms of emotional dysregulation in adults, showed small-to-
medium effects (Lenzi, Cortese, Harris, & Masi, 2017), slightly lower than the meta-
analysis I conducted. Several methodological differences could explain this 
discrepancy. First, Lenzi et al. (2017) included six additional trials with a cross-over 
design, which was an exclusion criterion in my study, and another two trials in which 
the active medication under investigation was duloxetine and bupropion. These two 
have a different mode of action from stimulants or atomoxetine, are not validated as 
effective treatments for ADHD according to the NICE guidelines (NICE, 2018), and 
therefore were excluded from my study. Second, three trials were published after the 
search and selection phase of the current study ended.  
Overall, emotional dysregulation was found to be less responsive to stimulants and 
atomoxetine than core ADHD symptoms, perhaps indicating the need for adjunctive 
psychotherapy in medication non-responsive forms of emotional dysregulation in 
adults with ADHD.  
7.3 General discussion 
Overall, this thesis addresses several gaps in the literature and clinical understanding 
of the nature of the relationship between ADHD and BPD. 
All the data chapters in this thesis point to the transdiagnostic nature of the 
overlapping symptoms of ADHD and BPD and of related impairments in various life 





LCA and DSM-5 classifications of the disorders showed that symptoms of BPD were 
not found to occur without at least some ADHD symptomatology and vice versa.  
7.3.1 Towards a dimensional classification 
The empirical findings of this thesis challenge the value of the categorical 
classification of ADHD and BPD, supporting instead a more dimensional and 
symptom-led approach of classification. For example, heightened intensity and 
instability of emotional symptoms, and frequency of mind wandering, were seen in 
both ADHD and BPD. Furthermore, subthreshold ADHD was seen in BPD cases 
and vice versa, indicating the somewhat arbitrary nature of the designated symptom 
count thresholds for both disorders.  Chapter 3 showed that the BPD only class, in 
addition to the BPD symptoms, also showed high probability for “difficulty 
sustaining attention”, which mostly characterises symptoms of mind wandering. 
This was then directly supported by the findings in chapter 4, where the BPD 
diagnosis showed equally heightened and more frequent mind wandering as the 
ADHD diagnosis. 
Regarding the LCA analyses, one could argue that the findings reported in chapter 3 
did not provide any novel finding, but rather showed a circular pattern of 
investigation because of the selected nature of the sample based on DSM-5 criteria. 
However, the LCA analysis was taken in addition to the DSM-5 classification 
because I was concerned about the use of pre-defined symptom thresholds and 
wanted to check that a more empirical approach to classifying the diagnostic groups 
(not relying on pre-determined symptom count thresholds) would not lead to 
significant changes in the results of the study. For example, LCA might have 
provided better separation of the groups than using the pre-defined DSM-5 criteria. 
This concern became apparent during data collection, when by using the thresholds 
set out to separate one condition from the other, some individuals fell just above or 
below the designated symptoms thresholds. I wanted to check whether a more 
symptom-based empirical approach would re-classify individuals who laid on one 
side or the other of these thresholds set out in the DSM-5. With only few cross-over 
cases and despite the overlap of individual items, the LCA showed comparable 





number of variables used in the LCA and a rather small sample size for this type of 
analysis, which statistically prevented the selection of a solution with more than four 
classes. Future studies using LCA to separate ADHD from BPD, should aim at 
replicating these findings in larger epidemiological samples unselected for high 
ADHD and BPD symptoms. 
The findings from this thesis suggest that the overlap of ADHD and BPD does not 
reflect how the disorders are classified, where there appears to be good distinction, 
but rather concerns the overlap of individual symptoms. This is one reason why 
emotional dysregulation is only specified as an ‘associated feature’ of ADHD 
supporting the diagnosis in DSM-5 (American Psychiatric Association, 2013) rather 
than a core symptom used in the classification of ADHD, as it is also seen in BPD 
and other disorders.  Emotional dysregulation appears to reflect a heterogenous 
domain of psychopathology present as a transdiagnostic symptom in ADHD and 
BPD, as well as in other psychiatric disorders such as post traumatic disorder and 
bulimia nervosa (Santangelo et al., 2014). So, it is intuitive to question the specificity 
of emotional dysregulation in BPD as a core diagnostic criterion, when it has been 
shown both in the literature and in the current thesis that it cannot be used to 
delineate it from other disorders. In fact, both ADHD and BPD reflect impairing 
extremes of dimensional traits (Chen et al., 2008; Clark, 2007), thus it is also intuitive 
to see symptoms of these disorders across a wide range of psychiatric conditions, as 
well as in healthy populations. Future studies could extend on the findings of 
emotional dysregulation and mind wandering reported in this thesis and utilise ESM 
in ADHD and BPD to investigate other core BPD symptoms such as identity 
disturbance, chronic feelings of emptiness or suicidality, where differences between 
the disorders might emerge. 
This potentially contributes to a lack of awareness of ADHD as a differential 
diagnosis for clinicians encountering adult patients with emotional dysregulation. 
Asherson (2005) and Wender, Wolf, and Wasserstein (2001) noted that adults with 
unrecognised ADHD are not infrequently misdiagnosed and treated for anxiety, 
depression, mixed affective disorder, cyclothymia, and borderline and unstable 
personality disorders. In the debate on the differentiation between ADHD and BPD, 





their presence as a major presenting problem suggests the presence of a mood 
disorder rather than ADHD (Wilens, et al., 2003). This interpretation could be in line 
with my finding whereby anxiety and depression symptoms accounted for emotional 
dysregulation in both ADHD and BPD. However, findings from converging 
evidence (genetics, treatment effects, impact on ADHD-associated impairment) does 
not support this assertion (Asherson, Buitelaar, Faraone, & Rohde, 2016). For 
example, Skirrow et al. (2014) found high levels of emotional dysregulation that had 
an independent effect on ADHD-associated impairment, in adult males with ADHD, 
where comorbid anxiety and depression disorders had been carefully excluded.  
The results presented here further extend the findings of Skirrow et al. (2014) by 
showing that emotional dysregulation in women with ADHD is elevated and is 
comparable to the pattern of emotional dysregulation seen in BPD. This fills an 
important gap in the literature, since to date it has not been possible to clarify whether 
emotional dysregulation has a similar profile in ADHD as it does in BPD. 
These findings suggest that ADHD should be considered an important differential 
diagnosis when encountering patients with unstable emotional symptoms; 
particularly in light of the meta-analytic (chapter 6) work presented in this thesis 
showing a good clinical response of emotional dysregulation to stimulants and 
atomoxetine when treating adults with ADHD. Overall, given the symptom overlap, 
clinicians should always consider the presence of ADHD or BPD when diagnosing 
the other condition and there should be more awareness of the co-occurrence of these 
disorders in mental health services. 
Findings in chapter 4 further support the phenotypic overlap between ADHD and 
BPD since, despite my prior hypothesis, high frequency of mind wandering was not 
specific to ADHD. However, depression and anxiety symptoms accounted for mind 
wandering in BPD, but not ADHD, pointing to the idea that MW in BPD most likely 
reflects depressive and anxious rumination, which is not uncommon in BPD 
populations (Stepp, Scott, Jones, Whalen, & Hipwell, 2016). In ADHD it is thought 
that the content of MW is less constrained, with no pattern of repeated thoughts or 
abnormality of content (Asherson et al., 2016; Christoff, Irving, Fox, Spreng, & 





chapter 4 of more negative content of mind wandering in BPD compared to controls, 
whereas the pattern of negative thoughts seen in ADHD was similar to than seen in 
controls. Yet, these findings need to be replicated in future studies specifically 
assessing the content of mind wandering (and not just the nature of content as defined 
in this study by ‘pleasant’ versus ‘unpleasant’ thoughts), and how this might differ 
across disorders. 
The issue of delineating overlapping psychiatric disorders has been shown in 
neurophysiological and neurobiological research. For example, as evidenced by the 
difficulties encountered in identifying polygenic risk scores that are specific to 
phenotypes, with considerable evidence for shared genetic aetiology across mental 
health disorders from large scale genome-wide association studies (GWAS) 
(Demontis et al., 2017). Similarly, overlap between functional neuroimaging findings 
is commonly seen when comparing between mental health disorders (Broyd et al., 
2009). 
Such matters have led to proposals by the National Institute of Mental Health of the 
Research Domain Criteria (RDoC), which suggests that researchers now need to 
move beyond categorical definitions of psychiatric disorders, to directly study 
common underlying impairments in neurocognitive systems that cross traditional 
diagnostic boundaries (Insel et al., 2010). The RDoC proposes that dimensional 
cross-disorder measures of symptoms and their neurobiological correlates might 
make better targets for treatment (Insel et al., 2010). 
This approach aims to find new ways of grouping or separating clusters of symptoms 
based on dimensional deviations from typical functioning and conceptualises existing 
diagnostic categories as the combined profile of several specific cognitive or 
emotional impairments. It has been suggested that this empirical data-driven 
neurobiological framework is necessary to tackle the heterogeneity and comorbidity 
observed in current clinical diagnostic categories such as ADHD and BPD, which 
are thought to be limiting the ability of neurophysiological and genetic studies to 
identify robust biomarkers, and specific treatments, associated with current disorder 





possible to identify stimulant responsive and non-responsive forms of emotional 
dysregulation and mind wandering, in both ADHD and BPD.   
Future studies might therefore include samples of individuals with common 
symptoms such as sustained attention deficits and mind wandering, as well as 
emotional dysregulation and impulsive responding, without having stringently 
defined diagnostic inclusion categories; and in doing so may then clarify the 
aetiologies of specific deficits at a level below that of clinical diagnosis, that would 
ultimately map better to specific treatments. This approach may also improve 
conceptualisation of co-occurring symptoms and disorders, which may or may not 
have common shared genes, environmental factors, and shared neurobiology. Such 
approaches could also include a greater range of participants such as: those with less 
severe forms of disorders; subthreshold cases not meeting the predefined categorical 
diagnosis but still impaired and requiring treatment; and those with comorbidities, 
which are often excluded from current research despite evidence that these are 
extremely common in psychiatric populations. Such samples would also be more 
representative of populations likely to present to mental health services, and therefore 
findings could offer further advantages of being more generalisable to typical clinical 
populations. 
7.3.2 Targeted treatments 
The meta-analytic evidence in chapter 6 confirms the clinically significant effect of 
stimulants and atomoxetine on reducing symptoms of emotional dysregulation in 
ADHD, yet not as effective as they were on core symptoms of inattention and 
hyperactivity/impulsivity. This could still however be due to limitations of sample 
selection for high ADHD symptoms and not symptoms of emotional dysregulation, 
and investigation of treatment effect on emotional dysregulation as a secondary 
outcome, as discussed in detail in chapter 6. In chapters 3 and 5, findings show that 
heightened intensity and instability of emotional dysregulation in ADHD was 
analogous to that seen in BPD. Therefore, medications such as stimulants could also 
be effective in reducing symptoms of emotional dysregulation in individuals with co-
occurring ADHD and BPD, and in other conditions marked with intense and 





interventions targeting emotional dysregulation such as dialectical behavioural 
therapy commonly used in BPD may be helpful for ADHD cases with high levels of 
emotional dysregulation with partial or no response to ADHD drug treatments. A 
more nuanced approach to the management of people presenting with both ADHD 
and BPD is therefore recommended (Moukhtarian, Mintah, Moran, & Asherson, 
2018). 
Findings in chapter 6 require replication, particularly in patients selected for high 
baseline levels of emotional dysregulation. However, there are as yet no 
investigations of ADHD drug treatments in patients with ADHD and comorbid 
BPD, or ADHD and other comorbidities in which emotional dysregulation is 
prominent. Further investigations are therefore required to clarify the role of 
stimulants and atomoxetine on emotional dysregulation in patients with ADHD and 
co-occurring disorders such as BPD, or bipolar disorder. Further studies are also 
needed to investigate the causes of lower clinical response, which could be due to the 
differences between medication respondent and non-respondent types of emotional 
dysregulation. Discovering markers of clinical response, such as neural biomarkers 
for example, are essential in developing more effective treatment protocols. 
An analogy of emotional dysregulation might be fever in physical health. Fever arises 
in the context of many different disorders, but the causes and therefore the treatments 
may or may not be entirely distinct; although some treatments such as anti-
inflammatory drugs may have a general effect on reducing fever. Further research is 
therefore needed to better understand the underlying causes and neurobiological 
mechanisms of emotional dysregulation across psychiatric disorders and the use and 
targeting of different treatments. 
Finally, there is no data on the response of either ADHD symptoms, excessive mind 
wandering, or emotional dysregulation in patients with comorbid ADHD/BPD; an 
important topic for future research. 
7.3.3 The effect of depression and anxiety symptoms 
The general role of depression and anxiety in the findings reported in this thesis on 





some of the limitations highlighted in the literature about the validity of the BSI 
subscales of depression and anxiety as diagnostic tools (Petkus et al., 2009), the aim 
here was to use it as a measure of anxiety and depressive symptom severity. ADHD 
and BPD showed comparable levels of anxiety and depression on the scales. 
Regarding emotional dysregulation, depression and anxiety had a similar 
relationship in ADHD and BPD as discussed in chapter 5, accounting for the 
differences found between the two disorders, and between the disorders and controls.  
In contrast, as discussed in chapter 4, in ADHD mind wandering seems to be 
independent of anxiety and depression, potentially reflecting a core characteristic of 
the disorder (Bozhilova, Michelini, Kuntsi, & Asherson, 2018); but in BPD 
potentially reflecting an underlying mechanism driving mind wandering. This was 
further supported by the significant findings on the unpleasant (i.e. negative) content 
of mind wandering in the BPD diagnoses, which were also driven by depression and 
anxiety. Although the results were somehow inconclusive, mind wandering about 
something unpleasant may reflect anxious thoughts and depressive ruminations in 
BPD, commonly reported in this population (Peters et al., 2017). Further studies 
should be conducted specifically examining the role of anxious and depressive 
symptoms in ADHD and BPD, their underlying neurobiological mechanisms and 
their relationship to overlapping symptoms such  sa emotional dysregulation a dn  
 dnim wandering, before further conclusions can be made. 
7.4 Strengths and general limitations 
7.4.1 Sample characteristics 
7.4.1.1 Exclusion criteria 
From the participant sampling procedure described in Chapter 2, it can be seen that 
due to stringent exclusion criteria, many individuals referred to the ADHD and BPD 
specialist clinics were not eligible to participate in the Personality Research in 
Emotional Instability and ADHD (PRIDE) study. This gave rise to two major 
limitations rof  this study. The first is that results may not generalise to many adults 
with ADHD, BPD or comorbid ADHD/BPD, who are frequently affected by 
comorbid psychiatric conditions and/or are on psychoactive medication (particularly 





which may have been underpowered for some investigations, where trending results 
were identified, and tests frequently did not withstand correction for multiple testing. 
Current guidance from the National Institute for Health and Care Excellence (NICE, 
2009) states that drug treatments should “not be used for borderline personality 
disorder or for the individual symptoms or behaviour (e.g. repeated self-harm, 
marked emotional instability, risk-taking behaviour and transient psychotic 
symptoms) associated with the disorder .”  Nevertheless, many BPD patients without 
comorbidities requiring treatment, were on psychoactive medications, and did not 
meet the inclusion criteria for this study. This led to considerable challenges for 
recruitment of the BPD sample. This was not surprising and in line with the findings 
from Crawford et al. (2011), who showed that individuals with an emotionally 
unstable personality disorder were more often prescribed with psychotropic 
medication (anti-depressants, anti-psychotics, benzodiazepine, mood stabilisers and 
hypnotic drugs) than those being treated for other personality disorders. They also 
found that individuals being treated for a personality disorder, despite the available 
guidance and lack of evidence, were prescribed at ael st one psychotropic medication, 
and one in five was prescribed three or more (Crawford et al., 2011). 
The restricted sampling procedure can also be considered a strength to the study. 
There is a disadvantage of including individuals with comorbid conditions or on 
psychoactive medications regulating symptoms commonly associated with ADHD 
and BPD, in a study with the primary purpose of investigating the overlap of 
symptoms between the disorders. This is because it then becomes unclear whether 
the symptoms which are expressed similarly in these conditions could be due to 
comorbid conditions or medications. Excluding co-occurring disorders helped to 
clarify that the overlap detected between ADHD and BPD can be attributed to the 
overlapping picture of the disorders rather than potential confounders. Additionally, 
in this cross-disorder comparative analysis of ADHD and BPD, the exploratory 
nature of the study served as a basis of much larger-scale investigations in the future, 






The sample was limited to female participants, and all results and conclusions in 
chapters 3, 4, and 5 can therefore only be generalised to females with ADHD and 
BPD. The initial aim was to include males as well as females in the study  
sample. However, the low rates of male referrals with BPD and low rates of female 
referrals with ADHD meant that recruitment of a sex-matched sample within the 
restricted timeframe of my PhD completion was not feasible. Additionally, given that 
it is mostly females who receive therapy for BPD while the sex ratio for adult patients 
with ADHD is more equally divided, the results of this study are more representative 
for the clinical population with BPD than those with ADHD.  
Although this limits interpretation to females, it has the advantage of removing 
potential sex differences which could confound some of the findings. Additionally, 
females are generally underrepresented in studies of ADHD, and the study here is 
complementary to the study of men with ADHD by Skirrow et al. (2014). 
Studies aiming to investigate similar research questions in a more sex balanced design 
would require a much longer duration of study recruitment, and/or less restrictive 
exclusionary criteria. 
7.4.1.3 Clinical heterogeneity 
Conceptually, the adoption of stringent inclusion criteria is undertaken to reduce 
sample heterogeneity by including only those participants meeting certain diagnostic 
criteria. However, even within these diagnoses, substantial heterogeneity may still be 
present due to different expressions of symptoms within the disorder between 
individuals, different aetiologies or other factors such as undiagnosed comorbidities, 
or the subclinical expressions of population traits which interact with the symptoms 
of the primary diagnosis.  
7.4.2 Diagnostic issues 
Diagnostic criteria for ADHD and BPD in the PRIDE study was applied as specified 
in the DSM-5 (American Psychiatric Association, 2013) (see section 2.3.3.1 in 





According to the DSM-5, ADHD diagnosis requires the presence of several 
inattentive or hyperactive/impulsive symptoms prior to age 12 years. In the PRIDE 
study, as mentioned in chapter 2, several was defined as three or more, which is the 
same approach taken by most researchers investigating the age of onset of ADHD 
and application of the DSM-5 criteria (Agnew-Blais et al., 2016; Polanczyk et al., 
2010). Reporting of three or more symptoms in childhood, could however be 
inaccurate due to problems of retrospective recall, leading to both false positive and 
negative cases. Furthermore, this relates to recent debate about the existence of late 
or adult onset forms of ADHD, based on several prospective longitudinal outcome 
studies of population or control samples. The Dunedin study that kicked off this 
debate, found that 90% of the individuals with adult ADHD at age 38 did not meet 
full diagnostic criteria for the disorder in childhood assessed at age 11, 13 and 15 
years (Moffitt et al., 2015).  
Subsequent studies provided information on late-onset ADHD up to the age of 18 
years, but there is as yet no further data up to the age of 38 to confirm or refute the 
findings reported in the Dunedin study. In another population-based longitudinal 
study, among those who met criteria for ADHD at age 18 (n=166), 67.5% (n=112) 
did not meet full ADHD criteria at any of the four childhood assessments (Agnew-
Blais et al., 2016). In the large Pelotas Birth Cohort Study (n=5249), at age 11 years 
childhood ADHD was estimated to be present in 8.9% (n=393) of the sample, while 
at age 18 to 19 years 12.2% (n=492) fulfilled all DSM-5 criteria for adult ADHD 
except for age of onset (Caye, Rocha, Anselmi, & et al., 2016). Their findings 
suggested that 17.2% (n=60) of the children with ADHD continued to meet 
diagnostic criteria as young adults, while only 12.6% (n=60) of those meeting ADHD 
criteria as adults would have met the diagnostic criteria for ADHD as children (Caye 
et al., 2016). These and other more recent studies point to the emergence of the full 
diagnosis of ADHD during late adolescence (late-onset ADHD) in some cases, 
although many would meet the DSM-5 criteria of several symptoms by the age of 12 
years. However, a full understanding of the emergence of ADHD beyond the 
childhood years remains to be fully elucidated, and debate remains about the 
existence of late-onset ADHD and whether it is a distinct disorder with different 
aetiologies. Investigation of this issue was not within the scope of this thesis, however 





who reported current symptoms and impairments, but not sufficient childhood 
symptoms, to meet DSM-5 criteria for ADHD. 
There are additional concerns regarding the assessment of ADHD in adulthood, 
particularly when a childhood ADHD diagnosis was not previously established, and 
onset of symptoms and impairments before age 12 years were determined by 
retrospective self-reports. A study investigating retrospective diagnoses of ADHD by 
semi-structured clinical interviews (without informants), showed a high rate of 
positive diagnosis in a large sample of adults with ADHD who had previously been 
diagnosed with ADHD as children (78%), however the rate of false positive 
classifications in control participants was also relatively high (11% (Mannuzza, 
Klein, Klein, Bessler, & Shrout, 2002). This indicates that while some individuals 
may not be able to recall their childhood symptoms, false positive rates might also be 
a problem.  
Based on these considerations, it was an evident decision to exclude childhood 
symptoms from the LCA in c hapter 3. However, this prevented the investigation of 
the developmental trajectory of ADHD symptoms from childhood predicting BPD 
diagnosis, using latent transition analysis. Future studies, particularly investigating 
symptoms in childhood and adulthood would be best conducted using prospective 
data from childhood to adulthood but note that this would have to include normative 
cases since late-onset of ADHD would include children who did not meet full criteria 
as children. An alternative could be the inclusion of informants, wherever possible, 
such as parents or siblings who may have known the patients during their childhood, 
however this does not remove the effects of retrospective report bias for informants. 
7.4.3 Treatment issues 
Referrals from the ADHD and BPD specialist clinics were done at different time-
points in the diagnostic and treatment process, from the moment a patient was 
admitted to the service to after they have been discharged. This was an issue for some 
of the participants with BPD referred to the study whilst receiving or after finishing 
psychological therapies, who could have reported reduced functional impairment 
and symptom severity, compared to individuals referred at assessment or on a 





psychological treatments are an evidence based treatment leading to reduced 
symptom  severity and related impairments (Gunderson et al., 2011). The McLean 
10-year follow-up study  found that BPD improves over time with remission rates 
(i.e. no longer meeting diagnostic criteria) of around 80% lasting eight years 
(Zanarini, Frankenburg, Reich, & Fitzmaurice, 2012). The sample was therefore 
heterogenous regarding symptom severity and non-significant differences across 
ADHD and BPD could have been due to less severe symptom profiles in BPD than 
that seen in untreated individuals. Future studies should therefore investigate 
overlapping features in ADHD and BPD in untreated samples. 
Many individuals in the clinical groups, notably in the BPD group, were on 
concomitant anti-depressants (n=32), which may have reduced the severity of 
ADHD or BPD symptoms and associated cognitive and functional deficits. In the 
ADHD sample, there were no differences in the current ADHD (F (1,30) = 1.7, 
p=.202) and BPD (F (1,30) = .01, p=.920) symptoms between those who were on 
anti-depressants (n=8) and those who were not (n=24). Similarly, in the BPD sample, 
there were no differences in the current ADHD (F (1,17) = 1.6, p=.223) and BPD (F 
(1,17) = 1.64, p=.217) symptoms between those who were on anti-depressants (n=15) 
and those who were not (n=4). Finally, in the comorbid ADHD/BPD sample, those 
who were on concomitant medication (n=9) and those were not (n=18) reported 
similar ADHD (F (1,25) = 3.19, p=.086) and BPD (F (1,25) = .57, p=.457) symptoms. 
Despite symptoms of ADHD and BPD not being significantly different between 
those taking anti-depressants and those who were not, i si t  feasibl taht e  concomitant 
medications may have led to differences in symptom severity. 
7.4.4 Losses to non-attendance 
Some problems with recruitment may be considered issues inherent to problems with 
disorganisation, which is a common feature seen in both ADHD and BPD 
conditions. Despite a reminder system being in place where all participants received 
a text message on the day before their appointment with details of their research 
session, a number of participants did not show up to their scheduled appointments. 





being given multiple appointments. Nonetheless, this was relatively a small 
proportion (4.4%) in view of the disorganised nature of the conditions. 
7.4.5 Measures in the study 
An additional limitation was the retrospective and self-report nature of some of the 
measures used in c hapters 3, 4 and 5, which inevitably are prone to bias. The 
diagnostic interviews may be less prone to this bias since the investigator is asking 
about specific examples of symptoms and behaviours, however this is still reliant on 
the accuracy of self-report. Regarding diagnostic interviews, the inclusion of 
informant reports may increase the accuracy of the assessments, strengthen the 
findings, and would be an important area in which to extend future investigations. 
In ADHD, differences between self and informant reports in adults and children 
(Barkley, Fischer, Smallish, & Fletcher, 2002; Wan Salwina, Baharudin, Nik 
Ruzyanei, Midin, & Rahman, 2013) have been documented, yet, much less is known 
about the validity of self-report measures in BPD. Some evidence indicates that 
patients with BPD overestimate emotions with negative valence and underestimate 
emotions with positive valence, when comparing retrospective with ESM rating 
(Ebner-Priemer et al., 2006).  However, despite this methodological drawback in 
diagnostic interviews used to establish presence or absence of symptom criteria, the 
accuracy of reporting dynamic changes and qualitative characterisation of symptoms 
of emotional dysregulation and mind wandering, which are internal rather than 
external symptoms, will have benefitted from the use of prospective ESM measures. 
By employing this type of ambulatory monitoring in the current study, I was able to 
reduce the effects of recall-bias. 
7.4.6 Multiple testing 
Due to the large number of measures employed in this study and therefore the 
multiple group comparisons conducted, Bonferroni correction was applied where 
appropriate to account for multiple testing. This rather conservative approach has its 
limitations. “A p value is no substitute for a brain”, a quote from Stone and Pocock 
(2010  ) emphas si ing the importance of making interpretations beyond just the 
significant/non-significant p values. When adopting such a strict method to correct 





findings disappear (Pocock, McMurray, & Collier, 2015). It is therefore important to 
make a distinction between statistical significance and clinical relevance of findings, 
more crucially in studies like the current one, in which a lot of clinical implications 
can be derived that could benefit patients and clinicians. Nevertheless, findings that 
arise from studies that are not fully powered for specific a priori hypotheses, should 
always be considered exploratory, requiring replication(s) to confirm or refute initial 
observations.   
7.4.7 Strengths of the meta-analytic and statistical methods employed 
The meta-analysis conducted in chapter 4 offered the most conclusive evidence of the 
treatment effect of stimulants and atomoxetine on emotional dysregulation in 
ADHD to date. The analyses were performed to recommended standards for 
systematic reviews and meta-analysis and care was taken to combine homogenous 
measures by, for example, having a very conservative approach in including parallel 
group trials or initial data before cross-over only, and conducting separate analyses 
for the different outcome measures and medications (stimulants versus atomoxetine) 
employed in the trials included. 
In chapters 4 and 5, multilevel models were used to analyse the longitudinal data 
collected by ESM. Multilevel models have become the primary method for analysis 
of clustered data since all available data is used for each subject, and models can 
effectively handle: 1) data which is correlated within subjects, 2) time effects which 
differ between participants, 3) binary and continuous covariates which can change 
over time, and 4) missing data which occurs at random in the dataset (Gueorguieva 
& Krystal, 2004).  
7.5 Concluding remarks 
The high level of phenotypic symptom and impairment overlap observed in ADHD 
and BPD, is a source of confusion for many healthcare professionals. This is 
particularly true for those who are less familiar with current best practice in relation 
to the key identifiers and treatment for each disorder. The identification of more 
objective biomarkers for either disorder may be diagnostically valuable in the future. 





aetiology of these disorders is still poorly understood, and studies such as those 
conducted for chapters  6 dna ,5 ,4 represent additional contributions to the  
growing body of work which ultimately aims to map out a new biologically grounded 
framework for understanding mental illness. Genetic and/or neurocognitive markers 
may be considered an important avenue for aiding in establishing differential 
diagnosis in the future. More cross-disorder studies are required to identify neural 
and cognitive markers which may be disorder specific or predict response to 
treatments. It is envisaged that future work will uncover new approaches to 
classification based on symptoms, biomarkers, rather than disorders, with improved 
targeting of effective treatments. 
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Appendix 1: Telephone screening- Control subjects 




Question Guidance Answer (Y/N) 
and notes 
1. Have you EVER had any problems that 
have troubled you with regards to your mental 
health? 
 
Exclude if they have had 
any mental health problems 
 
2. Have you ever had distinct episodes of 
depression or sadness different from what 
you’re normally like lasting a week or more?  
If so, when was this? 
 
If no – go to Q 5 
Exclude if currently 
experiencing a distinct 
episode of major depression. 
 
3. Have you had a period recently where you 
felt sad, depressed, empty or tearful nearly 
every day for at least 2 weeks? 
     If yes: 
• Did you lose all interest in things, or 
got no pleasure from things which 
would usually make you happy? 
• When did you first feel like this? 
• Are you still feeling like this? 
If answer is yes, try to gauge 
severity of depressed 
episode using additional 
questions. 
 
Exclude if currently 
experiencing a distinct 
episode of depression 
 
4. Have you had more than one spell like this 
in the last 2 years?  I mean more than just one 
period when you have been seriously 
depressed or anxious 
 
Consider excluding if 
depression is recurrent 
 
5. Have you had periods of feeling far more 
happy or energetic than your usual self, lasting 
for a week or more? So that your friends told 
you were talking too fast or that you were too 
'hyper, compared to usual? If so, when was 
this? 
Exclude if participant has 
experienced distinct 
episodes of mania/elation 
but not rapid cycling 
 
6. How often do you have a drink containing 
alcohol? 
(Never, Monthly or less, 2-4 times per month, 
2-3 times per week, 4+ times per week) 
  
7. Approximately how many units of alcohol 
do you drink per day? 
Recommended limit for women 2-3 Units, for 
men 3-4 Units.   
To calculate: 
• Single shot is 1 unit 
• Alcopop is 2 Units 
• Can/pint of light beer is 1 unit. 
• Can/pint of lager is 2 Units 
• Can/pint of extra strong lager is 4 
units 
• Party cocktail is 5 units 
• Glass of wine (175ml) is 2 units 
Exclude women who drink 
more than 14 Units a week, 




8.  Do you take any other drugs, legal or 
illegal?  Which ones do you take?  And how 
often do you take these? 
(prescribed or over the counter medications, 
cannabis (marijuana, hash), solvents, 
tranquilizers (Valium), barbiturates, cocaine, 
stimulants (speed), hallucinogens (LSD) or 
narcotics (heroin) 
Exclude if illegal drugs 
taken more often than twice 
weekly. 
 
9.  Have you ever been addicted or dependent 
on any drugs or alcohol?  If so, when was this? 
Exclude if major history of 
drug or alcohol addiction, 
exclude if current substance 
abuse or addiction 
 
10.  Have you ever suffered any injury to your 
head? If yes have you recovered from this/has 
it affected you in the long-term?  
 
Have you suffered from any neurological 
disorder (e.g. epilepsy, stroke, and dementia)? 
Exclude if they feel this has 
affected them in the long-
term (e.g. if symptoms 
began from the injury). 
Exclude if answer to this 
question is yes 
 
 
Follow up questions from question 3a 
ASK ONLY IF UNCERTAIN OR WANT TO GET BETTER PICTURE OF 
DEPRESSIVE STATE 
 
During this time when you had worst two weeks where you felt sad, miserable or 
depressed…. 
 
How was your appetite? 
 
 
(check for weight loss/gain)  
How was your sleep pattern? (check if slept too much or 
trouble falling asleep or erratic 
sleep pattern) 
 
Nearly every day, were you 
unable to make up your mind 
about things you ordinarily 
would have had no trouble 
deciding about? 
  
Did you lack in energy or feel 
much more tired than usual 
even if you had not been 
working very hard? 
 
  




Did you think a lot about your 
own death, or someone else’s 







Appendix 2: Telephone screening- Clinical subjects 




Question Guidance Answer 
(Y/N) 
and notes 
1. Have you been diagnosed with a personality disorder? 
When? 
  
2. Have you been diagnosed with ADHD? When?   
3. Are you currently taking medication? 
• What medication are you taking and how many 
mg a day? 
• How long have you been taking this?  
Exclude if on 
medication 






4. Have you EVER had any other problems that have 
troubled you with regards to your mental health (apart 
from ADHD or BPD)? 
  
5. Have you ever had distinct episodes of depression or 
sadness different from what you’re normally like lasting a 
week or more?   
If no – go to Q 8 
If all the time, 
then skip to Q7 
 
6. Have you had a period recently where you felt sad, 
depressed, empty or tearful nearly every day for at least 2 
weeks? 
     If yes: 
• Did you lose all interest in things, or got no pleasure 
from things which would usually make you happy? 
• When did you first feel like this? 
• Are you still feeling like this? 
If answer to Q6 is 






Exclude if currently 
experiencing a 
distinct episode of 
depression 
 
7. Have you had more than one spell like this in the last 2 
years?  I mean more than just one period when you have been 
seriously depressed or anxious. 
Consider excluding 
if depression is 
recurrent 
 
8. Have you had periods of feeling far more happy or 
energetic than your usual self, lasting for a week or more? So 
that your friends told you were talking too fast or that you 






not rapid cycling 
 
9. How often do you have a drink containing alcohol? 
(Never, Monthly or less, 2-4 times per month, 2-3 times per 
week, 4+ times per week) 
  
10. Approximately how many units of alcohol do you drink 
per day? 
To calculate: 
• Single shot is 1 unit 
• Alcopop is 2 Units 
• Can/pint of light beer is 1 unit. 
• Can/pint of lager is 2 Units 
• Can/pint of extra strong lager is 4 units 
• Party cocktail is 5 units 
• Glass of wine (175ml) is 2 units 
Recommended 
limit for women 2-3 
Units, for men 3-4 




11.  Do you take any other drugs, legal or illegal?  Which 
ones do you take?  And how often do you take these? 
(prescribed or over the counter medications, cannabis 
(marijuana, hash), solvents, tranquilizers (Valium), 
barbiturates, cocaine, stimulants (speed), hallucinogens (LSD) 
or narcotics (heroin) 
  
12.  Have you ever been addicted or dependent on any drugs 
or alcohol?  If so, when was this? 
Exclude if major 
history of drug or 
alcohol addiction, 
exclude if current 
substance abuse or 
addiction 
 
13.  Have you ever suffered any injury to your head? If yes 
have you recovered from this/has it affected you in the long-
term?  
 
Have you suffered from any neurological disorder (e.g. 
epilepsy, stroke or dementia)? 
Exclude if they feel 
this has affected 
them in the long-
term (e.g. if 
symptoms began 
from the injury). 
Exclude if answer 




Follow up questions from question 6 
ASK ONLY IF UNCERTAIN OR WANT TO GET BETTER PICTURE OF 
DEPRESSIVE STATE 
 
During this time when you had worst two weeks where you felt sad, miserable or 
depressed… 
 
How was your appetite? 
 
 
(check for weight 
loss/gain) 
 
How was your sleep pattern? (check if slept too much 
or trouble falling asleep 
or erratic sleep pattern) 
 
Nearly every day, were you unable to 
make up your mind about things you 




Did you lack in energy or feel much 
more tired than usual even if you had 
not been working very hard? 
  
Did you feel worthless nearly every day? 
 
  
Did you think a lot about your own 







Appendix 3: Affective Lability Scale- short form (ALS-SF)  
Please complete these questions reflecting how well these questions describe how 
you have been feeling over the past week. Please tick one box for each question. 








1 At times I feel just as relaxed as 
everyone else and then within 
minutes I become so nervous 
that I feel light-headed and 
dizzy. 
    
2 There are times when I have 
very little energy and then just 
afterwards I have about the 
same energy level as most 
people. 
    
3 One minute I can be feeling OK 
and then the next minute I’m 
tense, jittery, and nervous. 
    
4 I frequently switch from being 
able to control my temper very 
well to not being able to control 
it very well at all. 
    
5 Many times I feel nervous and 
tense and then I suddenly feel 
very sad and down. 
    
6 Sometimes I go from feeling 
extremely anxious about 
something to feeling very down 
about  
    
7 I shift back and forth from 
feeling perfectly calm to feeling 
uptight and nervous. 
    
8 There are times when I feel 
perfectly calm one minute and 
then the next minute the least 
little thing makes me furious. 
    
9 Frequently, I will be feeling OK 
but then I suddenly get so mad 
that I could hit something. 
    
10 Sometimes I can think clearly 
and concentrate well one 
minute and then the next 
minute I have a great deal of 
difficulty concentrating and 
thinking clearly. 
    
11 There are times when I am so 
mad that I can barely stop 
yelling and other times shortly 
afterwards when I wouldn’t 
think of yelling at all. 





12 I switch back and forth between 
being extremely energetic and 
having so little energy that it’s a 
huge effort just to get where I 
am going. 
    
13 There are times when I feel 
absolutely wonderful about 
myself but soon afterwards I 
often feel that I am just about 
the same as everyone else. 
    
14 There are times when I’m so 
mad that my heart starts 
pounding and/or I start shaking 
and then shortly afterwards I 
feel quite relaxed. 
    
15 I shift back and forth between 
being very unproductive and 
being just as productive as 
everyone else. 
    
16 Sometimes I feel extremely 
energetic one minute and then 
the next minute I might have so 
little energy that I can barely do 
a thing. 
    
17 There are times when I have 
more energy than usual and 
more than most people and then 
soon afterwards I have about 
the same energy level as 
everyone else. 
    
18 At times I feel that I’m doing 
everything at a very slow pace 
but then soon afterwards I feel 
that I’m no more slowed down 
than anyone else. 
    
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Appendix 4: Affective Reactivity Index (ARI) 
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Appendix 5: The Wender-Reimherr Adult Attention Deficit Disorder Scale- 
Emotional dysregulation subscale (WRAADDS-EDS) 
 
The individual questions should be followed by general probes: 
Has this occurred in the last week? 
Have others commented about this? 
What have they said? 
What difficulties or problems has this caused with other people or work? 
 
The individual items should be rated as follows: 
0 – None, not present 
1 – Mild, somewhat or sometimes true 
2 – Clearly present or often true 
 
The summary scores should be based on the ratings of the specific questions, together with 
any other symptoms in the area reported by the subject. The summary score should not be 
a simple average of the individual ratings. ~If only one question group is rated as clearly as 






3- Quite a bit 
4- Very much 
 
1. Temper 
Do you frequently feel irritable or angry 0 1 2  
with your spouse, children, or other family members     
or at work, driving, or in other situations?     
     
Do you have angry outbursts or lose your temper easily? 0 1 2  
Do you have a ‘short fuse’ or a ‘low boiling point’?     
     
Does your temper cause problems for you? 0 1 2  
Do you lose control during temper outbursts?     
(saying things you regret, becoming aggressive,     
acting in a threatening manner, or behaving impulsively)     
 
Temper Summary Rating 0-4: 
 
2. Affective Lability 
Prior to scoring this question, the rater must differentiate between a major mood disorder 
and the lability of mood in subjects with ADHD. ADHD related dysphoria is generally 
brief, lasting hours, and usually has an identifiable precipitant. The exception is when the 
subject experiences persistent life problems (often self-produced), when the period of 
dysphoria may be extended. Similarly, distinguish between excitement (which may be 
mild) and over-enthusiasm from mood elevation with a manic quality. 
 
AHDH clients may be comorbid for a major depression. Determine duration and frequency 
of episodes and presence of somatic concomitants to help distinguish discouragement, 
moodiness, and demoralization found in ADHD from major depression with its loss of 
interest and loss of the ability to experience pleasure. 
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Does your mood change frequently, going up and down 0 1 2  
-  like a rollercoaster in the sense of getting sad or feeling ‘up’?     
     
Do you often have periods of being sad, blue, or discouraged? 0 1 2  
During these periods, are you overly self-critical or down on yourself?     
     
Do you often feel bored? 0 1 2  
Do you easily lose interest in things?     
     
Do you have periods of being excessively active, hyper,  0 1 2  
getting too excited, going too fast, or talking too much?     
 
Affective Lability Summary Rating 0-4:  
 
 
3. Emotional Over-Reactivity 
Do you easily get feelings of being overwhelmed? 0 1 2  
Do you frequently feel ‘hassled’, frustrated?     
     
Do you overreact to pressure, blow things out of proportion? 0 1 2  
Do small problems seem too difficult;     
do you ‘make mountains out of molehills’?     
     
When these reactions occur, 0 1 2  
do you have difficulties in managing tasks or getting things done?     
With pressures or stresses, do you become anxious, disorganized or 
confused? 
    
 
Emotional Over-Reactivity Summary Rating 0-4:  
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Appendix 6: Mind Excessively Wandering Scale (MEWS) 



















1.  I have difficulty controlling my thoughts 0 1 2 3 
2.  I find it hard to switch my thoughts off  0 1 2 3 
3.  I have two or more different thoughts 
going on at the same time 
0 1 2 3 
4.  My thoughts are disorganised and ‘all 
over the place’ 
0 1 2 3 
5.  My thoughts are ‘on the go’ all the time  0 1 2 3 
6.  Because my mind is ‘on the go’ at 
bedtime, I have difficulty falling off to 
sleep 
0 1 2 3 
7.  I experience ceaseless mental activity 0 1 2 3 
8.  I find it difficult to think about one thing 
without another thought entering my 
mind 
0 1 2 3 
9.  I find my thoughts are distracting and 
prevent me from focusing on what I am 
doing 
0 1 2 3 
10.  I try to distract myself from my thoughts 
by doing something else or listening to 
music 
0 1 2 3 
11.  I have difficulty slowing my thoughts 
down and focusing on one thing at a 
time 
0 1 2 3 
12.  I find it difficult to think clearly, as if my 
mind is in a fog 
0 1 2 3 
13.  I find myself flitting back and forth 
between different thoughts 
0 1 2 3 
14.  I use alcohol or other drugs to slow 
down my thoughts and stop constant 
‘mental chatter’ 
0 1 2 3 
15.  I can only focus my thoughts on one 
thing at a time with considerable effort 
0 1 2 3 
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Appendix 7: Weiss Functional Impairment Rating Scale-Self-report (WFIRS-S)  
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Appendix 8: Childhood Trauma Questionnaire (CTQ) 
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Appendix 9: Brief Symptom Inventory (BSI) 
For each one, please tell me how much that problem has bothered or distressed 
you during the past week, including today. Please tell me whether each problem 
has bothered you not at all, a little bit, moderately, quite a bit, or extremely. 
 
DURING THE PAST 7 DAYS, how much 











1. Nervousness or shakiness inside 0 1 2 3 4 
2. Faintness or dizziness 0 1 2 3 4 
3. The idea that someone else can control your 
thoughts 
0 1 2 3 4 
4. Feeling others are to blame for most of your 
troubles 
0 1 2 3 4 
5. Trouble remembering things  0 1 2 3 4 
6. Feeling easily annoyed or irritated 0 1 2 3 4 
7. Pains in the heart or chest 0 1 2 3 4 
8. Feeling afraid in open spaces 0 1 2 3 4 
9. Thoughts of ending your life 0 1 2 3 4 
10. Feeling that most people cannot be trusted 0 1 2 3 4 
11. Poor appetite 0 1 2 3 4 
12. Suddenly scared for no reason 0 1 2 3 4 
13. Temper outbursts that you could not 
control 
0 1 2 3 4 
14. Feeling lonely even when you are with 
people 
0 1 2 3 4 
15. Feeling blocked in getting things done 0 1 2 3 4 
16. Feeling lonely 0 1 2 3 4 
17. Feeling blue 0 1 2 3 4 
18. Feeling no interest in things 0 1 2 3 4 
19. Feeling fearful 0 1 2 3 4 
20. Your feelings being easily hurt 0 1 2 3 4 
21. Feeling that people are unfriendly or dislike 
you 
0 1 2 3 4 
22. Feeling inferior to others 0 1 2 3 4 
23. Nausea or upset stomach 0 1 2 3 4 
24. Feeling that you are watched or talked 
about by others 
0 1 2 3 4 
25. Trouble falling asleep 0 1 2 3 4 
26. Having to check and double check what 
you do 
0 1 2 3 4 
27. Difficulty making decisions 0 1 2 3 4 
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28. Feeling afraid to travel on buses, subways, 
or trains 
0 1 2 3 4 
29. Trouble getting your breath 0 1 2 3 4 
30. Hot or cold spells 0 1 2 3 4 
31. Having to avoid certain things, places, or 
activities because they frighten you 
0 1 2 3 4 
32. Your mind going blank 0 1 2 3 4 
33. Numbness or tingling in parts of your body 0 1 2 3 4 
34. The idea that you should be punished for 
your sins 
0 1 2 3 4 
35. Feeling hopeless about the future 0 1 2 3 4 
36. Trouble concentrating 0 1 2 3 4 
37. Feeling weak in parts of your body 0 1 2 3 4 
38. Feeling tense or keyed up 0 1 2 3 4 
39. Thoughts of death or dying 0 1 2 3 4 
40. Having urges to beat, injure, or harm 
someone 
0 1 2 3 4 
41. Having urges to break or smash things 0 1 2 3 4 
42. Feeling very self-conscious with others 0 1 2 3 4 
43. Feeling uneasy in crowds 0 1 2 3 4 
39. Thoughts of death or dying 0 1 2 3 4 
40. Having urges to beat, injure, or harm 
someone 
0 1 2 3 4 
41. Having urges to break or smash things 0 1 2 3 4 
42. Feeling very self-conscious with others 0 1 2 3 4 
43. Feeling uneasy in crowds 0 1 2 3 4 
44. Never feeling close to another person 0 1 2 3 4 
45. Spells of terror or panic 0 1 2 3 4 
46. Getting into frequent arguments 0 1 2 3 4 
47. Feeling nervous when you are left alone 0 1 2 3 4 
48. Others not giving you proper credit for your 
achievements 
0 1 2 3 4 
49. Feeling so restless you couldn’t sit still 0 1 2 3 4 
50. Feelings of worthlessness 0 1 2 3 4 
51. Feeling that people will take advantage of 
you if you let them 
0 1 2 3 4 
52. Feeling of guilt 0 1 2 3 4 
53. The idea that something is wrong with your 
mind 




Appendix 10: Alcohol and Drug use 
Alcohol Use Disorders Identification Test (AUDIT-C) 
Questions 
Scoring system Your 
score 0 1 2 3 4 
How often do you have a 

















How many units of alcohol do 
you drink on a typical day 
when you are drinking? 
1 -2 3 - 4 5 - 6 7 - 9 10+  
How often have you had 6 or 
more units if female, or 8 or 
more if male, on a single 
















0 1 2 3 4 
How often during the last year have 
you found that you were not able to 











How often during the last year have 
you failed to do what was normally 












How often during the last year have 
you needed an alcoholic drink in the 
morning to get yourself going after a 











How often during the last year have 












How often during the last year have 
you been unable to remember what 
happened the night before because 











Have you or somebody else been 













Has a relative or friend, doctor or 
other health worker been concerned 
about your drinking or suggested that 





















A. Drug and Alcohol Use 
The following two self-report measures were used to check for elevated drug and 
alcohol use and were not used as outcome measures in the analyses. Frequent alcohol 
use in the last 12 months (i.e. a score of 20 and above) was assessed by the AUDIT-
C, an alcohol screen that can help identify individuals who are hazardous drinkers 
or have active alcohol use disorders (abuse or dependence).  It was scored on a scale 
of 0 (no alcohol use) to 12 (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001). 
Frequent drug use in the last 12 months (i.e. use of recreational drugs several times a 
week) was assessed by the Substance Use Checklist (SUC- Appendix 10), a short 
screen to identify patterns of illegal drug use in the past 12 months measured on a 
scale of 0 (never used) to 5 (several times a day). We identified five individuals from 
the clinical groups who reported elevated alcohol consumption. In addition, seven 
individuals of which one was a control subject, reported elevated substance use (i.e. 
legal highs, opiates, cocaine, and cannabis), and finally two clinical participants 
reported elevated substance and alcohol use. 
We run sensitivity analyses on the main outcomes of MW measured by ESM and 
retrospective rating scale after removing the above-mentioned 14 participants. 
Overall key findings were not altered by excluding these individuals, and we can 
therefore assume results were not driven by these cases. Regarding MW intensity 
while controlling for anxiety and depression, sensitivity analyses no longer showed 
the significant differences between ADHD and BPD diagnoses our models revealed 
by including the individuals with elevated use of drug and alcohol. These results 
should be interpreted with a pinch of salt; with an even smaller sample size, the 
models might not have enough power to detect small effect sizes. Moreover, the 
significance values of the models before and after the sensitivity analyses only 
marginally changed from being nearly significant to not. 
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B. Correlations of the MW Items 
Table 1 Correlations of the multiple MW measures all significant at the .01 level (2-tailed) 
 Item-1 Item-2 Item-3 Item-4 Item-5 
Item-1  .901 .883 .876 .812 
Item-2 .901  .971 .951 .903 
Item-3 .883 .971  .957 .930 
Item-4 .876 .951 .957  .946 
Item-5 .812 .903 .930 .946  
C. Multilevel Models for MW Intensity- ADHD*BPD Interactions 
Table 2 Type III tests of fixed effects 
 Unadjusted model Adjusted model for anxiety and 
depression 
Num DF Den 
DF 




F value p value 
Item-1 1 93.99 10.94 .001 1 93.24 9.16 .003 
Item-2 1 93.81 10.70 .001 1 92.28 8.74 .004 
Item-3 1 94.21 14.60 <.001 1 92.13 11.92 <.001 
Item-4 1 93.93 21.70 <.001 1 91.77 20.03 <.001 
Item-5 1 93.92 16.69 <.001 1 91.02 15.09 <.001 
 
D. Estimated Means for MW Intensity Models 




No diagnosis ADHD diagnosis BPD diagnosis Comorbid 
ADHD/BPD 
diagnosis 
Item-1 35.47 53.97 47.69 46.90 
Item-2 36.15 56.02 41.96 42.90 
Item-3 37.07 59.18 42.70 41.59 
Item-4 33.29 61.30 46.71 46.75 
Item-5 28.11 59.35 46.10 48.20 
Inspection of the interactions and the estimated means showed a consistent pattern. 
The effects of ADHD and BPD were not additive. While we found differences 
between controls and all clinical diagnosis groups, the highest MW intensity was 
found for the ADHD diagnosis, whereas BPD and the comorbid ADHD/BPD 
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diagnosis group were comparable. The effect of an ADHD diagnosis seems to depend 
on the presence of a BPD diagnosis. 
E. Multilevel models for MW instability 










































































F. Cross-validation between the MEWS and ESM measures of MW 
Using Pearson correlations, we cross-validated ambulatory assessments of MW with 
retrospective self-report measures of MW (the MEWS) to examine the strength of 
association between these measures and establish whether the scale reflects the same 
construct as the ESM data. To control for confounding effects of potential comorbid 
anxiety and depression, we first examined if the measures of interest correlated with 
these covariates, and if so controlled for these in correlation analyses using partial 
correlations. 
Anxiety and depression were significantly and moderately correlated with 
retrospective and ESM ratings of MW (Pearson’s r between .5 and .7) and were 
therefore partialled out in the below analyses. Partial correlations between mean 
ratings of MW from ESM assessments and total scores obtained from the MEWS 
confirmed significant moderate to strong associations between the two measures (see 
Table 5).  
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Table 5 Correlation coefficients for relationship between MEWS total scores and mean 
intensity of MW from ESM data 
MEWS total scores Mean_Item1 Mean_Item2 Mean_Item3 Mean_Item4 Mean_Item5 
(ρ) partial 
correlation adjusted 
for anxiety and 
depression 





.59* .65* .66* .74* .72* 






A. Drug and alcohol use 
Frequent alcohol and drug use in the last 12 months were assessed by the Alcohol 
Use Disorders Identification Test and the Substance Use Checklist respectively (see 
section 2.4.1.6 in chapter 2 for details on the measures). Five individuals from the 
clinical groups were identified as reporting elevated alcohol consumption. In 
addition, seven individuals of which one was a control subject, reported elevated 
substance use (i.e. legal highs, opiates, cocaine, and cannabis), and finally two 
clinical participants reported elevated substance and alcohol use. 
Sensitivity analyses were conducted on the main outcomes of emotional 
dysregulation measured by ESM and retrospective rating scales after removing the 
above-mentioned 14 participants. Findings from the ESM data were not altered by 
excluding these individuals, and we can therefore assume ESM results were not 
driven by these cases. 
Regarding retrospective self-report measures of emotional dysregulation (ALS-SF 
and WRAADDS-EDS), findings revealed that in addition to the significant case-
control differences (similar to findings for the tests without excluding the 14 
individuals), all three clinical groups also significantly differed from one another 
(p<.001) on both scales, with the ADHD group reporting lower scores compared to 




B. ROC analyses 
The sensitivity of emotional dysregulation measures for predicting ADHD and BPD 
diagnostic accuracy were examined by applying receiver operating characteristic 
(ROC) analysis to the individual data of participants, with diagnosis as the state 
variable and emotional dysregulation as the independent variable (see Table 1). ROC 
analysis for predicting BPD diagnosis by retrospective emotional dysregulation 
measures showed marginally better but non-significant predictive ability (ranging 
between .83 and .88) than for predicting ADHD diagnosis (ranging between .74 and 
.82). 
Table 1 Discriminatory accuracy of ADHD and BPD diagnosis on symptoms of emotional 
dysregulation estimated by the area under the receiver operating characteristic curve (AUC) 
 ADHD 
AUC (95% CI) 
BPD 
AUC (95% CI) 
ALS-SF .80 (.71-.88) .83 (.76-.90) 
WRAADDS-EDS .82 (.74-.90) .88 (.82-.94) 
 
